[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 411
1. Gil-Salú JL, Nieto A, Rodríguez-Gutiérrez JF, Almarcha J: [Allelic loss at 1p/19q analysis in brain tumors of glial lineage]. Neurocirugia (Astur); 2007 Aug;18(4):285-93; discussion 293
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Análisis de la presencia de mutaciones por pérdida de heterocigocidad de 1p/19q en tumores cerebrales de estirpe glial.
  • RESULTS: Were included in the first part of this study 45 sample of neuroepithelial tissue supratentorial tumors: 29 glioblastoma, 1 gliosarcoma, 7 diffuse astrocytoma grade II, 1 oligoastrocytoma, 3 oligodendroglioma, 1 anaplastic oligodendroglioma, 1 xanthoastrocytoma, 1 dysembryoplastic neuroepithelial tumour and 1 pilocytic astrocytoma.
  • 80% of oligodendroglial tumors, 14% glioblastoma and 14% of diffuse astrocytoma grade II.
  • [MeSH-minor] Base Sequence. DNA, Neoplasm / analysis. Genetic Markers. Humans. Microsatellite Repeats. Molecular Sequence Data. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17882335.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers
  •  go-up   go-down


2. Shamsadini S, Varesvazirian M, Shamsadini A: Urticaria and lip fasciculation may be prodromal signs of brain malignancy. Dermatol Online J; 2006;12(3):23
MedlinePlus Health Information. consumer health - Hives.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a girl who suffered with chronic urticaria for 3 months before lip fasciculation began to be observed.
  • CT scan revealed a brain tumor adjacent to the cerebellum, which was diagnosed as astrocytoma grade II.
  • Because of the location, the tumor was not operable, but after one course of radiotherapy, both the urticaria and lip fasciculation disappeared.
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Fasciculation / etiology. Lip. Urticaria / etiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638437.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


3. Shen CF, Yuan XR, Qin ZQ: [Clinical significance of the expression of the RCAS1 mRNA and protein in astrocytic tumors]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Oct;32(5):836-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of the expression of the RCAS1 mRNA and protein in astrocytic tumors].
  • OBJECTIVE: To determine the mRNA and protein expressions of RCAS1 in human astrocytic tumors, and to explore the relation between their expression and the genesis and development of tumor.
  • METHODS: The RCAS1 mRNA expression in human astrocytic tumors was evaluated by RT-PCR, and the RCAS1 protein expression was studied by immunohistochemical staining.
  • RESULTS: The quantities of RCAS1 mRNA expression between diffusive astrocytoma(Grade II) and anaplastic astrocytoma(Grade III), anaplastic astrocytoma and glioblastoma(Grade IV) were significantly different(P<0.05), while the expression scores of RCAS1 protein were different only between the anaplastic astrocytoma and glioblastoma(P<0.01).
  • RCAS1 protein expression was positively correlated with the tumor grade (r=0.573,P<0.001).
  • CONCLUSION: The RCAS1 expression is related to the histological grade of astrocytic tumor.
  • In astrocytic tumors, the RCAS1 expression is regulated transcriptionally and posttranscriptionally.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Astrocytoma / metabolism. Brain Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18007080.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / EBAG9 protein, human; 0 / RNA, Messenger
  •  go-up   go-down


Advertisement
4. Fujita A, Sato JR, Festa F, Gomes LR, Oba-Shinjo SM, Marie SK, Ferreira CE, Sogayar MC: Identification of COL6A1 as a differentially expressed gene in human astrocytomas. Genet Mol Res; 2008;7(2):371-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of COL6A1 as a differentially expressed gene in human astrocytomas.
  • Diffuse infiltrating gliomas are the most common tumors of the central nervous system.
  • Gliomas are classified by the WHO according to their histopathological and clinical characteristics into four classes: grade I (pilocytic astrocytoma), grade II (diffuse astrocytoma), grade III (anaplastic astrocytoma), and grade IV (glioblastoma multiforme).
  • Several genes have already been correlated with astrocytomas, but many others are yet to be uncovered.
  • By analyzing the public SAGE data from 21 patients, comprising low malignant grade astrocytomas and glioblastomas, we found COL6A1 to be differentially expressed, confirming this finding by real time RT-PCR in 66 surgical samples.
  • The expression of this gene has significantly different means when normal glia is compared with low-grade astrocytomas (grades I and II) and high-grade astrocytomas (grades III and IV), with a tendency to be greater in higher grade samples, thus rendering it a powerful tumor marker.
  • [MeSH-major] Astrocytoma / genetics. Collagen Type VI / genetics. Gene Expression Profiling
  • [MeSH-minor] Gene Expression Regulation, Neoplastic. Humans. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18551403.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Collagen Type VI; 0 / RNA, Neoplasm
  •  go-up   go-down


5. Spadaro E, Migliacci ML, Romano LM, Zoppi J: [Astrocytoma grade II. Atypical image]. Medicina (B Aires); 2008;68(4):305
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Astrocytoma grade II. Atypical image].
  • [Transliterated title] Astrocitoma grado II. Imagen atípica.
  • [MeSH-major] Astrocytoma / pathology. Brain / pathology. Brain Neoplasms / pathology. Demyelinating Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18786888.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


6. Wright AJ, Fellows GA, Griffiths JR, Wilson M, Bell BA, Howe FA: Ex-vivo HRMAS of adult brain tumours: metabolite quantification and assignment of tumour biomarkers. Mol Cancer; 2010 Mar 23;9:66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: 1D and 2D 1H HRMAS NMR was used to determine that 29 small molecule metabolites, along with 8 macromolecule signals, account for the majority of the HRMAS spectrum of the main types of brain tumour (astrocytoma grade II, grade III gliomas, glioblastomas, metastases, meningiomas and also lymphomas).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Magnetic Resonance Spectroscopy / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1999 Jul-Aug;19(4B):3125-32 [10652601.001]
  • [Cites] NMR Biomed. 2000 May;13(3):129-53 [10861994.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Oct;21(9):1645-9 [11039343.001]
  • [Cites] Neuro Oncol. 2000 Apr;2(2):87-95 [11303625.001]
  • [Cites] Int J Mol Med. 2002 Mar;9(3):299-310 [11836637.001]
  • [Cites] Eur Radiol. 2002 Feb;12(2):329-40 [11870430.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1890-7 [11912170.001]
  • [Cites] J Neurosurg. 2002 Jun;96(6):1023-31 [12066902.001]
  • [Cites] NMR Biomed. 2002 Aug;15(5):327-37 [12203224.001]
  • [Cites] NMR Biomed. 2002 Oct;15(6):375-84 [12357551.001]
  • [Cites] Magn Reson Med. 2003 Apr;49(4):632-7 [12652533.001]
  • [Cites] NMR Biomed. 2003 May;16(3):123-31 [12884355.001]
  • [Cites] Magn Reson Imaging. 2003 Jul;21(6):663-72 [12915198.001]
  • [Cites] J Biol Chem. 2003 Nov 14;278(46):45915-23 [12954643.001]
  • [Cites] Magn Reson Med. 2004 Feb;51(2):225-9 [14755644.001]
  • [Cites] NMR Biomed. 2004 Jun;17(4):191-205 [15229932.001]
  • [Cites] J Magn Reson Imaging. 2004 Aug;20(2):187-92 [15269942.001]
  • [Cites] Magn Reson Med. 1992 Mar;24(1):123-36 [1556919.001]
  • [Cites] Neurol Med Chir (Tokyo). 1993 Jun;33(6):350-9 [7689180.001]
  • [Cites] Magn Reson Med. 1993 Dec;30(6):672-9 [8139448.001]
  • [Cites] J Neurochem. 1994 Oct;63(4):1538-43 [7931308.001]
  • [Cites] NMR Biomed. 1995 Sep;8(6):253-64 [8732181.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6408-13 [9177231.001]
  • [Cites] NMR Biomed. 1997 Jan;10(1):2-12 [9251109.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1997 Jul;43(5):659-73 [9298589.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1825-32 [9581820.001]
  • [Cites] J Neurochem. 1998 Aug;71(2):827-32 [9681475.001]
  • [Cites] J Magn Reson. 1999 Nov;141(1):104-20 [10527748.001]
  • [Cites] Magn Reson Med. 2005 Jan;53(1):41-8 [15690501.001]
  • [Cites] NMR Biomed. 2005 Oct;18(6):371-82 [15959923.001]
  • [Cites] Eur J Radiol. 2006 Jun;58(3):394-403 [16527438.001]
  • [Cites] NMR Biomed. 2006 Jun;19(4):411-34 [16763971.001]
  • [Cites] Int J Mol Med. 2006 Nov;18(5):859-69 [17016616.001]
  • [Cites] Magn Reson Med. 2006 Dec;56(6):1211-9 [17029227.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D521-6 [17202168.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D402-8 [17984079.001]
  • [Cites] Magn Reson Med. 2008 Jun;59(6):1266-73 [18506844.001]
  • [Cites] Exp Neurol. 2008 Aug;212(2):377-85 [18538323.001]
  • [Cites] NMR Biomed. 2008 Aug;21(7):677-85 [18186027.001]
  • [Cites] Magn Reson Med. 2008 Nov;60(5):1237-42 [18836999.001]
  • [Cites] Eur Radiol. 2008 Dec;18(12):2901-11 [18641997.001]
  • [Cites] NMR Biomed. 2008 Nov;21(10):1138-47 [18666093.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D603-10 [18953024.001]
  • [Cites] NMR Biomed. 2009 Feb;22(2):213-9 [19067434.001]
  • [Cites] Acta Radiol. 2009 Mar;50(2):217-25 [19096950.001]
  • [Cites] Mol Cancer. 2009;8:6 [19208232.001]
  • [Cites] Neurotherapeutics. 2009 Jul;6(3):598-603 [19560748.001]
  • [Cites] NMR Biomed. 2009 Jul;22(6):629-37 [19322812.001]
  • [Cites] J Magn Reson Imaging. 2010 Feb;31(2):289-97 [20099340.001]
  • (PMID = 20331867.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0601327
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2858738
  •  go-up   go-down


7. Durmaz R, Vural M, Işildi E, Coşan E, Ozkara E, Bal C, Ciftçi E, Arslantaş A, Atasoy MA: Efficacy of prognostic factors on survival in patients with low grade glioma. Turk Neurosurg; 2008 Oct;18(4):336-44
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of prognostic factors on survival in patients with low grade glioma.
  • AIM: In this report, we aim to determine the prognostic factors influencing the length of survival in patients with low-grade gliomas.
  • MATERIAL AND METHODS: In a retrospective evaluation, we have reviewed fiftythree patients who had been operated between the years of 1980 and 2006.
  • The diagnoses of the patients were histopathologically verified as low-grade glioma(LGG).
  • The medical records of the patients were reviewed for age, gender, tumor locations, extent of resection, and presence of seizure, the neurological status as defined by the Karnofsky Performance Scale (KPS) and radiotherapy treatment after surgery as possible prognostic factors.
  • Median survival time was 216+/-78.52 months for astrocytoma Grade I; 115+/-8.22 months for astrocytoma Grade II, and 242+/-76.36 months for oligodendroglioma.
  • [MeSH-minor] Adolescent. Adult. Aged. Aging. Astrocytoma / mortality. Astrocytoma / pathology. Astrocytoma / surgery. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Karnofsky Performance Status. Magnetic Resonance Imaging. Male. Middle Aged. Neurosurgical Procedures. Oligodendroglioma / mortality. Oligodendroglioma / pathology. Oligodendroglioma / surgery. Prognosis. Reoperation. Retrospective Studies. Seizures / etiology. Survival. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19107679.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


8. Opstad KS, Bell BA, Griffiths JR, Howe FA: Toward accurate quantification of metabolites, lipids, and macromolecules in HRMAS spectra of human brain tumor biopsies using LCModel. Magn Reson Med; 2008 Nov;60(5):1237-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toward accurate quantification of metabolites, lipids, and macromolecules in HRMAS spectra of human brain tumor biopsies using LCModel.
  • We determined a minimum set of in vitro metabolite and simulated lipid and macromolecule resonances needed for LCModel analysis and quantification of brain tumor biopsy HRMAS spectra.
  • We also demonstrate the quality of the LCModel fit for the four main brain tumor types (astrocytoma grade II, glioblastoma, metastasis, and meningioma).
  • However, LCModel is shown to provide a user-independent method of analyzing HRMAS brain tumor spectra.
  • [MeSH-major] Algorithms. Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Lipids / analysis. Magnetic Resonance Spectroscopy / methods. Nerve Tissue Proteins / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836999.001).
  • [ISSN] 1522-2594
  • [Journal-full-title] Magnetic resonance in medicine
  • [ISO-abbreviation] Magn Reson Med
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / C1459/A4350
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lipids; 0 / Nerve Tissue Proteins; 0 / Protons
  •  go-up   go-down


9. Habek M, Brinar VV, Mubrin Z, Barun B, Zarković K: Bilateral thalamic astrocytoma. J Neurooncol; 2007 Sep;84(2):175-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral thalamic astrocytoma.
  • We present a 68-year-old woman who presented with symptoms of frontotemporal dementia.
  • Brain MRI revealed tumor mass in both thalami and according to WHO classification, the tumor corresponded to diffuse fibrillary astrocytoma grade II.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Thalamus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroradiology. 2000 Oct;42(10):732-4 [11110074.001]
  • (PMID = 17522784.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Salvati M, D'Elia A, Melone GA, Brogna C, Frati A, Raco A, Delfini R: Radio-induced gliomas: 20-year experience and critical review of the pathology. J Neurooncol; 2008 Sep;89(2):169-77
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 14 cases of glioblastoma (grade IV WHO) and 2 cases of astrocytoma (grade II WHO), with a mean latency time of 17 years (range: 6-26 years).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1987 Dec;67(6):915-8 [2824720.001]
  • [Cites] Pediatr Neurosci. 1989;15(4):176-80 [2485912.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3761-7 [9850019.001]
  • [Cites] J Neurosurg. 1989 Mar;70(3):469-74 [2536806.001]
  • [Cites] Tumori. 1994 Jun 30;80(3):220-3 [8053080.001]
  • [Cites] Ann Neurol. 1978 Oct;4(4):319-21 [727737.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1431-8 [10329596.001]
  • [Cites] Cancer. 1979 Jun;43(6):2243-7 [222421.001]
  • [Cites] Br Med J (Clin Res Ed). 1984 Oct 20;289(6451):1038-9 [6435760.001]
  • [Cites] Transplant Proc. 1982 Dec;14(4):770-4 [6301119.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):426-9 [6581853.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2227-33 [8374881.001]
  • [Cites] No To Shinkei. 2000 May;52(5):413-8 [10845210.001]
  • [Cites] No Shinkei Geka. 2001 Jul;29(7):673-7 [11517510.001]
  • [Cites] Cancer. 1980 Apr 15;45(8):2051-5 [7370950.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Aug;66(8):740-9 [17882018.001]
  • [Cites] Cancer. 1978 Sep;42(3):1185-91 [100207.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1978 Nov;41(11):1005-12 [213536.001]
  • [Cites] Lancet. 2000 Nov 4;356(9241):1576-7 [11075777.001]
  • [Cites] J Neurosurg Sci. 1989 Jul-Sep;33(3):271-9 [2693630.001]
  • [Cites] Cancer. 1986 Aug 15;58(4):886-94 [2424587.001]
  • [Cites] Cancer. 1987 Apr 15;59(8):1506-8 [3545441.001]
  • [Cites] Cancer. 1986 May 15;57(10):1979-85 [3006906.001]
  • [Cites] Neurosurg Rev. 2005 Jul;28(3):226-8 [15614578.001]
  • [Cites] Cancer. 1991 Jan 15;67(2):392-7 [1845944.001]
  • [Cites] J Neurooncol. 1990 Feb;8(1):67-72 [2319293.001]
  • [Cites] Radiology. 1960 Jun;74:889-904 [14440717.001]
  • [Cites] Br J Radiol. 1985 May;58(689):480-2 [4063702.001]
  • [Cites] Surg Neurol. 2003 Jul;60(1):60-7; discussion 67 [12865017.001]
  • [Cites] Neurol Med Chir (Tokyo). 1998 May;38(5):287-91 [9640965.001]
  • [Cites] No Shinkei Geka. 1995 Feb;23(2):151-5 [7877736.001]
  • [Cites] J Neurosurg. 1985 Feb;62(2):300-3 [3855445.001]
  • [Cites] Pediatr Neurosurg. 1996 Oct;25(4):214-9 [9293548.001]
  • [Cites] Neurosurgery. 1988 Jun;22(6 Pt 1):1095-7 [3419575.001]
  • [Cites] Med J Aust. 1986 Jul 21;145(2):96-7 [3461240.001]
  • [Cites] Cancer. 1981 Jun 1;47(11):2563-6 [6266634.001]
  • [Cites] Childs Nerv Syst. 1988 Oct;4(5):296-301 [3072075.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 May-Jun;12(3):554-6 [2058514.001]
  • [Cites] Neurosurgery. 1991 Oct;29(4):606-8 [1658678.001]
  • [Cites] J Neurosurg. 1978 Apr;48(4):622-7 [632887.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):393-6 [9007876.001]
  • [Cites] J Neurosurg. 2001 Oct;95(4):710-3 [11596968.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10 (6):1871-4 [15041700.001]
  • [Cites] Neurol India. 1999 Jun;47(2):142-4 [10402343.001]
  • [Cites] Cancer. 1987 Oct 1;60(7):1510-8 [3476182.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] J Neurosurg. 2001 May;94(5):816-21 [11354416.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3326-34 [15867231.001]
  • [Cites] Neurosurgery. 1985 Sep;17(3):436-45 [2995867.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1979 Fall;1(3):285-7 [317418.001]
  • [Cites] J Neurosurg. 1980 Jun;52(6):838-41 [7381543.001]
  • [Cites] Neurosurgery. 1987 Jul;21(1):33-8 [3614601.001]
  • [Cites] Neuroradiology. 1990;32(4):331-3 [2234396.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(8):763-70 [9810442.001]
  • [Cites] Neurology. 1981 May;31(5):616-9 [7194977.001]
  • [Cites] Neurosurgery. 1980 May;6(5):546-51 [6251397.001]
  • [Cites] Neurol Med Chir (Tokyo). 1985 Jul;25(7):528-33 [2415845.001]
  • [Cites] Arch Environ Health. 1976 Jan-Feb;31(1):21-8 [1244805.001]
  • [Cites] Dtsch Med Wochenschr. 1979 Jul 6;104(27):969-72 [456271.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):154-62 [7782835.001]
  • [Cites] Childs Brain. 1982;9(1):1-9 [6277573.001]
  • [Cites] Can J Neurol Sci. 1984 Nov;11(4):475-8 [6518432.001]
  • [Cites] Cancer. 1948 May;1(1):3-29 [18867438.001]
  • [Cites] Arch Ophthalmol. 1988 Dec;106(12 ):1701-5 [3196211.001]
  • [Cites] Ann R Coll Surg Engl. 1960 Nov;27:310-54 [13790479.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1436-40; discussion 1440-2 [12762888.001]
  • [Cites] Neurol Med Chir (Tokyo). 1977;17 (1 Pt 1):55-62 [74032.001]
  • [Cites] Onkologie. 2001 Feb;24(1):66-72 [11441284.001]
  • [Cites] Gynecol Oncol. 1982 Feb;13(1):108-14 [7060984.001]
  • [Cites] Neurosurgery. 1983 Jul;13(1):85-9 [6308498.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):445-9 [682008.001]
  • [Cites] Am J Public Health Nations Health. 1966 Dec;56(12):2114-20 [5334312.001]
  • [Cites] J Neurosurg. 1989 Jul;71(1):77-82 [2661743.001]
  • [Cites] Neurosurgery. 1986 Jul;19(1):114-9 [3018623.001]
  • (PMID = 18566750.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Zhen L, Yufeng C, Zhenyu S, Lei X: Multiple extracranial metastases from secondary glioblastoma multiforme: a case report and review of the literature. J Neurooncol; 2010 May;97(3):451-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extracranial metastasis of glioblastoma multiforme (GBM) is very rare, in spite of very aggressive tumor behavior and being documented in only a few patients.
  • Histology revealed a diffuse astrocytoma (grade II).
  • The tumor recurred 1 year later and the patient received a second craniotomy.
  • [MeSH-minor] Adult. Craniotomy / methods. Humans. Magnetic Resonance Imaging. Male. Receptor, Epidermal Growth Factor / metabolism. S100 Proteins / metabolism. Tomography, X-Ray Computed / methods. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1990 Jul 1;66(1):180-4 [2162242.001]
  • [Cites] Cancer. 1978 Dec;42(6):2854-64 [215298.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Cancer. 1976 Mar;37(3):1577-83 [177171.001]
  • [Cites] Acta Cytol. 1993 Nov-Dec;37(6):938-42 [8249517.001]
  • [Cites] Brain Pathol. 1996 Jul;6(3):217-23; discussion 23-4 [8864278.001]
  • [Cites] Brain Pathol. 2001 Apr;11(2):159-68 [11303791.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Clin Exp Neurol. 1987;23:111-7 [2822301.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 Jul;118(7):755-6 [1320896.001]
  • [Cites] Cancer. 1980 Jan 1;45(1):112-25 [6985826.001]
  • [Cites] J Neurosurg. 1969 Jul;31(1):50-8 [4307543.001]
  • [Cites] J Neurosurg. 1970 Jul;33(1):88-94 [4316740.001]
  • [Cites] J Korean Med Sci. 2001 Aug;16(4):481-8 [11511795.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Nov-Dec;17 (10 ):1929-31 [8933881.001]
  • [Cites] Cancer Treat Rev. 1984 Mar;11(1):1-26 [6203642.001]
  • [Cites] J Neurosurg. 1985 Jun;62(6):918-21 [2987441.001]
  • [Cites] Ann Neurol. 1980 Dec;8(6):605-8 [6260012.001]
  • (PMID = 19898745.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / S100 Proteins; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 19
  •  go-up   go-down


12. Abacioglu MU, Caglar HB, Yumuk PF, Akgun Z, Atasoy BM, Sengoz M: Efficacy of protracted dose-dense temozolomide (TMZ) in patients with progressive high-grade glioma. J Clin Oncol; 2009 May 20;27(15_suppl):e13018

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of protracted dose-dense temozolomide (TMZ) in patients with progressive high-grade glioma.
  • : e13018 Background: The study was aimed to evaluate the efficacy of TMZ on a protracted dose-dense schedule after standard 5-day TMZ regimen in patients with progressive high-grade glioma.
  • METHODS: In this phase II prospective study, patients who had progression on standard 5-day TMZ for recurrence (group 1) or recurrence after concurrent radiotherapy+TMZ and ≥ 2 cycles of adjuvant TMZ (group 2) for high-grade glioma received TMZ 100 mg/m2× 21 q28 days until progression according to MacDonald's criteria.
  • The histopathology was glioblastoma in 18 and grade 3 glioma (anaplastic astrocytoma, anaplastic oligoastrocytoma or anaplastic oligodendroglioma) in 7.
  • Out of 80 cycles received there was no anemia; 5 (6%) grade 1, 8 (10%) grade 2, 2 (3%) grade 3 leucopenia; 1 (1%) grade 1, 2 (3%) grade 2, 1 (1%) grade 3, 1 (1%) grade 4 thrombocytopenia; 9 (11%) grade 1, 7 (9%) grade 2, 32 (40%) grade 3, and 11 (14%) grade 4 lymphopenia.
  • Study was terminated in 2 patients (one with grade 4 thrombocytopenia and the other with grade 4 hepatic toxicity).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962826.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Osoba AO, Kutub H, Waliuddin A, Sharab MO: Enterococcus avium. An unusual cause of cerebral abscess. Neurosciences (Riyadh); 2005 Oct;10(4):297-300

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we report a 19-year-old Saudi girl diagnosed as a case of astrocytoma grade II arising from the right thalamus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22473142.001).
  • [ISSN] 1319-6138
  • [Journal-full-title] Neurosciences (Riyadh, Saudi Arabia)
  • [ISO-abbreviation] Neurosciences (Riyadh)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


14. Martínez C, Molina JA, Alonso-Navarro H, Jiménez-Jiménez FJ, Agúndez JA, García-Martín E: Two common nonsynonymous paraoxonase 1 (PON1) gene polymorphisms and brain astrocytoma and meningioma. BMC Neurol; 2010;10:71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two common nonsynonymous paraoxonase 1 (PON1) gene polymorphisms and brain astrocytoma and meningioma.
  • Aiming to identify genetic variations related to the risk of developing brain tumors, we investigated the putative association between common nonsynonymous PON1 polymorphisms and the risk of developing astrocytoma and meningioma.
  • METHODS: Seventy one consecutive patients with brain tumors (43 with astrocytoma grade II/III and 28 with meningioma) with ages ranging 21 to 76 years, and 220 healthy controls subjects were analyzed for the frequency of the nonsynonymous PON1 genotypes L55M rs854560 and Q192R rs662.
  • RESULTS: The frequencies of the PON1 genotypes and allelic variants of the polymorphisms PON1 L55M and PON1 Q192R did not differ significantly between patients with astrocytoma and meningioma and controls.
  • The minor allele frequencies were as follows: PON1 55L, 0.398, 0.328 and 0.286 for patients with astrocytoma, meningioma and control individuals, respectively; PON1 192R, 0.341, 0.362 and 0.302 for patients with astrocytoma, meningioma and control individuals, respectively.
  • Haplotype association analyses did not identify any significant association with the risk of developing astrocytoma or meningioma.
  • CONCLUSIONS: Common nonsynonymous PON1 polymorphisms are not related with the risk of developing astrocytoma and meningioma.
  • [MeSH-major] Aryldialkylphosphatase / genetics. Astrocytoma / genetics. Brain Neoplasms / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ind Med. 1998 Sep;34(3):252-60 [9698994.001]
  • [Cites] Atherosclerosis. 1998 Aug;139(2):341-9 [9712341.001]
  • [Cites] Biochem Pharmacol. 1998 Sep 1;56(5):547-51 [9783722.001]
  • [Cites] Int J Cancer. 2005 Jan 1;113(1):116-25 [15386358.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Environ Health Perspect. 2005 May;113(5):546-51 [15866761.001]
  • [Cites] Environ Health Perspect. 2005 Jul;113(7):909-13 [16002382.001]
  • [Cites] Liver Int. 2005 Oct;25(5):935-9 [16162149.001]
  • [Cites] Toxicology. 2005 Nov 15;215(3):182-90 [16102884.001]
  • [Cites] Occup Environ Med. 2005 Nov;62(11):786-92 [16234405.001]
  • [Cites] World J Gastroenterol. 2006 Jan 28;12(4):615-20 [16489678.001]
  • [Cites] Acta Neurol Scand. 2006 May;113(5):322-6 [16629768.001]
  • [Cites] Oncol Rep. 2006 Jun;15(6):1513-6 [16685388.001]
  • [Cites] Pharmacogenomics. 2006 Jul;7(5):711-8 [16886896.001]
  • [Cites] Cell Biochem Funct. 2006 Sep-Oct;24(5):455-60 [16142697.001]
  • [Cites] J Agric Saf Health. 2006 Nov;12(4):255-74 [17131948.001]
  • [Cites] Drug Metab Dispos. 2007 Feb;35(2):315-20 [17132760.001]
  • [Cites] Occup Environ Med. 2007 Aug;64(8):509-14 [17537748.001]
  • [Cites] Am J Hum Genet. 2007 Sep;81(3):559-75 [17701901.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 2007 Jan-Mar;10(1-2):81-99 [18074305.001]
  • [Cites] Pharmacogenet Genomics. 2008 Jan;18(1):37-43 [18216720.001]
  • [Cites] Am J Epidemiol. 2008 Apr 15;167(8):976-85 [18299277.001]
  • [Cites] Clin Chem. 2008 Aug;54(8):1390-4 [18664443.001]
  • [Cites] Curr Drug Metab. 2008 Jul;9(6):520-31 [18680472.001]
  • [Cites] Neuro Oncol. 2008 Oct;10(5):709-15 [18682580.001]
  • [Cites] Psychiatr Genet. 2008 Dec;18(6):289-94 [19018234.001]
  • [Cites] Toxicol Appl Pharmacol. 2009 Apr 15;236(2):142-53 [19371602.001]
  • [Cites] Cell Biochem Funct. 2009 Dec;27(8):558-67 [19902425.001]
  • [Cites] Environ Health Perspect. 2010 Jan;118(1):144-9 [20056567.001]
  • [Cites] Adv Exp Med Biol. 2010;660:47-60 [20221870.001]
  • [Cites] Eur J Neurol. 2010 Jun 1;17(6):879-81 [20050883.001]
  • [Cites] Chem Biol Interact. 2010 Sep 6;187(1-3):355-61 [20338154.001]
  • [Cites] Neuromolecular Med. 2010 Sep;12(3):217-23 [19826962.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1999 Feb;45(1):15-23 [10099836.001]
  • [Cites] Pharmacogenetics. 2000 Dec;10(9):767-79 [11191881.001]
  • [Cites] J Lipid Res. 2001 Apr;42(4):528-35 [11290824.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 May 15;173(1):1-6 [11350209.001]
  • [Cites] Carcinogenesis. 2001 Aug;22(8):1323-6 [11470765.001]
  • [Cites] Environ Health Perspect. 2001 Sep;109(9):909-13 [11673119.001]
  • [Cites] Ann Diagn Pathol. 2002 Feb;6(1):44-8 [11842378.001]
  • [Cites] Curr Opin Lipidol. 2002 Aug;13(4):357-62 [12151850.001]
  • [Cites] Am J Ind Med. 2002 Sep;42(3):214-27 [12210690.001]
  • [Cites] Cancer Causes Control. 2003 Mar;14(2):139-50 [12749719.001]
  • [Cites] Br J Neurosurg. 2003 Apr;17(2):182-4 [12820764.001]
  • [Cites] Am J Hum Genet. 2003 Nov;73(5):1162-9 [14574645.001]
  • [Cites] J Mol Med (Berl). 2003 Dec;81(12):766-79 [14551701.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):434-42 [15026468.001]
  • [Cites] Am J Ind Med. 2004 May;45(5):395-407 [15095422.001]
  • [Cites] Curr Drug Metab. 2004 Jun;5(3):211-24 [15180491.001]
  • [Cites] Arch Pathol Lab Med. 1979 Dec;103(13):676-9 [583126.001]
  • [Cites] J Neurol. 1982;227(3):165-9 [6181224.001]
  • [Cites] Indian J Cancer. 1983 Mar;20(1A):86-8 [6873998.001]
  • [Cites] Am J Epidemiol. 1988 Oct;128(4):778-85 [3421243.001]
  • [Cites] Neurologia. 1988 Mar-Apr;3(2):68-70 [2856211.001]
  • [Cites] J Neurosci Nurs. 1992 Oct;24(5):260-4 [1328422.001]
  • [Cites] Am J Hum Genet. 1993 Mar;52(3):598-608 [7916578.001]
  • [Cites] Nat Genet. 1993 Jan;3(1):73-6 [8098250.001]
  • [Cites] Neurosurgery. 1995 Mar;36(3):599-604; discussion 604-5 [7753363.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4237-9 [7671227.001]
  • [Cites] J Neurosurg Sci. 1995 Mar;39(1):27-35 [8568553.001]
  • [Cites] Epidemiol Rev. 1995;17(2):382-414 [8654518.001]
  • [Cites] Curr Opin Lipidol. 1996 Apr;7(2):69-76 [8743898.001]
  • [Cites] Nat Genet. 1996 Nov;14(3):334-6 [8896566.001]
  • [Cites] Environ Health Perspect. 1998 Jun;106 Suppl 3:893-908 [9646054.001]
  • [Cites] Nature. 1998 Jul 16;394(6690):284-7 [9685159.001]
  • (PMID = 20723250.001).
  • [ISSN] 1471-2377
  • [Journal-full-title] BMC neurology
  • [ISO-abbreviation] BMC Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.1.8.1 / Aryldialkylphosphatase; EC 3.1.8.1 / PON1 protein, human
  • [Other-IDs] NLM/ PMC2936881
  •  go-up   go-down


15. Ramos Martínez A, Sánchez Romero I, Saura Lorente PA, Parajón Díaz A: [Suppurative thrombophlebitis central venous catheterization]. An Med Interna; 2008 Jun;25(6):284-6
Hazardous Substances Data Bank. CLOXACILLIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 22-year-old colombian-woman, student, without toxic habits was admitted because of temporary left astrocytoma (grade II).
  • The patient evolved satisfactorily with cloxacillin, gentamycin and low molecular weight heparin.
  • [MeSH-minor] Adult. Anti-Bacterial Agents / administration & dosage. Anti-Bacterial Agents / therapeutic use. Anticoagulants / administration & dosage. Anticoagulants / therapeutic use. Cloxacillin / administration & dosage. Cloxacillin / therapeutic use. Drug Therapy, Combination. Female. Follow-Up Studies. Gentamicins / administration & dosage. Gentamicins / therapeutic use. Heparin, Low-Molecular-Weight / administration & dosage. Heparin, Low-Molecular-Weight / therapeutic use. Humans. Neck / radiography. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19295976.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anticoagulants; 0 / Gentamicins; 0 / Heparin, Low-Molecular-Weight; O6X5QGC2VB / Cloxacillin
  •  go-up   go-down


16. Ohnishi M, Matsumoto T, Nagashio R, Kageyama T, Utsuki S, Oka H, Okayasu I, Sato Y: Proteomics of tumor-specific proteins in cerebrospinal fluid of patients with astrocytoma: usefulness of gelsolin protein. Pathol Int; 2009 Nov;59(11):797-803
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomics of tumor-specific proteins in cerebrospinal fluid of patients with astrocytoma: usefulness of gelsolin protein.
  • Changes in cerebrospinal fluid (CSF) composition have been shown to accurately reflect pathological processes in the CNS, and are potential indicators of abnormal CNS states, such as tumor growth.
  • To detect biomarkers in high-grade astrocytomas, the differential expression of proteins in the cerebrospinal fluid was analyzed from two cases each of diffuse astrocytoma (grade II), and glioblastoma (grade IV) using agarose 2-D gel electrophoresis (2-DE).
  • It was found that the expression of gelsolin protein decreased with histological grade.
  • To examine whether gelsolin is a useful indicator of tumor aggressiveness or patient outcome, its expression was further studied on immunohistochemistry in 41 formalin-fixed and paraffin-embedded astrocytomas.
  • The positive cell rate of gelsolin in tumors was 59.4% in grade II, 30.0% in grade III and 29.4% in grade IV, respectively.
  • Gelsolin expression was significantly lower in high-grade astrocytomas (grade III or IV) than in low-grade astrocytomas (grade II; P < 0.05).
  • Moreover, in astrocytomas the overall survival of patients in the low-expression group was significantly poorer than in the high expression group (P < 0.05).
  • These data suggest that gelsolin is a prognostic factor in astrocytoma.
  • [MeSH-major] Astrocytoma / cerebrospinal fluid. Biomarkers, Tumor / cerebrospinal fluid. Brain Neoplasms / cerebrospinal fluid. Gelsolin / cerebrospinal fluid

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19883430.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Gelsolin
  •  go-up   go-down


17. Ren ZP, Olofsson T, Qu M, Hesselager G, Soussi T, Kalimo H, Smits A, Nistér M: Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors. J Neuropathol Exp Neurol; 2007 Oct;66(10):944-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors.
  • We investigated genetic heterogeneity of astrocytic gliomas using p53 gene mutations as a marker.
  • Different parts of morphologically heterogeneous astrocytic gliomas were microdissected, and direct DNA sequencing of p53 gene exons 5 through 8 was performed.
  • Thirty-five glioma samples and tumor-adjacent normal-appearing brain tissue from 11 patients were analyzed.
  • The mutations were present in grade II, III, and IV astrocytic glioma areas.
  • Both severe functionally dead mutants and mutants with remaining transcriptional activity could be observed in the same tumor.
  • Coexistence of p53 gene mutations and the locus of heterozygosity was common, at least in astrocytomas grade III and in glioblastomas, and also occurred in astrocytoma grade II areas.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Genes, p53 / genetics
  • [MeSH-minor] Adult. Aged. DNA Primers. DNA, Neoplasm / genetics. Female. Gene Frequency. Humans. Immunohistochemistry. Loss of Heterozygosity. Male. Microdissection. Middle Aged. Mutation / genetics. Mutation / physiology. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17917588.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Neoplasm
  •  go-up   go-down


18. Gimenez M, Souza VC, Izumi C, Barbieri MR, Chammas R, Oba-Shinjo SM, Uno M, Marie SK, Rosa JC: Proteomic analysis of low- to high-grade astrocytomas reveals an alteration of the expression level of raf kinase inhibitor protein and nucleophosmin. Proteomics; 2010 Aug;10(15):2812-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of low- to high-grade astrocytomas reveals an alteration of the expression level of raf kinase inhibitor protein and nucleophosmin.
  • The aim of this study was to identify differentially expressed proteins in diffuse astrocytoma grade II, anaplastic astrocytoma grade III and glioblastoma multiforme grade IV in human tumor samples and in non-neoplastic brain tissue as control using 2-DE and MS.
  • Tumor and control brain tissue dissection was guided by histological hematoxylin/eosin tissue sections to provide more than 90% of tumor cells and astrocytes.
  • Six proteins were detected as up-regulated in higher grade astrocytomas and the most important finding was nucleophosmin (NPM) (p<0.05), whereas four proteins were down-regulated, among them raf kinase inhibitor protein (RKIP) (p<0.05).
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Nuclear Proteins / genetics. Phosphatidylethanolamine Binding Protein / genetics. Proteomics


19. Rathi KR, Radotra BD, Khosla VK: Proliferative index in astrocytic tumours. Indian J Pathol Microbiol; 2007 Oct;50(4):754-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferative index in astrocytic tumours.
  • The accurate grading of astrocytic tumours is of prime importance because it is critical to the patient management and survival/outcome.
  • Although internationally accepted WHO grading system of CNS tumours is based on histological features of H&E stained sections, yet there are cases where differentiation between grade II and grade III is difficult particularly when the biopsy is small.
  • Formalin-fixed paraffin-embedded surgical specimens from 90 cases of astrocytic tumours, 30 each of low-grade astrocytoma (grade II), anaplastic astrocytoma (grade III), and glioblastoma multiforme (grade IV), were immunostained by standard indirect immunoperoxidase technique using MIB-1 monoclonal antibody.
  • The mean MIB-1 LI values of astrocytomas, anaplastic astrocytomas and glioblastomas were 1.75 +/- 1.5%, 8.74 +/- 6.2%, and 20.54 +/- 12.2% respectively and there was statistically significant difference between grade II and III (Unpaired "t" test, T value 5.907, p value < 0.001) and grade III and grade IV (T value 4.734, p value < 0.001).
  • The statistical analysis also revealed that the mean MIB-1 LI increased with histological grade of malignancy (One way ANOVA test, p value < 0.001).
  • This investigation further reinforces and corroborates the findings that MIB-1 LI is useful tool in assigning grading to the astrocytic tumours and hence in treatment modalities and should be used routinely.
  • [MeSH-major] Astrocytoma / classification. Astrocytoma / pathology. Cell Proliferation. Glioblastoma / classification. Glioblastoma / pathology. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306542.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


20. Belda-Iniesta C, de Castro Carpeño J, Casado Sáenz E, Cejas Guerrero P, Perona R, González Barón M: Molecular biology of malignant gliomas. Clin Transl Oncol; 2006 Sep;8(9):635-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular biology of malignant gliomas.
  • For example, gliomas of astrocytic origin (astrocytomas) are classified into pilocytic astrocytoma (grade I), astrocytoma (grade II), anaplastic astrocytoma (grade III) and glioblastoma multiforme (GMB) (grade IV).
  • Tumors derived from oligodendrocytes include grade II (oliogodendrogliomas) and grade III neoplasms (oligoastrocytoma).
  • Obviously, prognosis and biological behaviour of malignant gliomas are closely related and supported by the different molecular background that possesses each type of glioma.
  • Furthermore, the ability that allows several low-grade gliomas to progress into more aggressive tumors has allowed cancer researchers to elucidate several pathways implicated in molecular biology of these devastating tumors.
  • In this review, we describe classical pathways involved in human malignant gliomas with special focus with recent advances, such as glioma stem-like cells and expression patterns from microarray studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasia. 2005 Jan;7(1):7-16 [15720813.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1033-43 [12937144.001]
  • [Cites] Glia. 2002 Sep;39(3):193-206 [12203386.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8 [16039986.001]
  • [Cites] Cell. 1995 Dec 15;83(6):993-1000 [8521522.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4088-96 [15899798.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6674-8 [11559533.001]
  • [Cites] Cell Cycle. 2006 Apr;5(7):783-91 [16582634.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):792-800 [16550607.001]
  • [Cites] Cancer Treat Rev. 2004 Apr;30(2):193-204 [15023437.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Nat Genet. 2000 May;25(1):55-7 [10802656.001]
  • [Cites] Int J Cancer. 1995 Aug 9;62(4):386-92 [7635563.001]
  • [Cites] Mol Cancer Ther. 2002 Nov;1(13):1229-36 [12479704.001]
  • [Cites] Cancer Cell. 2003 Apr;3(4):311-6 [12726857.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):269-77 [12086863.001]
  • [Cites] Physiol Genomics. 2001 Feb 07;5(1):21-33 [11161003.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6617-22 [11118044.001]
  • [Cites] Oncogene. 2003 Dec 8;22(56):9030-40 [14663481.001]
  • [Cites] Cancer Res. 2005 May 15;65(10 ):4051-8 [15899794.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):212-21 [14734472.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4183-6 [9331071.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Feb;57(2):122-30 [9600204.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3644-9 [9851971.001]
  • [Cites] Cell. 2004 Apr 16;117(2):211-23 [15084259.001]
  • [Cites] J Neurooncol. 1998 Jan;36(2):123-40 [9525812.001]
  • [Cites] Cancer Res. 1995 May 1;55(9):1941-5 [7728764.001]
  • [Cites] Oncogene. 2001 Mar 1;20(9):1103-9 [11314047.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5804-7 [7954404.001]
  • [Cites] Oncogene. 2004 Jun 3;23 (26):4594-602 [15077177.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6885-91 [11559565.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Oct;11(2):91-6 [7529554.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] J Neuropathol Exp Neurol. 1994 Jan;53(1):11-21 [8301315.001]
  • (PMID = 17005465.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Number-of-references] 36
  •  go-up   go-down


21. Lymbouridou R, Soufla G, Chatzinikola AM, Vakis A, Spandidos DA: Down-regulation of K-ras and H-ras in human brain gliomas. Eur J Cancer; 2009 May;45(7):1294-303
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the mutational, mRNA and protein expression profile of the ras genes in 21 glioblastomas multiforme (grade IV), four fibrillary astrocytoma (grade II), four anaplastic astrocytoma (grade III) and 15 normal specimens.
  • Our findings provide evidence of K- and H-ras involvement in brain malignant transformation through transcriptional down-regulation, while N-ras seems to contribute less to brain carcinogenesis.
  • [MeSH-minor] Adult. Aged. Astrocytoma / genetics. Astrocytoma / metabolism. Astrocytoma / mortality. Blotting, Western / methods. Case-Control Studies. Codon. Female. Gene Expression. Glioblastoma / genetics. Glioblastoma / metabolism. Glioblastoma / mortality. Humans. Male. Middle Aged. Oncogene Protein p21(ras) / analysis. Oncogene Protein p21(ras) / metabolism. Polymorphism, Restriction Fragment Length. Reverse Transcriptase Polymerase Chain Reaction / methods. Statistics, Nonparametric. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179066.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Codon; EC 3.6.5.2 / Oncogene Protein p21(ras)
  •  go-up   go-down


22. Krafft C, Sobottka SB, Geiger KD, Schackert G, Salzer R: Classification of malignant gliomas by infrared spectroscopic imaging and linear discriminant analysis. Anal Bioanal Chem; 2007 Mar;387(5):1669-77
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification of malignant gliomas by infrared spectroscopic imaging and linear discriminant analysis.
  • An approach is described to apply this methodology to human astrocytic gliomas, which are graded according to their malignancy from one to four.
  • Multiple IR images of three tissue sections from one patient with a malignant glioma are acquired and assigned to the six classes normal brain tissue, astrocytoma grade II, astrocytoma grade III, glioblastoma multiforme grade IV, hemorrhage, and other tissue by a linear discriminant analysis model which was trained by data from a single-channel detector.
  • The first specimen contained approximately 95% malignant glioma regions, that means astrocytoma grade III or glioblastoma.
  • The smaller percentage of 12-34% malignant glioma in the second specimen is consistent with its location at the tumor periphery.
  • The detection of less than 0.2% malignant glioma in the third specimen points to a location outside the tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17103151.001).
  • [ISSN] 1618-2642
  • [Journal-full-title] Analytical and bioanalytical chemistry
  • [ISO-abbreviation] Anal Bioanal Chem
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


23. Znidaric MT, Pucer A, Fatur T, Filipic M, Scancar J, Falnoga I: Metal binding of metallothioneins in human astrocytomas (U87 MG, IPDDC-2A). Biometals; 2007 Oct;20(5):781-92
Hazardous Substances Data Bank. CADMIUM CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metal binding of metallothioneins in human astrocytomas (U87 MG, IPDDC-2A).
  • For this reason astroglia cells possess high cytosolic levels of metallothioneins I, II and III (MT-I,II,III).
  • Our aim was to establish the inducibility and metal binding of MTs in two human astrocytoma cell lines, U87 MG (astrocytoma-glioblastoma, grade IV) and IPDDC-2A (astrocytoma, grade II), on exposure to cadmium chloride (1 microM).
  • We showed that MTs are constitutively expressed in both human astrocytoma cell lines.
  • In accordance with the higher malignancy grade of U87 MG, the amount of MTs was higher in U87 MG than in IPDDC-2A cells.
  • Isoform III (identified by chromatographic separation of isoform III from I/II) was present at all exposure times, but only in traces with respect to the prevailing amounts of MT-I/II isoforms.
  • So induction can be attributed to isoform I/II only.
  • [MeSH-major] Astrocytoma / metabolism. Metallothionein / metabolism. Metals / metabolism
  • [MeSH-minor] Cadmium Chloride / metabolism. Cadmium Chloride / pharmacology. Cadmium Chloride / toxicity. Cell Line, Tumor. Cell Survival / drug effects. Dose-Response Relationship, Drug. Humans. Protein Binding / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17115260.001).
  • [ISSN] 0966-0844
  • [Journal-full-title] Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine
  • [ISO-abbreviation] Biometals
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Metals; 9038-94-2 / Metallothionein; J6K4F9V3BA / Cadmium Chloride
  •  go-up   go-down


24. Bentsion DL, Gvozdev PB, Sakovich VP, Fialko NV, Kolotvinov VS, Baiankina SN: [The first experience in interstitial brachytherapy for primary and metastatic tumors of the brain]. Zh Vopr Neirokhir Im N N Burdenko; 2006 Jan-Mar;(1):18-21; discussion 21
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histostructural distribution was as follows: low-grade astrocytoma (grade II according to the WHO classification) in 2 patients, anaplastic astrocytoma (AA) in 3, glioblastoma multiforme (GBM) in 5.
  • Five patients had solid tumor deposits in the brain.
  • After having histological findings, plastic intrastats whose number had been determined by the volume of a target were implanted into a tumor by the predetermined path.
  • All patients with low-grade astrocytoma and one patient with anaplastic astrocytoma were alive at month 24 after treatment termination.
  • The mean lifespan of patients with malignant gliomas and solid tumor metastasis was 11.5 and 5.8 months, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16739930.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


25. Agrawal R: Synchronous dual malignancy: successfully treated cases. J Cancer Res Ther; 2007 Jul-Sep;3(3):153-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The occurrence of a second malignancy in a patient with a known malignant tumour is not uncommon.
  • HPE mastectomy specimen showed infiltrating duct carcinoma and stage II.
  • HPE brain tissue showed astrocytoma grade II and HPE parotid tumour showed low grade muco-epidermoid carcinoma.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / therapy. Carcinoma, Squamous Cell / therapy. Neoplasms, Multiple Primary / therapy. Uterine Cervical Neoplasms / therapy


26. Suárez JC, Viano JC, Zunino S, Herrera EJ, Gomez J, Tramunt B, Marengo I, Hiramatzu E, Miras M, Pena M, Sonzini Astudillo B: Management of child optic pathway gliomas: new therapeutical option. Childs Nerv Syst; 2006 Jul;22(7):679-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosed using computed tomography or/and magnetic resonance imaging, histological studies showed pilocytic astrocytomas in 13 cases and a fibrillary astrocytoma grade II in 1 case.
  • Five patients died; the causes were secondary tumors in two children, tumor recurrence in one, sepsis secondary to respiratory and urinary tract infections in the child with Down syndrome, and finally, hydrocephaly due to hyperproteinorachia of tumor origin in one.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Neurosurg. 1993 Jul-Aug;19(4):186-95 [8329303.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):215-25 [8420869.001]
  • [Cites] Ann Neurol. 1988 Jan;23 (1):79-85 [3345069.001]
  • [Cites] Childs Nerv Syst. 1999 May;15(5):256-60; discussion 261 [10392498.001]
  • [Cites] Cancer. 1987 Mar 1;59(5):1000-4 [2434201.001]
  • [Cites] Neurochirurgie. 1981;27(5):295-8 [7038523.001]
  • [Cites] Can J Neurol Sci. 2002 May;29(2):132-8 [12035834.001]
  • [Cites] Acta Neurochir (Wien). 1992;119(1-4):53-61 [1481753.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):807-12 [12788189.001]
  • [Cites] J Neurosurg. 1991 May;74(5):701-8 [1901597.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Dec;23(9):572-7 [11902299.001]
  • [Cites] Childs Nerv Syst. 2003 Mar;19(3):145-51 [12644865.001]
  • (PMID = 16389565.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


27. Benesch M, Eder HG, Sovinz P, Raith J, Lackner H, Moser A, Urban C: Residual or recurrent cerebellar low-grade glioma in children after tumor resection: is re-treatment needed? A single center experience from 1983 to 2003. Pediatr Neurosurg; 2006;42(3):159-64
Genetic Alliance. consumer health - Glioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residual or recurrent cerebellar low-grade glioma in children after tumor resection: is re-treatment needed? A single center experience from 1983 to 2003.
  • PURPOSE: The aim of this study was to report on children with cerebellar low-grade glioma (LGG), who were found to have progressive or nonprogresssive residual tumors or tumor recurrence after tumor resection.
  • RESULTS: Of 289 patients with CNS tumors referred between 1983 and 2003, 28 (9.7%) (15 male, 13 female; median age at diagnosis: 71 months) had cerebellar LGG (pilocytic astrocytoma grade I: n = 21; fibrillary astrocytoma grade II: n = 5; mixed hamartoma/pilocytic astrocytoma: n = 1; radiographic diagnosis: n = 1).
  • CONCLUSIONS: A 'wait and see' strategy is justified in patients with nonprogressive recurrent or residual cerebellar LGG after primary tumor resection.
  • [MeSH-major] Astrocytoma / surgery. Cerebellar Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel
  • (PMID = 16636617.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


28. Opstad KS, Ladroue C, Bell BA, Griffiths JR, Howe FA: Linear discriminant analysis of brain tumour (1)H MR spectra: a comparison of classification using whole spectra versus metabolite quantification. NMR Biomed; 2007 Dec;20(8):763-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 145 histologically diagnosed brain tumour spectra were acquired [14 astrocytoma grade II (AS2), 15 astrocytoma grade III (AS3), 42 glioblastoma (GBM), 41 metastases (MET) and 33 meningioma (MNG)], and linear discriminant analyses (LDA) were performed on the LCModel analysis of the spectra and the original spectra.
  • LDA of AS2, MNG and high-grade tumours (HG, comprising GBM and MET) correctly classified 94% using the LCModel dataset compared with 93% using the spectral dataset.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17326043.001).
  • [ISSN] 0952-3480
  • [Journal-full-title] NMR in biomedicine
  • [ISO-abbreviation] NMR Biomed
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


29. Gumprecht H, Grosu AL, Souvatsoglou M, Dzewas B, Weber WA, Lumenta CB: 11C-Methionine positron emission tomography for preoperative evaluation of suggestive low-grade gliomas. Zentralbl Neurochir; 2007 Feb;68(1):19-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 11C-Methionine positron emission tomography for preoperative evaluation of suggestive low-grade gliomas.
  • OBJECTIVE: The treatment regimen for cerebral gliomas is different, depending on the histological grade of the lesion.
  • The management for low-grade gliomas is still under discussion, operation or "wait and see" tactics are possible options.
  • Although most of the low-grade gliomas appear as hypointense lesions without contrast medium (CM) enhancement on magnetic resonance images, in some cases lesions without CM enhancement can be anaplastic tumours as well.
  • 11C-Methionine positron emission tomography (MET-PET) was performed for preoperative evaluation of non or low CM enhancing intracerebral lesions, so-called suggestive low-grade gliomas.
  • METHOD: 20 patients harbouring suggestive low-grade gliomas were included.
  • Histologically the 2 patients with sparse CM enhancement and MET uptake were glioblastoma multiforme, 10/14 patients with MET uptake and without CM enhancement had an anaplastic astrocytoma WHO III, 3/14 with MET uptake and no CM enhancement had an anaplastic oligoastrocytoma WHO III, and 1/14 had an oligoastrocytoma grade II.
  • The lesions of the 4 patients without MET uptake and without CM enhancement were classified as astrocytoma grade II in 2 cases, as astrocytoma grade I in 1 case and as astrocytoma III in one case.
  • CONCLUSION: According to the results of this study, we find MET-PET to be a helpful tool for pretreatment evaluation of non-CM enhancing, suggestive low-grade intracerebral lesions.
  • [MeSH-minor] Astrocytoma / radionuclide imaging. Astrocytoma / surgery. Glioblastoma / radionuclide imaging. Glioblastoma / surgery. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Neurosurgical Procedures. Positron-Emission Tomography

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487804.001).
  • [ISSN] 0044-4251
  • [Journal-full-title] Zentralblatt für Neurochirurgie
  • [ISO-abbreviation] Zentralbl. Neurochir.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; AE28F7PNPL / Methionine
  •  go-up   go-down


30. Ahmed N, Bhurgri Y, Sadiq S, Shakoor KA: Pediatric brain tumours at a tertiary care hospital in Karachi. Asian Pac J Cancer Prev; 2007 Jul-Sep;8(3):399-404
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The morphological distribution of cases was astrocytoma (28 cases, 34.6%), primitive neuroectodermal tumor or PNET (40 cases; 49.4%), ependymoma (8 cases, 10%), mixed glioma (4 cases; 5%) and a case of oligodendroglioma.
  • The morphological categorization of supratentorial tumors was astrocytoma (17 cases; 63%), ependymoma (5 cases; 18.5%), mixed glioma (2 cases; 7.4%).
  • The 17 supratentorial astrocytoma were sub-categorized as follows - pilocytic astrocytoma (5 cases; 29.4%), grade II astrocytoma (6 cases; 35.3%); grade III astrocytoma (2 cases; 11.8%), anaplastic astrocytoma (1 case; 5.9%) and glioblastoma multiforme (3 cases; 17.7%).
  • The morphological categorization of infratentorial tumors was astrocytoma (11 cases; 20.4%), medulloblastoma (38 cases; 70.4%), ependymoma (3 cases; 5.6%) and mixed glioma - astroependymoma (2 cases, 3.7%).
  • The morphological sub-categorization of infratentorial astrocytoma was pilocytic astrocytoma (7 cases, 63.6%), with gemistocytic astrocytoma, grade II, grade III and anaplastic astrocytoma comprising 1 (9.1%) case each.
  • The morphological categorization of medulloblastoma was classical medulloblastoma (15 cases; 39.5%), desmoplastic medulloblastoma (8 cases; 21.1%), medulloblastoma with astrocytic differentiation (12 cases; 31.5%), medulloblastoma with neural differentiation (2 cases; 5.3%), and neuroblastic medulloblastoma (1 case; 2.6%).
  • There is a predominance of medulloblastoma and a paucity of astrocytomas.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18159977.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


31. Yue WY, Yu SH, Zhao SG, Chen ZP: Molecular markers relating to malignant progression in Grade II astrocytoma. J Neurosurg; 2009 Apr;110(4):709-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular markers relating to malignant progression in Grade II astrocytoma.
  • OBJECT: Astrocytoma may progress rapidly or remain stable for many years.
  • To clarify whether molecular characteristics could be prognostic factors, several cell cycling-associated molecular alterations in the diffuse astrocytoma have been investigated.
  • METHODS: Thirty-three patients in whom WHO Grade II astrocytoma had been initially diagnosed were assigned to 1 of 3 groups.
  • Group 1 consisted of 10 patients with malignant progression; the tumor had recurred within 5 years and histological analysis had confirmed that the tumor progressed to Grade III or IV.
  • Group 2 consisted of 10 patients in whom there was no malignant progression; the tumor recurred within 5 years, but histological analysis confirmed that the tumor remained at Grade II.
  • Group 3 consisted of 13 patients who did not experience recurrence within 5 years.
  • Expression of Ki 67, TP53, p27, and p21 was examined using immunohistochemical analysis for the tumor samples obtained during the first and second (in recurrent cases) surgeries.
  • CONCLUSIONS: Overexpression of TP53, TP53 mutation, and Ki 67 labeling index could be molecular markers in astrocytomas predicting malignant progression.
  • [MeSH-major] Astrocytoma / chemistry. Astrocytoma / pathology. Biomarkers, Tumor / analysis. Brain Neoplasms / chemistry. Brain Neoplasms / pathology. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Ki-67 Antigen / analysis. Proliferating Cell Nuclear Antigen / analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Adult. Base Sequence. Disease Progression. Female. Humans. Immunohistochemistry. Male. Neoplasm Recurrence, Local. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19025355.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53; 0 / p27 antigen
  •  go-up   go-down


32. Klase D, Gottschalk S, Reusche E, Hagel C, Goebel E, Tronnier V, Giese A: Lumbosacral glioblastoma and leptomeningeal gliomatosis complicating the course of a cervicothoracic astrocytoma WHO grade II. Childs Nerv Syst; 2007 Aug;23(8):907-12
Genetic Alliance. consumer health - Glioblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lumbosacral glioblastoma and leptomeningeal gliomatosis complicating the course of a cervicothoracic astrocytoma WHO grade II.
  • CASE REPORT: The reported female patient underwent sub-total resection of an intra-medullary cervicothoracic astrocytoma classified as WHO grade II in 1984 at the age of 18 months and received local irradiation.
  • DISCUSSION AND CONCLUSION: Anaplastic progression and dissemination of spinal astrocytomas even two decades after initial diagnosis and treatment are rare.
  • [MeSH-major] Astrocytoma / complications. Glioblastoma / complications. Meningeal Neoplasms / complications. Spinal Cord Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 1987;3(2):89-92 [3040249.001]
  • [Cites] Pediatr Blood Cancer. 2004 Nov;43(6):629-32 [15390309.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2001 Feb;70(2):256-8 [11160482.001]
  • [Cites] Neurosurg Clin N Am. 2001 Oct;12(4):775-97, ix [11524298.001]
  • [Cites] J Neurosurg. 2000 Oct;93(2 Suppl):183-93 [11012047.001]
  • [Cites] Neurosurgery. 1989 Dec;25(6):855-9 [2601814.001]
  • [Cites] Neurosurgery. 1994 Jan;34(1):68-78 [8121571.001]
  • [Cites] J Neurosurg. 1995 Apr;82(4):536-47 [7897512.001]
  • [Cites] Childs Nerv Syst. 1997 Jul;13(7):375-82 [9298273.001]
  • [Cites] J Neurooncol. 2003 Jul;63(3):305-12 [12892238.001]
  • [Cites] J Neurooncol. 2000 May;47(3):219-24 [11016738.001]
  • [Cites] Acta Neurochir (Wien). 1993;120(1-2):59-65 [7679540.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1060-71 [16373081.001]
  • [Cites] J Neurosurg. 1990 Apr;72 (4):523-32 [2319309.001]
  • [Cites] J Neurosurg. 1996 Dec;85(6):1036-43 [8929492.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):704-10 [11597812.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1624-36 [12697889.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):227-35 [12675316.001]
  • (PMID = 17440736.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


33. Jang SY, Kong MH, Song KY, Frazee JG: Intracranial Metastases of Cervical Intramedullary Low-Grade Astrocytoma without Malignant Transformation in Adult. J Korean Neurosurg Soc; 2009 Jun;45(6):381-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial Metastases of Cervical Intramedullary Low-Grade Astrocytoma without Malignant Transformation in Adult.
  • The first case of intracranial metastases of a cervical intramedullary low-grade astrocytoma without malignant transformation in adult is presented in this report.
  • Seven years ago, a 45 year-old male patient underwent biopsy to confirm pathologic characteristics and received craniocervical radiation and chemotherapy for a grade II astrocytoma in the cervical spinal cord.
  • The tumor at the cervical and brain lesions was classified as an astrocytoma (WHO grade II).
  • When a patient with low-grade astrocytoma in the spinal cord has new cranial symptoms after surgery, radiaton, and chemotherapy, the possibility of its metastasis should be suspected because it can spread to the intracranial cavity even without malignant transformation as shown in this case.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2000 Dec;50(3):239-43 [11263503.001]
  • [Cites] J Clin Neurosci. 2001 Jul;8(4):374-7 [11437586.001]
  • [Cites] Spinal Cord. 2006 Dec;44(12):740-5 [16670687.001]
  • [Cites] Childs Nerv Syst. 2005 Jun;21(6):477-81 [15378329.001]
  • [Cites] Neurosurgery. 2005;56(1):191 [15617606.001]
  • [Cites] Med Pediatr Oncol. 1997 Dec;29(6):560-2 [9324344.001]
  • [Cites] Neurosurgery. 1997 Jan;40(1):141-51 [8971836.001]
  • [Cites] J Neurooncol. 1995;25(3):245-50 [8592175.001]
  • [Cites] J Neurosurg. 1995 Sep;83(3):480-5 [7666226.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):590-5 [7674006.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):67-71 [7782852.001]
  • [Cites] J Neurooncol. 1994;18(1):49-52 [8057134.001]
  • [Cites] Neurol Med Chir (Tokyo). 1992 May;32(5):281-4 [1378944.001]
  • [Cites] J Neurosurg. 1992 Sep;77(3):355-9 [1506881.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):295-300 [3392575.001]
  • [Cites] Cancer. 1982 Aug 15;50(4):732-5 [7093908.001]
  • [Cites] Br J Surg. 1975 Feb;62(2):92-5 [1115920.001]
  • [Cites] Pediatr Blood Cancer. 2004 Nov;43(6):629-32 [15390309.001]
  • [Cites] Childs Nerv Syst. 2004 Feb;20(2):114-8 [14762681.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):554-61 [12879473.001]
  • [Cites] Curr Opin Neurol. 2001 Dec;14(6):679-82 [11723373.001]
  • [Cites] Surg Neurol. 2001 Jul;56(1):39-41 [11546571.001]
  • [Cites] J Neurosurg. 2006 Dec;105(6 Suppl):508-14 [17184088.001]
  • (PMID = 19609424.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2711238
  • [Keywords] NOTNLM ; Astrocytoma / Cranial metastases / Intramedullary / Spinal cord tumor
  •  go-up   go-down


34. Watanabe Y, Yamasaki F, Kajiwara Y, Saito T, Nishimoto T, Bartholomeusz C, Ueno NT, Sugiyama K, Kurisu K: Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis. J Neurooncol; 2010 Dec;100(3):449-57
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis.
  • Despite its many important roles, the clinical significance of PEA-15 expression levels in astrocytic tumors has yet to be properly defined.
  • We studied the PEA-15 expression pattern of 65 patients [diagnosed according to World Health Organization (WHO) criteria] with diffuse astrocytoma (WHO grade II), anaplastic astrocytoma (grade III), and glioblastoma (grade IV).
  • PEA-15 expression levels were immunohistochemically measured and categorized as no, low, or high expression.
  • Twenty-three (35.4%) and 42 (64.6%) tumors expressed low and high PEA-15 levels, respectively.
  • In grade II astrocytoma (diffuse astrocytoma) and grade III astrocytoma (anaplastic astrocytoma), 100% and 88.9% of patients expressed high PEA-15 levels, respectively, while a smaller number (50%) of patients with grade IV astrocytoma (glioblastoma) expressed high PEA-15 levels.
  • PEA-15 expression level was inversely associated with WHO grade (P = 0.0006).
  • Next, we evaluated prognosis and PEA-15 expression levels in 43 patients with high-grade astrocytomas based on the following parameters: age, gender, WHO grade, surgical resection extent, MIB-1 labeling index (LI), and PEA-15 expression level.
  • Multivariable analyses revealed that high PEA-15 expression level displayed a significant correlation with longer overall survival (OS) in high-grade astrocytomas (P = 0.0024).
  • In conclusion, PEA-15 expression level was inversely associated with WHO grade and may serve as an important prognostic factor for high-grade astrocytomas.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / metabolism. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Phosphoproteins / metabolism. Statistics as Topic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Health Statistics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Nov 15;62(10):2152-65 [3179928.001]
  • [Cites] J Neurosci. 1999 Oct 1;19(19):8244-51 [10493725.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25020-5 [11976344.001]
  • [Cites] Radiother Oncol. 2007 Dec;85(3):371-8 [18035440.001]
  • [Cites] Mol Cancer Ther. 2008 May;7(5):1013-24 [18445660.001]
  • [Cites] Oncogene. 2005 Oct 27;24(47):7012-21 [16044159.001]
  • [Cites] Oncogene. 2008 Feb 14;27(8):1155-66 [17700518.001]
  • [Cites] Mol Biol Cell. 2006 Dec;17(12):5141-52 [16987961.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(11):5005-15 [15143191.001]
  • [Cites] J Neurochem. 1998 Sep;71(3):1307-14 [9721757.001]
  • [Cites] Lancet Oncol. 2005 May;6(5):322-7 [15863380.001]
  • [Cites] Mol Cell Biol. 2003 Jul;23(13):4511-21 [12808093.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1162-70 [11221847.001]
  • [Cites] Biochem J. 2005 Sep 15;390(Pt 3):729-35 [15916534.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1536-44 [17308092.001]
  • [Cites] Oncogene. 1999 Aug 5;18(31):4409-15 [10442631.001]
  • [Cites] J Cell Mol Med. 2008 Dec;12(6A):2416-26 [18284607.001]
  • [Cites] Dev Cell. 2001 Aug;1(2):239-50 [11702783.001]
  • [Cites] Mol Biol Cell. 2005 Aug;16(8):3552-61 [15917297.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9302-10 [19010903.001]
  • [Cites] Neuropathology. 2008 Oct;28(5):507-15 [18410277.001]
  • [Cites] J Biol Chem. 1993 Mar 15;268(8):5911-20 [8449955.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12840-7 [14707138.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1491-9 [16452205.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1215-22 [17192900.001]
  • (PMID = 20455002.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Ki-67 Antigen; 0 / PEA15 protein, human; 0 / Phosphoproteins
  •  go-up   go-down


35. Pareés I, Alonso J, Rovira A, Martínez E, Montalban X: [Diffuse astrocytoma presenting as an optic-spinal syndrome]. Rev Neurol; 2009 Apr 1-15;48(7):354-6
Genetic Alliance. consumer health - Diffuse Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diffuse astrocytoma presenting as an optic-spinal syndrome].
  • [Transliterated title] Síndrome opticomedular como forma de presentación de un astrocitoma difuso.
  • INTRODUCTION: Spinal cord involvement is a rare presentation of grade II astrocytomas.
  • A patient with an optic-spinal syndrome due to a fibrillary astrocytoma is described.
  • A new MRI with spectroscopy revealed an infiltrative lesion involving the right frontal lobe, optic chiasm, internal capsule, brainstem and cervical spinal cord, which was suggestive of low-grade astrocytoma.
  • Brain biopsy confirmed the diagnosis of diffuse fibrillary astrocytoma.
  • [MeSH-major] Astrocytoma. Demyelinating Diseases. Optic Neuritis. Spinal Cord / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19319816.001).
  • [ISSN] 1576-6578
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Oligoclonal Bands
  •  go-up   go-down


36. Mursch K, Halatsch ME, Markakis E, Behnke-Mursch J: Intrinsic brainstem tumours in adults: results of microneurosurgical treatment of 16 consecutive patients. Br J Neurosurg; 2005 Apr;19(2):128-36

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Between 1986 and 1997, we operated upon 16 consecutive patients over 16 years of age (five female, 11 male, mean age 36.9 years) who were suffering from intrinsic tumours located in the pons and/or medulla oblongata.
  • Eight patients had from WHO grade II astrocytoma and a similar course as patients with higher-grade gliomas (n = 4).
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / diagnosis. Astrocytoma / mortality. Astrocytoma / surgery. Child. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16120515.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


37. Kreth S, Heyn J, Grau S, Kretzschmar HA, Egensperger R, Kreth FW: Identification of valid endogenous control genes for determining gene expression in human glioma. Neuro Oncol; 2010 Jun;12(6):570-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the current study, we tested 19 commonly used reference genes for their expression stability in human astrocytoma WHO Grade II, astrocytoma WHO Grade III, and glioblastoma (WHO Grade IV) both alone and compared with normal brain.
  • Even though Normfinder analyses revealed a large number of genes suitable for normalization in each of the tumor subgroups and across these groups, this number was drastically reduced after inclusion of normal brain into the analyses: Only GAPDH, IPO8, RPL13A, SDHA, and TBP were expected not to be differentially expressed; NormFinder analysis indicated favorable stability values for all of these genes, with TBP and IPO8 being the most stable ones.
  • These 5 genes represent different physiological pathways and may be regarded as universal reference genes applicable for accurate normalization of gene expression in human astrocytomas of different grades (WHO Grades II-IV) alone and compared with normal brain, thereby enabling longitudinally designed studies (eg, in astrocytoma before and after malignant transformation).
  • [MeSH-minor] Astrocytoma / diagnosis. Astrocytoma / genetics. Astrocytoma / metabolism. Glioblastoma / diagnosis. Glioblastoma / genetics. Glioblastoma / metabolism. Humans. Middle Aged

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Synapse. 2008 Apr;62(4):302-9 [18241047.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):1933-42 [17763848.001]
  • [Cites] Cancer. 2008 Apr 1;112(7):1575-84 [18260157.001]
  • [Cites] Cancer Cell. 2008 Apr;13(4):355-64 [18394558.001]
  • [Cites] Cancer. 2008 May 15;112(10):2258-66 [18327814.001]
  • [Cites] Nat Protoc. 2008;3(6):1101-8 [18546601.001]
  • [Cites] BMC Mol Biol. 2008;9:53 [18505597.001]
  • [Cites] Int J Cancer. 2008 Aug 15;123(4):787-92 [18508317.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):492-507 [18669428.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Sep;134(9):979-86 [18317805.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Anal Biochem. 2002 Oct 15;309(2):293-300 [12413463.001]
  • [Cites] Neurosci Lett. 2003 Mar 13;339(1):62-6 [12618301.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5245-50 [15289330.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Mar;87(5):1663-7 [1689846.001]
  • [Cites] Genes Immun. 2005 Jun;6(4):279-84 [15815687.001]
  • [Cites] J Pathol. 2008 Oct;216(2):218-24 [18729076.001]
  • [Cites] BMC Mol Biol. 2008;9:79 [18786244.001]
  • [Cites] Mol Cell Proteomics. 2008 Oct;7(10):1810-23 [18421009.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8657-60 [18974105.001]
  • [Cites] BMC Mol Biol. 2008;9:102 [19014500.001]
  • [Cites] Methods Mol Biol. 2009;479:61-77 [19083175.001]
  • [Cites] J Neurosurg. 2009 Jan;110(1):147-55 [18991494.001]
  • [Cites] Brain Pathol. 2009 Apr;19(2):279-92 [18616639.001]
  • [Cites] BMC Mol Biol. 2009;10:17 [19257903.001]
  • [Cites] Int J Cancer. 2009 Aug 1;125(3):603-11 [19405126.001]
  • [Cites] Neuro Oncol. 2009 Aug;11(4):348-56 [19224763.001]
  • [Cites] Biotechniques. 2005 Jul;39(1):75-85 [16060372.001]
  • [Cites] Anal Biochem. 2005 Sep 1;344(1):141-3 [16054107.001]
  • [Cites] J Nucl Med. 2006 Mar;47(3):393-403 [16513607.001]
  • [Cites] Mol Aspects Med. 2006 Apr-Jun;27(2-3):95-125 [16460794.001]
  • [Cites] Acta Neuropathol. 2006 May;111(5):483-8 [16596424.001]
  • [Cites] Nat Protoc. 2006;1(3):1559-82 [17406449.001]
  • [Cites] Brain Pathol. 2007 Jan;17(1):5-10 [17493032.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2458-64 [17691113.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):1945-52 [18339876.001]
  • (PMID = 20511187.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2940642
  •  go-up   go-down


38. López JI, Scheithauer BW, Giannini C, Torp SH: Concurrent solitary fibrous tumor and low-grade fibrillary astrocytoma of the cerebellum. Clin Neuropathol; 2010 Sep-Oct;29(5):301-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent solitary fibrous tumor and low-grade fibrillary astrocytoma of the cerebellum.
  • OBJECTIVE: We report the clinicopathologic features of a solitary fibrous tumor (SFT) having undergone malignant transformation and being intimately associated with a WHO Grade II astrocytoma.
  • Resection was initially employed and the SIOP protocol employing vincristine and carboplatin was applied upon tumor recurrence.
  • CONCLUSION: The biologic basis for the association of SFT and astrocytoma is unknown.
  • The complex lesion differs substantially from WHO Grade IV gliosarcoma and from gliofibroma, lesions in which the disparate elements are linked by metaplasia.
  • Indeed, it may represent a collision tumor.
  • Lastly, induction of the glioma by the solitary fibrous tumor, a mechanism invoked to explain the poorly understood "sarcoglioma," deserves consideration.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / epidemiology. Cerebellar Neoplasms / diagnosis. Cerebellar Neoplasms / epidemiology. Solitary Fibrous Tumors / diagnosis. Solitary Fibrous Tumors / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20860893.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


39. Shuangshoti S, Thorner PS, Ruangvejvorachai P, Saha B, Groshen S, Taylor CR, Malhotra S, Imam SA: J1-31 protein expression in astrocytes and astrocytomas. Neuropathology; 2009 Oct;29(5):521-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] J1-31 protein expression in astrocytes and astrocytomas.
  • J1-31 is one of the astrocytic proteins, the expression of which has not been evaluated in astrocytomas.
  • In the present study, we studied the expression of J1-31 protein in astrocytes and astrocytomas in comparison with GFAP, p53 and Ki-67.
  • Materials consisted of formalin-fixed paraffin-embedded tissue specimens that included five cases of normal brain, 17 of gliosis, 15 of pilocytic astrocytoma (WHO grade I), 26 of low-grade diffuse astrocytoma (WHO grade II), four of anaplastic astrocytoma (WHO grade III), and eight of glioblastoma (WHO grade IV).
  • The antibody showed reactivity with tumor cells in 12/15 (80%) cases of pilocytic astrocytoma, although intensity of staining was generally weaker and more focal than observed in reactive gliosis.
  • J1-31-positive tumor cells were detected in only 9/26 (35%) cases of the low-grade diffuse astrocytoma and none of the cases of anaplastic astrocytoma and glioblastoma.
  • Increasing Ki-67 indices paralleled advancing tumor grades. p53 protein was expressed more commonly in infiltrating astrocytomas compared to pilocytic astrocytoma.
  • In conclusion, down-regulation of J1-31 expression correlates with advancing grade of astrocytomas.
  • The result suggests this protein plays some role in astrocytes that is progressively lost in malignant progression.
  • The anti-J1-31 antibody may help further our understanding of astrocytes in disease and may be useful as an aid in the pathologic diagnosis of astrocytic lesions.
  • [MeSH-major] Astrocytes / metabolism. Astrocytoma / metabolism. Nerve Tissue Proteins / metabolism
  • [MeSH-minor] Cytoplasm / metabolism. Down-Regulation. Glial Fibrillary Acidic Protein / metabolism. Glioblastoma / metabolism. Gliosis / metabolism. Humans. Ki-67 Antigen / metabolism. Neoplasm Staging. Tumor Suppressor Protein p53 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19019178.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / J1-31 protein, human; 0 / Ki-67 Antigen; 0 / Nerve Tissue Proteins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


40. Yap L, Crooks D, Warnke P: Low grade astrocytoma of the pituitary stalk. Acta Neurochir (Wien); 2007 Mar;149(3):307-11; discussion 311-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low grade astrocytoma of the pituitary stalk.
  • A case of low grade astrocytoma (WHO grade II) localised in the pituitary stalk is reported in a 46 year old female who presented with central diabetes insipidus.
  • [MeSH-major] Astrocytoma / surgery. Pituitary Neoplasms / surgery
  • [MeSH-minor] Biopsy. Combined Modality Therapy. Female. Follow-Up Studies. Glial Fibrillary Acidic Protein / analysis. Humans. Hypophysectomy. Ki-67 Antigen / analysis. Magnetic Resonance Imaging. Middle Aged. Neoplasm Invasiveness. Optic Nerve / pathology. Pituitary Gland / pathology. Pituitary Irradiation. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17242848.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen
  •  go-up   go-down


41. Garcés-Ambrossi GL, McGirt MJ, Mehta VA, Sciubba DM, Witham TF, Bydon A, Wolinksy JP, Jallo GI, Gokaslan ZL: Factors associated with progression-free survival and long-term neurological outcome after resection of intramedullary spinal cord tumors: analysis of 101 consecutive cases. J Neurosurg Spine; 2009 Nov;11(5):591-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, factors associated with tumor resectability, tumor recurrence, and long-term neurological outcome are poorly understood.
  • Pathological type included ependymoma in 51 cases, hemangioblastoma in 15, pilocytic astrocytoma in 16, WHO Grade II astrocytoma in 10, and malignant astrocytoma in 9.
  • Independent of histological tumor type, an intraoperatively identifiable tumor plane (OR 25.3, p < 0.0001) and decreasing tumor size (OR 1.2, p = 0.05) were associated with GTR.
  • In 31 patients (31%) tumor progression developed by last follow-up (mean 19 months).
  • Tumor histology (p < 0.0001) and the presence of an intraoperatively identified tumor plane (hazard ratio [HR] 0.44, p = 0.027) correlated with improved PFS.
  • A GTR resulted in improved PFS for hemangioblastoma (HR 0.004, p = 0.04) and ependymoma (HR 0.2, p = 0.02), but not astrocytoma.
  • The presence of an identifiable tumor plane (HR 3.1, p = 0.0004) and improvement in neurological symptoms before discharge (HR 2.3, p = 0.004) were associated with overall neurological improvement by last follow-up (mean 19 months).
  • A GTR should be attempted for ependymoma and hemangioblastoma, but it may not affect PFS for astrocytoma.
  • For all tumors, the intraoperative finding of a clear tumor plane of resection carries positive prognostic significance across all pathological types.
  • [MeSH-minor] Adolescent. Adult. Astrocytoma / mortality. Astrocytoma / pathology. Astrocytoma / surgery. Disease Progression. Disease-Free Survival. Ependymoma / mortality. Ependymoma / pathology. Ependymoma / surgery. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Predictive Value of Tests. Prognosis. Recovery of Function. Retrospective Studies. Risk Factors. Therapeutics. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg Spine. 2009 Nov;11(5):588-9; discussion 590 [19929362.001]
  • (PMID = 19929363.001).
  • [ISSN] 1547-5646
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Weber MA, Vogt-Schaden M, Bossert O, Giesel FL, Kauczor HU, Essig M: [MR perfusion and spectroscopic imaging in WHO grade II astrocytomas]. Radiologe; 2007 Sep;47(9):812-8
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MR perfusion and spectroscopic imaging in WHO grade II astrocytomas].
  • [Transliterated title] MR-Perfusions- und spektroskopische Bildgebung bei WHO-Grad-II-Astrozytomen.
  • BACKGROUND: This study evaluates whether MR perfusion imaging and spectroscopic imaging (MRSI) can depict anaplastic areas in WHO grade II astrocytomas, whether these areas are co-localized, and whether the prognosis can be better predicted.
  • MATERIAL AND METHODS: Fifteen patients (nine female, six male, aged 42+/-14 years) with WHO grade II astrocytomas but without preceding radio- or chemotherapy were examined every 3 months with MR perfusion imaging and MRSI (mean follow-up 18 months).
  • Using a region of interest analysis, the regional relative cerebral blood volume (rrCBV) and blood flow (rrCBF) were measured in tumor tissue.
  • In six patients, the tumor showed progression and contrast-enhancement.
  • The progressing tumors had already had higher perfusion (rrCBF 2.1+/-1.4; rrCBV 1.9+/-1.1) parameters than the stable astrocytomas (rrCBF 1.2+/-0.6, p=0.01; rrCBV 1.4+/-0.8, p=0.05) at first examination.
  • However, the Cho/NAA and Cho/Cr ratios only tended to be higher than in stable astrocytomas (Cho/NAA 2.4+/-1.0 vs. 2.0+/-1.5, p=0.23; Cho/Cr 1.7+/-0.6 vs. 1.4+/-0.5, p=0.06).
  • CONCLUSIONS: MR perfusion imaging can depict anaplastic areas in WHO grade II astrocytomas earlier than conventional MRI and thus enables a better prediction of prognosis.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2001 Aug;22(7):1316-24 [11498420.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):996-1003 [14575830.001]
  • [Cites] Eur Radiol. 2004 Apr;14(4):679-85 [14610685.001]
  • [Cites] Australas Radiol. 2001 Nov;45(4):472-82 [11903181.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Feb;25(2):214-21 [14970020.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 [10200775.001]
  • [Cites] Radiology. 2002 Apr;223(1):11-29 [11930044.001]
  • [Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1479-86 [9843274.001]
  • [Cites] Magn Reson Med. 1996 Nov;36(5):715-25 [8916022.001]
  • [Cites] J Neurosurg. 1993 Oct;79(4):533-6 [8410222.001]
  • [Cites] Neuroradiology. 2005 Nov;47(11):826-34 [16142479.001]
  • [Cites] Radiology. 2006 Feb;238(2):658-67 [16396838.001]
  • [Cites] Neurosci Lett. 2003 May 22;342(3):163-6 [12757890.001]
  • [Cites] Radiologe. 2000 Oct;40(10):849-57 [11103407.001]
  • [Cites] Magn Reson Med. 1996 Nov;36(5):726-36 [8916023.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):478-82 [11567824.001]
  • [Cites] Invest Radiol. 2004 May;39(5):277-87 [15087722.001]
  • [Cites] Surg Neurol. 1998 Apr;49(4):436-40 [9537664.001]
  • [Cites] Radiology. 1994 Apr;191(1):41-51 [8134596.001]
  • [Cites] Rofo. 1999 Jul;171(1):38-43 [10464503.001]
  • [Cites] Radiology. 2003 Aug;228(2):523-32 [12819338.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] Lancet Neurol. 2005 Nov;4(11):760-70 [16239183.001]
  • [Cites] Nat Med. 1996 Mar;2(3):323-5 [8612232.001]
  • [Cites] Radiologe. 2002 Nov;42(11):909-15 [12458444.001]
  • [Cites] Radiologe. 2005 Jul;45(7):618-32 [15098092.001]
  • (PMID = 16924439.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


43. Essig M, Giesel F, Stieltjes B, Weber MA: [Functional imaging for brain tumors (perfusion, DTI and MR spectroscopy)]. Radiologe; 2007 Jun;47(6):513-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In cases of brain tumor, PWI aids in grading and better differentiation in diagnostics as well as for pre-therapeutic planning.
  • PWI allows better estimates of biological activity and aggressiveness in low grade brain tumors, and in the case of WHO grade II astrocytoma showing anaplasically transformed tumor areas, allows more rapid visu-alization and a better prediction of the course of the disease than conventional MRI diagnostics.
  • Diffusion imaging can be used for describing brain tumors, for evaluating contralateral involvement and the course of the nerve fibers near the tumor.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Diffusion Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiologe. 2005 Apr;45(4):327-39 [15800783.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Oct;21(9):1603-10 [11039338.001]
  • [Cites] Neuroradiology. 2006 Apr;48 Suppl 1:3-8 [16699847.001]
  • [Cites] Radiologe. 2004 Jul;44(7):723-32; quiz 733-4 [15241598.001]
  • [Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1479-86 [9843274.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):478-82 [11567824.001]
  • [Cites] Radiology. 1994 Dec;193(3):637-41 [7972800.001]
  • [Cites] Rofo. 1999 Jul;171(1):38-43 [10464503.001]
  • [Cites] Radiologe. 2004 Jan;44(1):81-95; quiz 96-7 [14997867.001]
  • [Cites] Radiologe. 2004 Feb;44(2):164-73 [14991136.001]
  • [Cites] Neuroimage. 2006 Jun;31(2):531-42 [16478665.001]
  • [Cites] Radiologe. 2003 Aug;43(8):661-4 [14504767.001]
  • [Cites] Radiology. 1990 Nov;177(2):401-5 [2217776.001]
  • [Cites] Radiologe. 2002 Nov;42(11):909-15 [12458444.001]
  • [Cites] Radiologe. 2005 Jul;45(7):618-32 [15098092.001]
  • [Cites] Nervenarzt. 2005 Apr;76(4):403-17 [15349736.001]
  • (PMID = 17505814.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 21
  •  go-up   go-down


44. Nakamura M, Tsuji O, Fujiyoshi K, Watanabe K, Tsuji T, Ishii K, Matsumoto M, Toyama Y, Chiba K: Cordotomy for patients with thoracic malignant astrocytoma. J Neurosurg Spine; 2010 Oct;13(4):418-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cordotomy for patients with thoracic malignant astrocytoma.
  • OBJECT: The optimal management of malignant astrocytomas remains controversial, and the prognosis of these lesions has been dismal regardless of the administered treatment.
  • In this study the authors investigated the surgical outcomes of cordotomy in patients with thoracic malignant astrocytomas to determine the effectiveness of this procedure.
  • METHODS: Cordotomy was performed in 5 patients with glioblastoma multiforme (GBM) and 2 with anaplastic astrocytoma (AA).
  • In the 2 patients with GBM, cordotomy was performed 2 and 3 weeks after a partial tumor resection.
  • In the 2 patients with AA, the initial treatment consisted of partial tumor resection and subtotal resection combined with radiotherapy, and rostral tumor growth and progressive paralysis necessitated cordotomy 2 and 28 months later.
  • One patient with a secondary GBM underwent cordotomy; the GBM developed 1 year after subtotal resection and radiotherapy for a WHO Grade II astrocytoma.
  • In patients with thoracic GBM, even if paralysis is incomplete, cordotomy should be performed before the tumor disseminates through the CSF.
  • If the tumor persists, radiotherapy and chemotherapy are indicated, and cordotomy should be reserved for lesions growing progressively after such second-line treatments.
  • [MeSH-major] Astrocytoma / surgery. Cordotomy. Thoracic Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Disease Progression. Encephalitis / etiology. Female. Glioblastoma / complications. Glioblastoma / pathology. Glioblastoma / surgery. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Pain, Postoperative. Paraplegia / etiology. Paraplegia / surgery. Prognosis. Radiotherapy, Adjuvant. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20887138.001).
  • [ISSN] 1547-5646
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Nozaki M, Ohnishi A, Fujimaki T, Nagashima K, Cho K, Sawamura Y: Congenital gemistocytic astrocytoma in a fetus. Childs Nerv Syst; 2006 Feb;22(2):168-71
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital gemistocytic astrocytoma in a fetus.
  • This report presents a case of a congenital gemistocytic astrocytoma diagnosed by antenatal intrauterine ultrasound.
  • The patient was delivered by cesarean section and a total excision of the hemorrhagic tumor was carried out on the third day of his life.
  • The histological study revealed gemistocytic astrocytoma (WHO grade II).
  • Ten months after his birth, a recurrent tumor was depicted on follow-up MRI.
  • The second total excision of the recurrent tumor and chemotherapy using cisplatin and vincristine were performed.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Fetus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 1994 Mar;10(2):104-10 [8033157.001]
  • [Cites] AJR Am J Roentgenol. 1990 Sep;155(3):587-93 [2167004.001]
  • [Cites] J Neuropathol Exp Neurol. 1964 Apr;23:280-92 [14137675.001]
  • [Cites] Childs Nerv Syst. 1997 Oct;13(10 ):556-9 [9403206.001]
  • [Cites] Neuroradiology. 1982;23 (5):267-74 [7121821.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(12):1213-22 [9932120.001]
  • [Cites] J Neurosurg. 1988 Oct;69(4):604-9 [3047342.001]
  • [Cites] Lab Invest. 1997 Feb;76(2):277-84 [9042164.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):399-406 [1993905.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):227-8 [15193038.001]
  • [Cites] Surg Neurol. 1984 Jun;21(6):597-609 [6372141.001]
  • [Cites] P R Health Sci J. 2002 Mar;21(1):43-5 [12013680.001]
  • [Cites] Fetal Diagn Ther. 2003 May-Jun;18(3):137-9 [12711864.001]
  • [Cites] Childs Brain. 1981;8(4):263-70 [7261690.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):171-8 [10758320.001]
  • [Cites] Med Pediatr Oncol. 1994;22(5):309-17 [8127254.001]
  • [Cites] Childs Nerv Syst. 1999 Apr;15(4):197-201 [10361971.001]
  • [Cites] Cancer. 1985 Sep 1;56(5):1106-11 [2990664.001]
  • [Cites] Pediatr Neurosurg. 2002 Nov;37(5):267-70 [12411720.001]
  • [Cites] Childs Nerv Syst. 2000 Aug;16(8):501-2 [11007501.001]
  • [Cites] J Neurosurg. 1951 May;8(3):315-9 [14841542.001]
  • [Cites] J Neurooncol. 1998 May;37(3):263-70 [9524084.001]
  • [Cites] Ultrasound Obstet Gynecol. 1995 Jan;5(1):63-6 [7850596.001]
  • (PMID = 15864706.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Synaptophysin
  •  go-up   go-down


46. Malhan P, Husain N, Bhalla S, Gupta RK, Husain M: Proliferating cell nuclear antigen, p53 and micro vessel density: Grade II vs. Grade III astrocytoma. Indian J Pathol Microbiol; 2010 Jan-Mar;53(1):20-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferating cell nuclear antigen, p53 and micro vessel density: Grade II vs. Grade III astrocytoma.
  • Histological classification and grading are prime procedures in the management of patients with astrocytoma, providing vital data for therapeutic decision making and prognostication.
  • However, it has limitations in assessing biological tumor behavior.
  • This study was carried out to compare proliferative indices using proliferating cell nuclear antigen (PCNA), extent of p53 expression and micro vessel morphometric parameters in patients with low grade and anaplastic astrocytoma.
  • Twenty-five patients, each of grade II and grade III astrocytoma were evaluated using monoclonal antibodies to PCNA, p53 protein and factor VIII related antigen.
  • Patients with grade III astrocytoma had higher PCNA and p53 labeling indices as compared with grade II astrocytoma (29.14 plus/minus 9.87% vs. 16.84 plus/minus 6.57%, p 0.001; 18.18 plus/minus 6.14% vs. 6.14 plus/minus 7.23%, p 0.001, respectively).
  • Micro vessel percentage area of patients with grade III astrocytoma was also (4.26 plus/minus 3.70 vs. 1.05 plus/minus 0.56, p 0.001), higher along with other micro vessel morphometric parameters.
  • Discordance between histology and one or more IHC parameters was seen in 5/25 (20%) of patients with grade III astrocytoma and 9/25 (36%) of patients with grade II disease.
  • Increased proliferative fraction, genetic alterations and neovascularization mark biological aggressiveness in astrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / pathology. Neovascularization, Pathologic. Proliferating Cell Nuclear Antigen / analysis. Tumor Suppressor Protein p53 / analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20090216.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


47. Srivastava T, Chosdol K, Chattopadhayay P, Sarkar C, Mahapatra AK, Sinha S: Frequent loss of heterozygosity encompassing the hMLH1 locus in low grade astrocytic tumors. J Neurooncol; 2007 Feb;81(3):249-55
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent loss of heterozygosity encompassing the hMLH1 locus in low grade astrocytic tumors.
  • In astrocytic tumors, the heterozygosity status of these genes with reference to tumor grade has not yet been determined.
  • We have analyzed the heterozygosity status and locus specific instability in 43 glial tumors comprising 22 low grades diffuses astrocytoma (WHO Grade II, DA) and 21 glioblastoma multiforme (Grade IV GBM) using 10 microsatellite markers at 2p and 3p to elucidate the involvement of these loci in astrocytic tumorigenesis.
  • Our results suggest that in the astrocytic tumorigenesis, LOH at the hMLH1 gene locus is an early event in tumorigenesis.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Carrier Proteins / genetics. Loss of Heterozygosity. Nuclear Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Neuropathol. 2003 Jul-Aug;22(4):180-6 [12908754.001]
  • [Cites] BMC Cancer. 2004 Sep 14;4:65 [15367334.001]
  • [Cites] Scand J Gastroenterol. 2004 Nov;39(11):1134-40 [15545173.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):776-81 [12552134.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Aug;153(1):32-8 [15325091.001]
  • [Cites] Nat Genet. 2003 Mar;33 Suppl:238-44 [12610533.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jul 15;144(2):156-64 [12850379.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] Int J Cancer. 2002 Sep 20;101(3):248-52 [12209975.001]
  • [Cites] Int J Oncol. 2005 Jan;26(1):201-10 [15586241.001]
  • [Cites] Oncogene. 2000 Aug 17;19(35):4079-83 [10962567.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Feb;131(2):87-93 [15672285.001]
  • [Cites] Oncogene. 2002 Oct 7;21(45):6915-35 [12362274.001]
  • [Cites] Clin Cancer Res. 1998 Jan;4(1):1-6 [9516945.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1539-44 [15746058.001]
  • [Cites] Am J Hum Genet. 2003 Nov;73(5):1157-61 [14526391.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1761-7 [11912152.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1035-8 [9067265.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):683-94 [10487825.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):119-30 [11438460.001]
  • [Cites] J Neurooncol. 2000 May;48(1):1-12 [11026691.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2124-8 [11280776.001]
  • [Cites] Genes Dev. 2000 Apr 15;14(8):927-39 [10783165.001]
  • [Cites] Virchows Arch. 2004 Nov;445(5):491-7 [15205952.001]
  • [Cites] Cancer Res. 1996 Nov 1;56(21):4836-40 [8895729.001]
  • [Cites] Br J Cancer. 1996 Nov;74(10 ):1514-7 [8932328.001]
  • [Cites] Int J Cancer. 2003 Feb 20;103(5):636-41 [12494471.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):51-7 [15015769.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):600-7 [10091733.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 May;61(5):396-402 [12025942.001]
  • [Cites] Oncogene. 1997 Aug 14;15(7):871-4 [9266974.001]
  • [Cites] J Neurosurg. 2004 Oct;101(4):653-8 [15481721.001]
  • [Cites] Genetics. 2005 May;170(1):355-63 [15781695.001]
  • (PMID = 17019533.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / DNA Primers; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.3 / MutL Protein Homolog 1
  •  go-up   go-down


48. Iwami K, Arima T, Ooka F, Asai T, Tambara M, Takaoka T: [Bilateral thalamic glioma in an adult: a case report and review of the literature]. No Shinkei Geka; 2009 Mar;37(3):285-90
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of a 36-year-old woman who had a rare bilateral thalamic glioma (BTG).
  • Histological examination of the biopsy specimen identified diffuse astrocytoma (WHO grade II).
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Thalamus

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19306649.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 16
  •  go-up   go-down


49. Porto L, Kieslich M, Franz K, Lehrbecher T, Pilatus U, Hattingen E: Proton magnetic resonance spectroscopic imaging in pediatric low-grade gliomas. Brain Tumor Pathol; 2010 Oct;27(2):65-70
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proton magnetic resonance spectroscopic imaging in pediatric low-grade gliomas.
  • Our purpose was to investigate whether in vivo proton magnetic resonance spectroscopic imaging, using normalized concentrations of total choline (tCho) and total creatine (tCr), can differentiate between WHO grade I pilocytic astrocytoma (PA) and diffuse, fibrillary WHO grade II astrocytoma (DA) in children.
  • Data from 16 children with astrocytomas (11 children with PA and 5 children with DA) were evaluated retrospectively.
  • MRS was performed before treatment in all patients with histologically proven low-grade astrocytomas.
  • We concluded that choline as a single parameter is not reliable in the differential diagnosis of low-grade astrocytomas in children.
  • [MeSH-minor] Adolescent. Astrocytoma / diagnosis. Astrocytoma / metabolism. Astrocytoma / pathology. Brain / pathology. Child. Child, Preschool. Choline / metabolism. Creatine / metabolism. Diagnosis, Differential. Female. Humans. Infant. Infratentorial Neoplasms / metabolism. Infratentorial Neoplasms / pathology. Magnetic Resonance Spectroscopy. Male. Supratentorial Neoplasms / metabolism. Supratentorial Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. CREATINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21046307.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


50. Salunke P, Badhe P, Sharma A: Cerebellar glioblastoma multiforme with non-contiguous grade 2 astrocytoma of the temporal lobe in the same individual. Neurol India; 2010 Jul-Aug;58(4):651-3
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebellar glioblastoma multiforme with non-contiguous grade 2 astrocytoma of the temporal lobe in the same individual.
  • We report a unique occurrence of such a combination in a 50-year-old man who presented with features of elevated intracranial pressure, ataxia and vertigo.
  • Magnetic resonance imaging showed a diffuse non-enhancing lesion in the temporal lobe and insula and another non-contigous well defined enhancing lesion in the cerebellum.
  • Histopathology revealed grade II astrocytoma in the temporal lobe and glioblastoma multiforme in the cerebellum.
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Glioblastoma / complications. Temporal Lobe / pathology

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20739816.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


51. Hagemann C, Anacker J, Gerngras S, Kühnel S, Said HM, Patel R, Kämmerer U, Vordermark D, Roosen K, Vince GH: Expression analysis of the autosomal recessive primary microcephaly genes MCPH1 (microcephalin) and MCPH5 (ASPM, abnormal spindle-like, microcephaly associated) in human malignant gliomas. Oncol Rep; 2008 Aug;20(2):301-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression analysis of the autosomal recessive primary microcephaly genes MCPH1 (microcephalin) and MCPH5 (ASPM, abnormal spindle-like, microcephaly associated) in human malignant gliomas.
  • Both proteins are also involved in the regulation of tumor growth.
  • Glioblastomas are the most prevalent malignant brain tumors in adults, characterized by increased invasiveness, an aggressive local growth pattern and short survival periods of patients.
  • In this study, we analysed the expression of microcephalin mRNA and ASPM mRNA and protein in a panel of 15 glioblastomas and 15 astrocytoma WHO grade II by semi-quantitative RT-PCR, Western blotting and immunohistochemistry.
  • Whereas microcephalin expression did not seem to be altered during glioma development, there was a clear increase in ASPM mRNA and protein expression that corresponded with the WHO grade of the tumor.
  • [MeSH-minor] Blotting, Western. Cell Nucleus / metabolism. Genes, Recessive. Humans. Immunoenzyme Techniques. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Microcephaly.
  • Genetic Alliance. consumer health - Microcephaly, primary autosomal recessive.
  • Genetics Home Reference. consumer health - ASPM gene.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18636190.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ASPM protein, human; 0 / MCPH1 protein, human; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger
  •  go-up   go-down


52. Jung CS, Foerch C, Schänzer A, Heck A, Plate KH, Seifert V, Steinmetz H, Raabe A, Sitzer M: Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain; 2007 Dec;130(Pt 12):3336-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A serum marker for malignant cerebral astrocytomas could improve both differential diagnosis and clinical management of brain tumour patients.
  • To evaluate whether the serum concentration of glial fibrillary acidic protein (GFAP) may indicate glioblastoma multiforme (GBM) in patients with single supratentorial space-occupying lesions, we prospectively examined 50 consecutive patients with histologically proven GBM, World Health Organization (WHO) grade IV, 14 patients with anaplastic astrocytoma (WHO grade III), 4 patients with anaplastic oligodendroglioma, 13 patients with diffuse astrocytoma (WHO grade II), 17 patients with a single cerebral metastasis and 50 healthy controls.
  • [MeSH-major] Biomarkers, Tumor / blood. Brain Neoplasms / diagnosis. Glial Fibrillary Acidic Protein / blood. Glioblastoma / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Necrosis. Neoplasm Proteins / blood. Prospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998256.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Neoplasm Proteins
  •  go-up   go-down


53. Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, Pfister S, von Deimling A, Hartmann C: Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol; 2009 Sep;118(3):401-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.
  • Separation of pilocytic astrocytoma from diffuse astrocytomas frequently poses problems mostly related to small sample size.
  • Precise classification and grading are essential due to different therapeutic strategies prompted by diagnoses of pilocytic astrocytoma WHO grade I, diffuse astrocytomas WHO grade II or anaplastic astrocytoma WHO grade III.
  • Pilocytic astrocytomas carry a duplication at chromosome band 7q34 containing a BRAF-KIAA1549 gene fusion in the majority of cases.
  • IDH1 mutations are observed very frequently in adult astrocytomas and IDH2 mutations have been reported in some astrocytomas.
  • We examined a series of 120 astrocytomas including 70 pilocytic astrocytomas WHO grade I and 50 diffuse astrocytomas WHO grade II for both, BRAF-KIAA1549 fusion with a newly developed FISH assay and mutations in IDH1 and IDH2 by direct sequencing.
  • Pilocytic astrocytomas contained the BRAF fusion in 49 cases (70%) but neither IDH1 nor IDH2 mutations.
  • Astrocytomas WHO grade II exhibited IDH1 mutations in 38 cases (76%) but neither IDH2 mutations nor BRAF fusions.
  • Thus, combined molecular analysis of BRAF and IDH1 is a sensitive and highly specific approach to separate pilocytic astrocytoma from diffuse astrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Isocitrate Dehydrogenase / genetics. Proto-Oncogene Proteins B-raf / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mutation. Tissue Array Analysis


54. Reis C, Carneiro E, Fonseca J, Pereira P, Vaz R, Pinto R, Capelinha AF, Lopes JM, Salgado A: Epithelioid hemangioendothelioma and multiple thoraco-lumbar lateral meningoceles: two rare pathological entities in a patient with NF-1. Neuroradiology; 2005 Feb;47(2):165-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of a 31-year-old woman, with NF-1 and past history of right thalamic/peduncular astrocytoma WHO grade II, admitted to the Neurosurgery Department in December 2003 due to severe low back pain, irradiating to the left leg without a radicular pattern.

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Verh Dtsch Ges Pathol. 1998;82:99-111 [10095422.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Jun;81(2):173-4 [7621416.001]
  • [Cites] J Comput Assist Tomogr. 1991 Nov-Dec;15(6):1062-4 [1939761.001]
  • [Cites] Neuroradiology. 1995 Apr;37(3):195-7 [7603594.001]
  • [Cites] J Pediatr. 1994 Jul;125(1):63-6 [8021787.001]
  • [Cites] Surg Neurol. 1986 Oct;26(4):409-12 [3092383.001]
  • [Cites] Minerva Chir. 1992 Dec;47(23-24):1845-57 [1289762.001]
  • [Cites] Curr Treat Options Neurol. 2003 May;5(3):199-206 [12670408.001]
  • [Cites] Acta Pathol Jpn. 1986 Mar;36(3):459-69 [3087135.001]
  • [Cites] Clin Sci (Lond). 1995 May;88(5):581-5 [7614817.001]
  • [Cites] Arq Neuropsiquiatr. 2003 Sep;61(3A):677-81 [14513180.001]
  • [Cites] J Neurol Sci. 1970 Dec;11(6):501-35 [4992482.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2125-31 [9179058.001]
  • [Cites] Oncologist. 2000;5(6):477-85 [11110599.001]
  • [Cites] N Engl J Med. 1986 Apr 17;314(16):1010-5 [3083258.001]
  • [Cites] J Am Acad Dermatol. 1997 Oct;37(4):625-30 [9344204.001]
  • [Cites] Arch Neurol. 1998 Apr;55(4):500-5 [9561977.001]
  • [Cites] Neuroradiology. 1990;32(6):535 [2126846.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):363-74 [9130982.001]
  • [Cites] J Neurosurg. 1996 May;84(5):867-73 [8622163.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 Mar;19(3):541-6 [9541315.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Oct;17(9):1691-4 [8896624.001]
  • [Cites] Med Radiogr Photogr. 1974;50(1):2-15 [4214464.001]
  • [Cites] Med Clin (Barc). 2001 Sep 29;117(9):336-8 [11749906.001]
  • (PMID = 15688204.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


55. Bristol RE: Low-grade glial tumors: are they all the same? Semin Pediatr Neurol; 2009 Mar;16(1):23-6
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade glial tumors: are they all the same?
  • The most common diagnosis for supratentorial brain tumors in children is a form of low-grade glioma.
  • Even though the numbers of any given tumor type are small, the question has been raised as to whether different pathologies require different treatments.
  • We reviewed the published articles on treatment and outcomes for all pathologies included under the heading "low-grade glioma" to answer this question.
  • The only pathologic subgroups that may benefit from more aggressive up-front treatment are the grade II astrocytomas.
  • [MeSH-minor] Astrocytoma / diagnosis. Astrocytoma / therapy. Chemotherapy, Adjuvant. Child. Ganglioglioma / diagnosis. Ganglioglioma / therapy. Humans. Oligodendroglioma / diagnosis. Oligodendroglioma / therapy. Radiotherapy, Adjuvant. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19410153.001).
  • [ISSN] 1558-0776
  • [Journal-full-title] Seminars in pediatric neurology
  • [ISO-abbreviation] Semin Pediatr Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


56. Rauscher A, Sedlacik J, Fitzek C, Walter B, Hochstetter A, Kalff R, Kaiser WA, Reichenbach JR: High resolution susceptibility weighted MR-imaging of brain tumors during the application of a gaseous agent. Rofo; 2005 Aug;177(8):1065-9
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To employ a high resolution blood oxygenation level dependent (BOLD) method called susceptibility weighted imaging (SWI) together with the breathing of carbogen to investigate the response of cerebral tumors to this breathing gas and to assess tumor anatomy at high resolution.
  • METHODS: Five patients with cerebral tumors (four glioblastoma multiforme, one astrocytoma [WHO grade II]) were studied using a susceptibility weighted 3D gradient echo, first order velocity compensated sequence (TE = 45 ms, TR = 67 ms, alpha = 25 degrees , FOV = 256 x 192 x 64 mm(3), typical matrix = 512 x 192 x 64), on a 1.5 T MR scanner while they were breathing air and carbogen.
  • The astrocytoma displayed a signal decrease during carbogen breathing (- 4.1 +/- 0.1 % to - 6.8 +/- 0.3 % in peritumoral areas that correspond to hyperintense regions on T (2)-weighted images, and - 3.1 +/- 0.1 % in the tumor-center).
  • Combined with hypercapnia it allows for regional assessment of tumor activity.
  • [MeSH-minor] Adult. Astrocytoma / diagnosis. Contrast Media. Female. Glioblastoma / diagnosis. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16021537.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; 142M471B3J / Carbon Dioxide; 8063-77-2 / carbogen; S88TT14065 / Oxygen
  •  go-up   go-down


57. Talos IF, Zou KH, Kikinis R, Jolesz FA: Volumetric assessment of tumor infiltration of adjacent white matter based on anatomic MRI and diffusion tensor tractography. Acad Radiol; 2007 Apr;14(4):431-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Volumetric assessment of tumor infiltration of adjacent white matter based on anatomic MRI and diffusion tensor tractography.
  • We hypothesized that white matter infiltration may be common among different types of tumor.
  • MATERIAL AND METHODS: Preoperative, anatomic (T1- and T2-weighted), and LINESCAN diffusion tensor MRI were obtained in 12 patients harboring supratentorial gliomas (World Health Organization [WHO] Grades II and III).
  • A second segmentation and volume measurement was performed on the tumor regions intersecting adjacent white matter fiber tracts.
  • Statistical methods included summary statistics to examine the fraction of tumor volume infiltrating adjacent white matter.
  • RESULTS: There were five patients with low-grade oligodendroglioma (WHO Grade II), one with low-grade mixed oligoastrocytoma (WHO Grade II), one with ganglioglioma, two with low-grade astrocytoma (WHO Grade II), and three with anaplastic astrocytoma (WHO Grade III).
  • We identified white matter tracts infiltrated by tumor in all 12 cases.
  • The median tumor volume (+/- standard deviation) in our patient population was 42.5 +/- 28.9 mL.
  • The median tumor volume (+/- standard deviation) infiltrating white matter fiber tracts was 5.2 +/- 9.9 mL.
  • The median percentage of tumor volume infiltrating white matter fiber tracts was 21.4% +/- 9.7%.
  • However, prospective, large population studies are required to definitively clarify this issue, and how infiltration relates to histologic tumor type, tumor size, and location.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Magn Reson Imaging. 2001 Jun;13(6):967-75 [11382961.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Oct;27(9):1969-74 [17032877.001]
  • [Cites] Ann Neurol. 2002 Mar;51(3):377-80 [11891834.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2076-84 [11956268.001]
  • [Cites] Med Image Anal. 2002 Jun;6(2):93-108 [12044998.001]
  • [Cites] J Neurosurg. 2002 Sep;97(3):568-75 [12296640.001]
  • [Cites] NMR Biomed. 2002 Nov-Dec;15(7-8):468-80 [12489096.001]
  • [Cites] J Neurosurg. 2002 Dec;97(6):1333-42 [12507131.001]
  • [Cites] Neurosurgery. 2004 Aug;55(2):358-70; discussion 370-1 [15271242.001]
  • [Cites] Radiology. 2004 Aug;232(2):451-60 [15215555.001]
  • [Cites] J Neurosurg. 1987 Jun;66(6):865-74 [3033172.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1937-45 [8137221.001]
  • [Cites] Surg Neurol. 1995 Sep;44(3):208-21; discussion 221-3 [8545771.001]
  • [Cites] Neurosurgery. 1996 Apr;38(4):678-84; discussion 684-5 [8692384.001]
  • [Cites] Neurosurgery. 1996 Aug;39(2):253-8; discussion 258-9 [8832661.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):37-59 [9210052.001]
  • [Cites] J Comput Assist Tomogr. 1997 Jul-Aug;21(4):554-66 [9216759.001]
  • [Cites] Brain Res. 1998 Jan 5;780(1):27-33 [9473573.001]
  • [Cites] Med Image Anal. 1996 Mar;1(1):35-51 [9873920.001]
  • [Cites] Clin Neurol Neurosurg. 2005 Apr;107(3):174-80 [15823671.001]
  • [Cites] Radiology. 2005 Aug;236(2):615-20 [16040917.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1358-63 [16470608.001]
  • [Cites] Radiology. 2006 Apr;239(1):217-22 [16484348.001]
  • [Cites] Neurosurgery. 2006 Apr;58(4 Suppl 2):ONS-292-303; discussion ONS-303-4 [16582653.001]
  • [Cites] Radiology. 2006 May;239(2):506-13 [16641355.001]
  • [Cites] J Neurooncol. 2006 Jun;78(2):179-85 [16739029.001]
  • [Cites] Neuroimage. 2006 Sep;32(3):1127-33 [16798013.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):735-45 [11702861.001]
  • (PMID = 17368212.001).
  • [ISSN] 1076-6332
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P41 RR013218-098542; United States / NCRR NIH HHS / RR / U41 RR019703; United States / NIGMS NIH HHS / GM / R01 GM074068; United States / NCRR NIH HHS / RR / U41 RR019703-03S1; United States / NIBIB NIH HHS / EB / P41 EB015898; United States / NLM NIH HHS / LM / R01 LM007861; United States / NCRR NIH HHS / RR / P41 RR013218-02; United States / NCRR NIH HHS / RR / RR019703-03S1; United States / NCRR NIH HHS / RR / P41 RR013218; United States / NCRR NIH HHS / RR / RR013218-108434; United States / NCRR NIH HHS / RR / RR013218-098542; United States / NCI NIH HHS / CA / P01 CA067165; United States / NCRR NIH HHS / RR / P41 RR013218-108434
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS21072; NLM/ PMC2397554
  •  go-up   go-down


58. Galldiks N, Kracht LW, Berthold F, Miletic H, Klein JC, Herholz K, Jacobs AH, Heiss WD: [11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors. J Neurooncol; 2010 Jan;96(2):231-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only a few Methyl-[11C]-L-methionine (MET) positron emission tomography (PET) studies have focused on children and young adults with brain neoplasm.
  • The MET tumor-uptake relative to a corresponding control region was calculated.
  • A differentiation between high grade malignant lesions (mean MET-uptake = 2.00 +/- 0.46) and low grade tumors (mean MET-uptake = 1.84 +/- 0.31) was not possible.
  • There was a significant difference in MET-uptake between the histologically homogeneous subgroups of astrocytoma WHO grade II and anaplastic astrocytoma WHO grade III (P = 0.02).

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Radiol. 1987 Nov-Dec;28(6):673-81 [2962599.001]
  • [Cites] J Comput Assist Tomogr. 1983 Dec;7(6):1062-6 [6415134.001]
  • [Cites] Pediatr Neurol. 1990 May-Jun;6(3):163-70 [2193641.001]
  • [Cites] J Comput Assist Tomogr. 1992 Sep-Oct;16(5):804-13 [1522276.001]
  • [Cites] J Comput Assist Tomogr. 1994 Jan-Feb;18(1):110-8 [8282858.001]
  • [Cites] Clin Neurol Neurosurg. 1995 Nov;97(4):349-53 [8599907.001]
  • [Cites] J Nucl Med. 1996 Feb;37(2):387-93 [8667081.001]
  • [Cites] Neurology. 1998 May;50(5):1316-22 [9595980.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7163-70 [15534088.001]
  • [Cites] J Neurosurg. 2006 Feb;104(2):238-53 [16509498.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 May;33(5):516-24 [16450140.001]
  • [Cites] Childs Nerv Syst. 2007 Jul;23(7):739-51 [17356889.001]
  • [Cites] Neurosurg Rev. 1999 Dec;22(4):210-4 [10682929.001]
  • [Cites] J Nucl Med. 2000 Jul;41(7):1250-5 [10914918.001]
  • [Cites] J Nucl Med. 2001 Mar;42(3):432-45 [11337520.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Feb;29(2):176-82 [11926379.001]
  • [Cites] Cancer. 2002 Sep 15;95(6):1376-86 [12216107.001]
  • [Cites] Pediatr Neurosurg. 2003 Mar;38(3):146-55 [12601239.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):868-73 [12692687.001]
  • [Cites] J Neuroimaging. 2003 Jul;13(3):269-71 [12889176.001]
  • [Cites] Mol Imaging. 2002 Oct;1(4):309-35 [12926228.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1389-97 [12920486.001]
  • [Cites] J Neuroimaging. 2004 Oct;14(4):372-6 [15358961.001]
  • [Cites] Int J Appl Radiat Isot. 1979 Jul;30(7):393-9 [478664.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • (PMID = 19575148.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; AE28F7PNPL / Methionine; BN630929UL / methionine methyl ester
  • [Other-IDs] NLM/ PMC2808525
  •  go-up   go-down


59. Zhang K, Li C, Liu Y, Li L, Ma X, Meng X, Feng D: Evaluation of invasiveness of astrocytoma using 1H-magnetic resonance spectroscopy: correlation with expression of matrix metalloproteinase-2. Neuroradiology; 2007 Nov;49(11):913-9
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of invasiveness of astrocytoma using 1H-magnetic resonance spectroscopy: correlation with expression of matrix metalloproteinase-2.
  • INTRODUCTION: Even low-grade astrocytomas infiltrate the entire brain, a feature that precludes their successful therapy.
  • So to assess the invasive potential of astrocytoma is very important.
  • The aim of this study was determine whether there is a significant correlation between the results of (1)H-magnetic resonance spectroscopy ((1)H-MRS) and tumor invasive potential of astrocytoma, which is reflected by expression of matrix metalloproteinase-2 (MMP-2).
  • METHODS: The (1)H-MRS spectra of 41 histologically verified astrocytomas were obtained on a 3-T MR scanner.
  • According to the World Health Organization classification criteria for central nervous system tumors, there were 16 low-grade astrocytomas (2 pilocytic astrocytomas, 14 grade II astrocytomas) and 25 high-grade astrocytomas (5 anaplastic astrocytomas, 20 glioblastomas).The choline/N-acetylaspartate (Cho/NAA) and choline/creatine (Cho/Cr) ratios were calculated.
  • Of the 41 astrocytomas, 19 (8 low-grade and 11 high-grade) were analyzed immunohistochemically.
  • The correlations between metabolite ratios and the quantitative data from the immunohistochemical tests in the 19 astrocytomas were determined.
  • RESULTS: The Cho/NAA and Cho/Cr ratios of high-grade astrocytoma were both significantly greater than those of low-grade astrocytoma (t = -6.222, P = 0.000; t = -6.533, P = 0.000, respectively).
  • MMP-2 COD values of high-grade astrocytomas were also significantly greater than those of low-grade astrocytomas (t = -5.892, P = 0.000).
  • CONCLUSION: (1)H-MRS is helpful in evaluating the invasiveness of astrocytomas and predicting prognosis preoperatively by determining the Cho/NAA and Cho/Cr ratios.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Magnetic Resonance Spectroscopy. Matrix Metalloproteinase 2 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aspartic Acid / analogs & derivatives. Aspartic Acid / metabolism. Choline / metabolism. Creatine / metabolism. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Mol Cell Biol. 2002 Mar;3(3):207-14 [11994741.001]
  • [Cites] Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):495-502 [10571411.001]
  • [Cites] Neuroradiology. 2006 May;48(5):312-8 [16552583.001]
  • [Cites] Radiology. 2006 Mar;238(3):958-69 [16424238.001]
  • [Cites] Pharmacol Res. 2002 Aug;46(2):155-63 [12220955.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):215-26 [11263501.001]
  • [Cites] NMR Biomed. 2004 Feb;17(1):10-20 [15011246.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8904-9 [12861074.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Jan;20(1):117-23 [9974066.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):52-5 [10638966.001]
  • [Cites] J Neurooncol. 2003 Jul;63(3):233-45 [12892229.001]
  • [Cites] Stereotact Funct Neurosurg. 2004;82(2-3):90-7 [15305081.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):429-37 [9708803.001]
  • [Cites] Neuroradiology. 2002 May;44(5):371-81 [12012120.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Apr;22(4):604-12 [11290466.001]
  • [Cites] Nat Rev Neurosci. 2001 Jul;2(7):502-11 [11433375.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Apr;21(4):659-65 [10782774.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Nov-Dec;23 (10 ):1775-8 [12427638.001]
  • (PMID = 17763847.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 30KYC7MIAI / Aspartic Acid; 997-55-7 / N-acetylaspartate; EC 3.4.24.24 / Matrix Metalloproteinase 2; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


60. Combs SE, Ahmadi R, Schulz-Ertner D, Thilmann C, Debus J: Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation. J Neurooncol; 2005 Feb;71(3):319-23
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation.
  • PURPOSE: To assess the effectiveness of re-irradiation in recurrent low-grade gliomas (LGG).
  • At primary diagnosis of the tumor, the histology was grade II astrocytoma, oligodendroglioma or oligoastrocytoma.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Dose Fractionation. Glioma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):996-1003 [14575830.001]
  • [Cites] Cancer. 1993 Jul 1;72 (1):190-5 [8508405.001]
  • [Cites] Eur J Cancer. 1998 Jan;34(1):98-102 [9624245.001]
  • [Cites] Cancer. 1994 Sep 15;74(6):1784-91 [8082081.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):145-51 [11285552.001]
  • [Cites] Arch Neurol. 1989 Nov;46(11):1238-9 [2818260.001]
  • [Cites] Arch Neurol. 1990 Oct;47(10):1138-40 [2222248.001]
  • [Cites] Cancer. 1985 Mar 1;55(5):919-27 [3967199.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1998 May;64(5):581-7 [9598670.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):232-8 [12865907.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]
  • [Cites] J Neurosurg. 1989 Jun;70(6):853-61 [2715812.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1405-9 [2542195.001]
  • [Cites] Semin Oncol. 1994 Apr;21(2):236-48 [8153667.001]
  • [Cites] Can J Surg. 1993 Jun;36(3):271-5 [8391917.001]
  • [Cites] Radiother Oncol. 2000 Nov;57(2):215-23 [11054526.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):393-8 [9069312.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1294-301 [9193320.001]
  • [Cites] Neurology. 2000 Apr 11;54(7):1402-3 [10751245.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):646-51 [12586801.001]
  • [Cites] Radiologe. 1995 Sep;35(9):583-6 [8588040.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):719-27 [8040017.001]
  • [Cites] J Neurosurg. 1984 Oct;61(4):665-73 [6470776.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12 ):2305-11 [12805331.001]
  • [Cites] Neurosurgery. 1987 Nov;21(5):615-21 [2827052.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1133-41 [10613305.001]
  • [Cites] J Neurosurg. 1993 Jun;78(6):909-14 [8487073.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):370-9 [9010111.001]
  • [Cites] Oncology. 2000 Feb;58(2):108-16 [10705237.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):977-82 [10192343.001]
  • [Cites] Neurology. 1999 Sep 22;53(5):1141-3 [10496285.001]
  • [Cites] Ann Oncol. 2003 Apr;14 (4):599-602 [12649108.001]
  • [Cites] Semin Surg Oncol. 2001 Jan-Feb;20(1):13-23 [11291128.001]
  • [Cites] Semin Oncol. 2003 Dec;30(6 Suppl 19):10-4 [14765378.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):291-6 [8795601.001]
  • [Cites] Neurology. 2000 Apr 11;54(7):1442-8 [10751254.001]
  • [Cites] Clin Neurosurg. 1995;42:488-94 [8846613.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24 [11872276.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] Neurosurgery. 1996 May;38(5):872-8; discussion 878-9 [8727811.001]
  • [Cites] Radiology. 1996 Oct;201(1):275-8 [8816559.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1937-45 [8137221.001]
  • (PMID = 15735924.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Lu ZQ, Wang YM, Cao YY, Zhang QJ, Zhang XH, Li YH, Wang HS, Xie HL, Jiao BH, Zhang JH: [Correlations of polymorphisms in matrix metalloproteinase-3 and -7 promoters to susceptibility to brain astrocytoma]. Ai Zheng; 2007 May;26(5):463-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlations of polymorphisms in matrix metalloproteinase-3 and -7 promoters to susceptibility to brain astrocytoma].
  • BACKGROUND & OBJECTIVE: Matrix metalloproteinases (MMPs) are key enzymes involved in tumor development, invasion and metastasis.
  • The single nucleotide polymorphisms (SNPs) in the promoter regions of MMP genes may influence tumor development and progression via modulating mRNA transcription and protein expression.
  • This study was to explore the correlations of the promoter SNPs in MMP-3 and MMP-7 genes to susceptibility to brain astrocytoma.
  • METHODS: The genotype of MMP-3 -1171 5A/6A and MMP-7 -181A/G polymorphisms in 236 patients with brain astrocytoma and 366 healthy controls was detected by polymerase chain reaction-restrictive fragment length polymorphism (PCR-RFLP).
  • RESULTS: The allelotype and overall genotype distribution of MMP-3 SNP among the astrocytoma patients and healthy controls were similar (P>0.05).
  • Stratified by sex, age, and histological grade, the susceptibility to brain astrocytoma among the subjects with 5A/5A and 5A/6A genotypes and the subjects with 6A/6A genotype were similar(P>0.05).
  • The overall genotype distribution of MMP-7 SNP among the astrocytoma patients and healthy controls were significantly different (P = 0.001).
  • Compared with the A/A genotype, both the G/G and the A/G genotypes significantly increased the susceptibility to astrocytoma [sex-and age-adjusted odds ratio (OR) = 2.77 and 1.69, 95% confidence interval (CI)=1.27-6.02 and 1.01-2.84, respectively].
  • Stratification analysis showed that the G/G genotype significantly increased the susceptibility to astrocytoma in men (adjusted OR = 3.24, 95% CI = 1.12-9.41) and in the individuals younger than 45 years (adjusted OR = 3.16, 95% CI = 1.09-9.16).
  • When stratified by histological grade, the A/G genotype increased the susceptibility to grade II astrocytoma by about 2 folds (adjusted OR = 2.06, 95% CI = 1.05 - 4.05), while the G/G genotype increased the susceptibility to grade II-IV astrocytoma by about 3 folds.
  • CONCLUSION: MMP-7 -181A/G polymorphism may influence the susceptibility to astrocytoma, while MMP-3-1171 5A/6A polymorphism has no correlation to the susceptibility.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Genetic Predisposition to Disease. Matrix Metalloproteinase 3 / genetics. Matrix Metalloproteinase 7 / genetics. Polymorphism, Single Nucleotide

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17672933.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 3.4.24.17 / MMP3 protein, human; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.23 / MMP7 protein, human; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


62. Lu Z, Wang Y, Zhang Q, Zhang X, Wang S, Xie H, Li Y, Jiao B, Zhang J: Association between the functional polymorphism in the matrix metalloproteinase-7 promoter and susceptibility to adult astrocytoma. Brain Res; 2006 Nov 6;1118(1):6-12
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between the functional polymorphism in the matrix metalloproteinase-7 promoter and susceptibility to adult astrocytoma.
  • To study the association between the A to G transition at the -181-bp position in the promoter of matrix metalloproteinase-7 gene (MMP-7-181A/G) and susceptibility to adult astrocytoma, the MMP-7-181A/G polymorphism was genotyped by PCR-RFLP analysis among 221 adult astrocytoma patients and 366 healthy controls in a population of northern China.
  • The result showed that the overall distribution of the MMP-7 genotypes among astrocytoma patients and healthy controls was significantly different (P<0.001).
  • Compared with the A/A genotype, the G/G genotype significantly increased the risk to the development of astrocytoma (age and gender adjusted OR=2.77, 95% CI=1.27-6.02), while the MMP-7 A/G genotype only marginally increased the risk of developing this cancer (age and gender adjusted OR=1.66, 95% CI=0.99-2.84).
  • Stratification analysis showed that the G/G genotype significantly increased the risk of astrocytoma only among male subjects (age adjusted OR=3.24, 95% CI=1.12-9.41) and individuals younger than 45 years (age and gender adjusted OR=3.16, 95% CI=1.09-9.16).
  • When stratified by histological grades, a significant higher risk for developing grade II astrocytoma was observed among individuals harboring the A/G genotype (age and gender adjusted OR=2.06, 95% CI=1.05-4.05), while an about 3-fold elevation of risk to develop grades II, III, and IV astrocytomas was observed among individuals with the G/G genotype.
  • The present result, for the first time, suggested that the MMP-7-181A/G polymorphism might be associated with the susceptibility to adult astrocytoma.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Genetic Predisposition to Disease / genetics. Matrix Metalloproteinase 7 / genetics. Polymorphism, Genetic / genetics. Promoter Regions, Genetic / genetics
  • [MeSH-minor] Adult. Age Factors. Biomarkers, Tumor / genetics. DNA Mutational Analysis. Female. Gene Frequency. Genetic Markers / genetics. Genetic Testing. Genotype. Humans. Male. Middle Aged. Sex Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16956593.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


63. Rorive S, Maris C, Debeir O, Sandras F, Vidaud M, Bièche I, Salmon I, Decaestecker C: Exploring the distinctive biological characteristics of pilocytic and low-grade diffuse astrocytomas using microarray gene expression profiles. J Neuropathol Exp Neurol; 2006 Aug;65(8):794-807
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exploring the distinctive biological characteristics of pilocytic and low-grade diffuse astrocytomas using microarray gene expression profiles.
  • Although World Health Organization (WHO) grade I pilocytic astrocytomas and grade II diffuse astrocytomas have been classified for decades as different clinicopathologic entities, few, if any, data are available on the biologic features explaining these differences.
  • Although more than 50 microarray-related studies have been carried out to characterize the molecular profiles of astrocytic tumors, we have identified only 11 that provide sound data on low-grade astrocytomas.
  • We have incorporated these data into a comparative analysis for the purpose of identifying the most relevant molecular markers characterizing grade I pilocytic and grade II diffuse astrocytomas.
  • Our analysis has identified various interesting genes that are differentially expressed in either grade I or grade II astrocytomas when compared with normal tissue and/or high-grade (WHO grade III and IV) astrocytomas.
  • Interestingly, a group of 6 genes (TIMP4, C1NH, CHAD, THBS4, IGFBP2, and TLE2) constitute an expression profile characteristic of grade I astrocytomas as compared with all other categories of tissue (normal brain, grade II, and high-grade astrocytomas).
  • The end products (proteins) of these genes act as antimigratory compounds, a fact that could explain why pilocytic astrocytomas behave as compact (well-circumscribed) tumors as opposed to all the other astrocytic tumor types that diffusely invade the brain parenchyma.
  • Having validated these molecular markers by means of real-time reverse transcriptase-polymerase chain reaction, an integrated model was proposed illustrating how and why pilocytic astrocytomas constitute a distinct biologic and pathologic entity when compared with diffuse astrocytomas.
  • [MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic / genetics. Genetic Predisposition to Disease / genetics
  • [MeSH-minor] Adult. Cell Adhesion / genetics. Cell Movement / genetics. Child. Extracellular Matrix Proteins / genetics. Extracellular Matrix Proteins / metabolism. Humans. Models, Neurological. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / physiopathology. Oligonucleotide Array Sequence Analysis / methods. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16896313.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Extracellular Matrix Proteins
  •  go-up   go-down


64. Ohgaki H, Kleihues P: Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol; 2005 Jun;64(6):479-89
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.
  • This review summarizes data on incidence rates, survival, and genetic alterations from population-based studies of astrocytic and oligodendrogliomas that were carried out in the Canton of Zurich, Switzerland (approximately 1.16 million inhabitants).
  • While survival rates for pilocytic astrocytomas were excellent (96% at 10 years), the prognosis of diffusely infiltrating gliomas was poorer, with median survival times (MST) of 5.6 years for low-grade astrocytoma WHO grade II, 1.6 years for anaplastic astrocytoma grade III, and 0.4 years for glioblastoma.
  • For oligodendrogliomas the MSTwas 11.6 years for grade II and 3.5 years for grade III.
  • TP53 mutations were most frequent in gemistocytic astrocytomas (88%), followed by fibrillary astrocytomas (53%) and oligoastrocytomas (44%), but infrequent (13%) in oligodendrogliomas.
  • LOH 1p/19q typically occurred in tumors without TP53 mutations and were most frequent in oligodendrogliomas (69%), followed by oligoastrocytomas (45%), but were rare in fibrillary astrocytomas (7%) and absent in gemistocytic astrocytomas.
  • Primary (de novo) glioblastomas prevailed (95%), while secondary glioblastomas that progressed from low-grade or anaplastic gliomas were rare (5%).
  • [MeSH-major] Astrocytoma. Brain Neoplasms. Loss of Heterozygosity. Oligodendroglioma. Tumor Suppressor Protein p53 / genetics


65. Frazier JL, Johnson MW, Burger PC, Weingart JD, Quinones-Hinojosa A: Rapid malignant transformation of low-grade astrocytomas: report of 2 cases and review of the literature. World Neurosurg; 2010 Jan;73(1):53-62; discussion e5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid malignant transformation of low-grade astrocytomas: report of 2 cases and review of the literature.
  • BACKGROUND: Low-grade gliomas have been documented to undergo transformation into high-grade astrocytomas, and the time interval of this transformation has been reported to generally occur within 5 years in about 50% of patients harboring these low-grade lesions.
  • Several studies have investigated the evolution of low-grade gliomas into malignant gliomas by CT and MRI characteristics, but many have not documented the timing of these transformation processes.
  • CASE DESCRIPTION: The authors discuss the cases of 2 patients with histopathologically confirmed grade II astrocytomas after craniotomies that underwent rapid evolution into malignant gliomas within 13 weeks.
  • Interestingly, both low-grade astrocytomas were positive with immunostaining for the epidermal growth factor receptor, in which its amplification has been implicated as a molecular marker of malignant gliomas.
  • In addition, the grade II astrocytomas were negative for p53 in both patients but were found to be positive upon transformation into malignant gliomas.
  • CONCLUSIONS: To our knowledge, this is the first report of rapid malignant transformation of low-grade gliomas, which were proven by histology, within 13 weeks.
  • There may be patients with a subtype of low-grade astrocytomas that may warrant molecular characterization to determine if aggressive adjuvant therapy would be of benefit.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology
  • [MeSH-minor] Cell Transformation, Neoplastic. Female. Humans. Male. Middle Aged. Receptor, Epidermal Growth Factor / metabolism. Time Factors. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20452869.001).
  • [ISSN] 1878-8769
  • [Journal-full-title] World neurosurgery
  • [ISO-abbreviation] World Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 49
  •  go-up   go-down


66. Liebrich M, Guo LH, Schluesener HJ, Schwab JM, Dietz K, Will BE, Meyermann R: Expression of interleukin-16 by tumor-associated macrophages/activated microglia in high-grade astrocytic brain tumors. Arch Immunol Ther Exp (Warsz); 2007 Jan-Feb;55(1):41-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of interleukin-16 by tumor-associated macrophages/activated microglia in high-grade astrocytic brain tumors.
  • MATERIALS AND METHODS: Expression of IL-16 was analyzed by immunohistochemistry in human astrocytic brain tumors and the rat C6 glioblastoma tumor model.
  • IL-16 was detected in both human astrocytic brain tumors and rat C6 glioma.
  • RESULTS: Compared with human control brains, a significant increase in the percentages of parenchymal IL-16+ macrophages/microglia was observed already in grade II astrocytomas, indicating that IL-16+ immunostaining could be a descriptor of a macrophage/microglia subset in astrocytic brain tumors.
  • A further increase was observed at the transition from grade II to III astrocytomas.
  • This increase in IL-16 immunoreactivity correlated with WHO grades of human astrocytic brain tumors.
  • CONCLUSIONS: Therefore, IL-16 might be a so far unknown factor in the regulation of the local inflammatory milieu of human and experimental astrocytomas.
  • [MeSH-major] Astrocytoma / immunology. Brain Neoplasms / immunology. Glioblastoma / immunology. Interleukin-16 / biosynthesis. Macrophages / immunology. Microglia / immunology
  • [MeSH-minor] Adult. Aged. Animals. Cell Line, Tumor. Female. Humans. Inflammation Mediators / metabolism. Male. Middle Aged. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 May 1;164(9):4429-32 [10779741.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):752-3 [15944689.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Int J Dev Neurosci. 2001 Feb;19(1):93-100 [11226758.001]
  • [Cites] Acta Neuropathol. 2001 Mar;101(3):249-55 [11307625.001]
  • [Cites] Microsc Res Tech. 2001 Jul 15;54(2):106-13 [11455617.001]
  • [Cites] J Neurooncol. 2001 Dec;55(3):141-7 [11859968.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):947-56 [12213723.001]
  • [Cites] Glia. 2002 Nov;40(2):252-9 [12379912.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] J Neurosci. 2003 Jun 1;23(11):4410-9 [12805281.001]
  • [Cites] J Neuroimmunol. 2004 Jan;146(1-2):39-45 [14698845.001]
  • [Cites] Glia. 2004 Jan 15;45(2):208-12 [14730714.001]
  • [Cites] J Leukoc Biol. 2004 Mar;75(3):388-97 [14612429.001]
  • [Cites] J Immunol. 1982 Jun;128(6):2563-8 [7042840.001]
  • [Cites] Semin Oncol. 1994 Apr;21(2):149-61 [8153661.001]
  • [Cites] Nature. 1996 May 2;381(6577):29-30 [8609983.001]
  • [Cites] J Neurosci Res. 1996 Jun 15;44(6):606-11 [8794952.001]
  • [Cites] Glia. 1997 Aug;20(4):365-72 [9262239.001]
  • [Cites] Nature. 1998 Apr 30;392(6679):936-41 [9582076.001]
  • [Cites] Int Rev Immunol. 1998;16(5-6):523-40 [9646175.001]
  • [Cites] Prog Neurobiol. 1999 Jun;58(3):233-47 [10341362.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):211-7 [15766659.001]
  • [Cites] Acta Neuropathol. 2000 Sep;100(3):313-22 [10965802.001]
  • (PMID = 17221335.001).
  • [ISSN] 0004-069X
  • [Journal-full-title] Archivum immunologiae et therapiae experimentalis
  • [ISO-abbreviation] Arch. Immunol. Ther. Exp. (Warsz.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Inflammation Mediators; 0 / Interleukin-16
  • [Other-IDs] NLM/ PMC3234149
  •  go-up   go-down


67. Matsuda K, Sakurada K, Mouri W, Saino M, Sato S, Saito S, Kayama T, Nakazato Y: [Operative case of isomorphic astrocytoma]. Brain Nerve; 2007 Aug;59(8):881-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Operative case of isomorphic astrocytoma].
  • Diffuse astrocytomas are classified as WHO Grade II tumors.
  • Recently, a subtype presenting with better prognosis has been proposed, and it is known as "isomorphic astrocytoma."
  • The tumor was resected under awake surgery.
  • The pathological diagnosis was diffuse astrocytoma, but this tumor was considered to be the isomorphic subtype.
  • Some parts of the tumor showed a relatively high MIB-1 labeling index (LI) of 9.2%, and additional 50-Gy radiotherapy was performed.
  • Isomorphic astrocytoma is characterized by prolonged epileptic seizures, a low MIB-1 LI, and better prognosis.
  • In our case, since the MIB-1 LI was higher in some parts of the tumor, the appropriate therapy for WHO Grade II tumors was performed.
  • However, this case was considered representative of isomorphic astrocytoma.
  • No reports of this tumor subtype have been previously described in Japan.
  • Therefore, this report is the first case of isomorphic astrocytoma reported to Japanese literature.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713125.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


68. Nakasu S, Fukami T, Jito J, Matsuda M: Prognostic significance of loss of O6-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytoma. Surg Neurol; 2007 Dec;68(6):603-8; discussion 608-9
Genetic Alliance. consumer health - Diffuse Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of loss of O6-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytoma.
  • If loss of function in MGMT is related to tumor progression, the immunohistochemical method may predict the malignant change of gliomas.
  • METHOD: We investigated the expression of MGMT by immunohistochemical method in 28 supratentorial hemispheric diffuse astrocytomas.
  • RESULTS: There were 19 MGMT-positive and 9 MGMT-negative astrocytomas.
  • Their rates of malignant transformation at 5 years were 12.3% and 51.4%, respectively.
  • Age, sex, extent of surgery, MIB-1 value, and radiation therapy at initial treatment did not correlate with the malignant progression.
  • Two long-term survivors with MGMT-negative tumor responded well to nitrosourea-based chemotherapy and lived more than 8 years after malignant transformation.
  • CONCLUSION: Although the status of MGMT did not affect the overall survival, immunohistochemical evaluation of MGMT expression may be a good marker for tumor progression.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Biomarkers, Tumor / metabolism. O(6)-Methylguanine-DNA Methyltransferase / metabolism. Supratentorial Neoplasms / metabolism. Supratentorial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17825378.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


69. Chen AY, Lee H, Hartman J, Greco C, Ryu JK, O'Donnell R, Boggan J: Secondary supratentorial primitive neuroectodermal tumor following irradiation in a patient with low-grade astrocytoma. AJNR Am J Neuroradiol; 2005 Jan;26(1):160-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary supratentorial primitive neuroectodermal tumor following irradiation in a patient with low-grade astrocytoma.
  • We report a case of a supratentorial primitive neuroectodermal tumor (PNET) that occurred 12 years after cranial irradiation for a grade II astrocytoma.
  • Neuroimaging was unable to distinguish between a recurrence of the original neoplasm and the development of a new, distinct entity.
  • Pathologic review assisted by immunohistochemical staining, however, revealed a high-grade PNET.
  • Although rare, PNET needs to be included in the differential diagnoses for previously irradiated patients, who develop recurrent brain tumors in the presence of uncharacteristic imaging features.
  • [MeSH-major] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Cranial Irradiation. Frontal Lobe. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Neoplasms, Radiation-Induced / diagnosis. Neoplasms, Second Primary / diagnosis. Neuroectodermal Tumors, Primitive / diagnosis. Supratentorial Neoplasms / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Female. Follow-Up Studies. Glial Fibrillary Acidic Protein / analysis. Humans. Radiotherapy, Adjuvant. Synaptophysin / analysis


70. Matusan-Ilijas K, Behrem S, Jonjic N, Zarkovic K, Lucin K: Osteopontin expression correlates with angiogenesis and survival in malignant astrocytoma. Pathol Oncol Res; 2008 Sep;14(3):293-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteopontin expression correlates with angiogenesis and survival in malignant astrocytoma.
  • The aim of the study was to analyze the expression of OPN in human astrocytomas and to correlate it with angiogenesis and patients' outcome.
  • Seventy-six human astrocytomas including eight pilocytic astrocytomas (grade I), 10 diffuse astrocytomas (grade II), 8 anaplastic astrocytomas (grade III) and 50 glioblastomas (grade IV) were immunohistochemically stained for OPN protein.
  • Astrocytomas were heterogeneous regarding the OPN expression.
  • Our results indicate the overexpression of OPN protein in astrocytoma cells and suggest the role of OPN in astrocytoma progression and angiogenesis.
  • [MeSH-major] Astrocytoma / blood supply. Astrocytoma / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / blood supply. Brain Neoplasms / metabolism. Neovascularization, Pathologic / metabolism. Osteopontin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Crit Care Med. 1999 Oct;160(4):1269-73 [10508818.001]
  • [Cites] Stroke. 1998 Aug;29(8):1698-706; discussion 1707 [9707214.001]
  • [Cites] J Surg Oncol. 2006 Sep 15;94(4):325-31 [16917865.001]
  • [Cites] Br J Cancer. 2000 Jun;82(12):1967-73 [10864205.001]
  • [Cites] J Vet Med Sci. 2004 Oct;66(10):1307-10 [15528873.001]
  • [Cites] Oncogene. 1999 Jul 22;18(29):4237-46 [10435636.001]
  • [Cites] FASEB J. 1993 Dec;7(15):1475-82 [8262332.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):293-305 [8686754.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4820-8 [12183442.001]
  • [Cites] Oncogene. 2006 May 4;25(19):2818-26 [16314830.001]
  • [Cites] Brain Res. 2005 Apr 11;1041(1):95-101 [15804504.001]
  • [Cites] J Cell Biochem. 1994 Sep;56(1):48-51 [7528752.001]
  • [Cites] Cancer Lett. 2003 Jul 30;198(1):107-17 [12893437.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3417-27 [12067984.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2A):807-12 [9615723.001]
  • [Cites] Lab Invest. 1995 Jan;72(1):55-63 [7837791.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90 [14734468.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(8):2734-42 [10733576.001]
  • [Cites] J Cell Biol. 1998 May 18;141(4):1083-93 [9585425.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2166-76 [16208410.001]
  • [Cites] J Neurooncol. 2001 Jun;53(2):161-76 [11716068.001]
  • [Cites] Oncogene. 2003 Feb 27;22(8):1198-205 [12606946.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5336-43 [12235004.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Jun;31(3):292-303 [15885066.001]
  • [Cites] Front Biosci. 1999 Feb 15;4:D188-99 [9989953.001]
  • [Cites] J Natl Cancer Inst. 1993 Feb 3;85(3):200-6 [8423624.001]
  • [Cites] Br J Cancer. 2004 May 17;90(10):1877-81 [15138464.001]
  • [Cites] Radiother Oncol. 2007 Jun;83(3):398-405 [17524506.001]
  • [Cites] Am J Pathol. 2006 May;168(5):1676-85 [16651633.001]
  • (PMID = 18493866.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 106441-73-0 / Osteopontin
  •  go-up   go-down


71. Blauwblomme T, Varlet P, Goodden JR, Cuny ML, Piana H, Roujeau T, Dirocco F, Grill J, Kieffer V, Boddaert N, Sainte-Rose C, Puget S: Forniceal glioma in children. Clinical article. J Neurosurg Pediatr; 2009 Sep;4(3):249-53
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On histological review, the tumors were confirmed as pilocytic astrocytoma (4 lesions), WHO Grade II astrocytoma (3), and ganglioglioma (1).
  • Additional treatment was required for 5 patients for tumor progression, with a median interval of 19 months from surgery.
  • CONCLUSIONS: In this series, forniceal gliomas were found to be low-grade gliomas.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19772409.001).
  • [ISSN] 1933-0707
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Miyajima Y, Sato Y, Oka H, Utsuki S, Kondo K, Tanizaki Y, Nagashio R, Tsuchiya B, Okayasu I, Fujii K: Prognostic significance of nuclear DJ-1 expression in astrocytoma. Anticancer Res; 2010 Jan;30(1):265-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of nuclear DJ-1 expression in astrocytoma.
  • The present study was conducted to determine whether any correlation exists between the expression of DJ-1 and WHO grading of the tumor or patient prognosis, and to analyze the function of this oncogene in astrocytomas.
  • Twenty-nine formalin-fixed and paraffin-embedded glioblastomas (grade IV), 21 anaplastic astorocytomas (grade III), and 14 diffuse astrocytomas (grade II) were immunohistochemically studied to identify the expression of DJ-1 protein.
  • The expression of DJ-1 was detected both in the nucleus and cytoplasm of tumor cells; however, such expression varied from case to case.
  • While there was no difference in the cytoplasmic expression of DJ-1 among astrocytomas, its nuclear expression was inversely correlated with the WHO grading of astrocytomas.
  • The present study demonstrated that the survival of patients with astrocytomas was correlated with the nuclear DJ-1 status of the tumor.
  • We herein demonstrated for the first time that the DJ-1 molecule might therefore play an important role as a tumor suppressor in astrocytomas.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Oncogene Proteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20150646.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Oncogene Proteins; 0 / PARK7 protein, human
  •  go-up   go-down


73. Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nakazato Y, Tanaka Y, Vital A, Mariani L, Stawski R, Watanabe T, De Girolami U, Kleihues P, Ohgaki H: Molecular classification of low-grade diffuse gliomas. Am J Pathol; 2010 Dec;177(6):2708-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular classification of low-grade diffuse gliomas.
  • The current World Health Organization classification recognizes three histological types of grade II low-grade diffuse glioma (diffuse astrocytoma, oligoastrocytoma, and oligodendroglioma).
  • The aim of our study was to establish genetic profiles for diffuse gliomas and to estimate their predictive impact.
  • In this study, we screened 360 World Health Organization grade II gliomas for mutations in the IDH1, IDH2, and TP53 genes and for 1p/19q loss and correlated these with clinical outcome.
  • [MeSH-major] Brain Neoplasms / classification. Glioma / classification. Molecular Diagnostic Techniques / methods. Neoplasm Staging / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Pathol. 1996 Jul;6(3):217-23; discussion 23-4 [8864278.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Oct;56(10):1098-104 [9329453.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] Neurology. 2007 May 22;68(21):1831-6 [17515545.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Jun;66(6):545-51 [17549014.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Acta Neuropathol. 2008 Dec;116(6):597-602 [18985363.001]
  • [Cites] Clin Cancer Res. 2009 Jan 1;15(1):330-7 [19118062.001]
  • [Cites] N Engl J Med. 2009 Feb 19;360(8):765-73 [19228619.001]
  • [Cites] Am J Pathol. 2009 Apr;174(4):1149-53 [19246647.001]
  • [Cites] Acta Neuropathol. 2009 Sep;118(3):401-5 [19543740.001]
  • [Cites] Neuro Oncol. 2009 Aug;11(4):341-7 [19435942.001]
  • [Cites] J Clin Oncol. 2009 Sep 1;27(25):4150-4 [19636000.001]
  • [Cites] Acta Neuropathol. 2009 Oct;118(4):469-74 [19554337.001]
  • [Cites] Clin Cancer Res. 2009 Oct 1;15(19):6002-7 [19755387.001]
  • [Cites] Neurology. 2009 Nov 24;73(21):1792-5 [19933982.001]
  • [Cites] Hum Mutat. 2010 Mar;31(3):E1186-99 [20077503.001]
  • [Cites] Clin Cancer Res. 2010 Mar 1;16(5):1597-604 [20160062.001]
  • [Cites] Oncogene. 1999 Oct 21;18(43):5870-8 [10557074.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1253-62 [11290543.001]
  • [Cites] Acta Neuropathol. 2002 Mar;103(3):267-75 [11907807.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1117-24 [12006527.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):313-9 [12107116.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4884-90 [14581362.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Nov;62(11):1118-28 [14656070.001]
  • [Cites] Acta Neuropathol. 2004 Jul;108(1):49-56 [15118874.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1381-93 [9083161.001]
  • (PMID = 21075857.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.41 / isocitrate dehydrogenase 2, human; EC 1.1.1.42. / IDH1 protein, human
  • [Other-IDs] NLM/ PMC2993282
  •  go-up   go-down


74. Somasundaram K, Reddy SP, Vinnakota K, Britto R, Subbarayan M, Nambiar S, Hebbar A, Samuel C, Shetty M, Sreepathi HK, Santosh V, Hegde AS, Hegde S, Kondaiah P, Rao MR: Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma. Oncogene; 2005 Oct 27;24(47):7073-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma.
  • Astrocytoma is the most common type of brain cancer constituting more than half of all brain tumors.
  • With an aim to identify markers describing astrocytoma progression, we have carried out microarray analysis of astrocytoma samples of different grades using cDNA microarray containing 1152 cancer-specific genes.
  • Data analysis identified several differentially regulated genes between normal brain tissue and astrocytoma as well as between grades II/III astrocytoma and glioblastoma multiforme (GBM; grade IV).
  • As ASCL has been implicated in neuroendocrine, medullary thyroid and small-cell lung cancers, we chose to examine the role of ASCL1 in the astrocytoma development.
  • Our data revealed that ASCL1 is overexpressed in progressive astrocytoma as evidenced by increased levels of ASCL1 transcripts in 85.71% (6/7) of grade II diffuse astrocytoma (DA), 90% (9/10) of grade III anaplastic astrocytoma (AA) and 87.5% (7/8) of secondary GBMs, while the majority of primary de novo GBMs expressed similar to or less than normal brain levels (66.67%; 8/12).
  • ASCL1 upregulation in progressive astrocytoma is accompanied by inhibition of Notch signaling as seen by uninduced levels of HES1, a transcriptional target of Notch1, increased levels of HES6, a dominant-negative inhibitor of HES1-mediated repression of ASCL1, and increased levels of Notch ligand Delta1, which is capable of inhibiting Notch signaling by forming intracellular Notch ligand autonomous complexes.
  • Our results imply that inhibition of Notch signaling may be an important early event in the development of grade II DA and subsequent progression to grade III AA and secondary GBM.
  • [MeSH-major] Astrocytoma / genetics. DNA-Binding Proteins / metabolism. Gene Expression Regulation, Neoplastic. Glioblastoma / genetics. Membrane Proteins / metabolism. Signal Transduction. Transcription Factors / metabolism
  • [MeSH-minor] Basic Helix-Loop-Helix Transcription Factors. Brain / metabolism. Brain / pathology. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Disease Progression. Gene Expression Profiling. Helix-Loop-Helix Motifs. Humans. Oligonucleotide Array Sequence Analysis. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Receptors, Notch. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103883.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ASCL1 protein, human; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / Membrane Proteins; 0 / RNA, Neoplasm; 0 / Receptors, Notch; 0 / Transcription Factors
  •  go-up   go-down


75. Hara A, Saegusa M, Ichinoe M, Okayasu I: Diagnostic and prognostic significance of cyclin A expression in low-grade astrocytomas: comparison with astrogliosis and high-grade tumours. J Clin Pathol; 2008 Mar;61(3):287-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and prognostic significance of cyclin A expression in low-grade astrocytomas: comparison with astrogliosis and high-grade tumours.
  • AIM: Definitive distinction between low-grade astrocytoma and astrogliosis is a long-standing difficulty due to their similar histopathological characteristics.
  • To clarify differences in biological significance, this study focused on various components of the cell cycle machinery and proliferation as key parameters, comparing expression in astrogliosis, as well as low- and high-grade astrocytomas.
  • METHODS: The expression of p16, p21 and p27, and cyclin A, cyclin D1, cyclin E, Rb and Ki-67 was immunohistochemically examined in 40 cases of astrogliosis and 48 cases of low-grade astrocytomas (grade II), as well as 50 high-grade tumours (grades III and IV).
  • The results were also compared with survival data for the astrocytomas.
  • RESULTS: Cell proliferation determined by Ki-67 immunoreactivity did not differ between astrogliosis and low-grade tumours.
  • Average labelling indices (LIs) for p16, p21, Rb, cyclin A and cyclin E showed a stepwise increase from astrogliosis, through low- to high-grade astrocytomas, indicating the possibility that over 9%, 6% and 4% of LIs for p16, p21 and cyclin A, respectively, may be useful predictors in the case of the latter, in contrast to significant decrease in p27 LIs.
  • Significantly higher mean LI values for cyclin D1 were also evident in astrogliosis (12.42) as compared with astrocytomas (low grade, 2.26; high grade, 4.60).
  • Positive correlations between LIs for Rb and Ki-67 were observed with astrogliosis and low- but not high-grade tumours.
  • In addition, high cyclin A LI values were independently associated with poor outcome in low-grade tumours.
  • CONCLUSION: These findings provide evidence that expression of cell-cycle-related molecules may be a reliable parameter for differential diagnosis of low-grade astrocytomas and astrogliosis.
  • Moreover, detection of cyclin A appears to be useful for predicting behaviour of low-grade astrocytomas.
  • [MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor. Cyclin A / genetics. Gene Expression Regulation, Neoplastic

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156430.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin A; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Ki-67 Antigen; 0 / Retinoblastoma Protein; 136601-57-5 / Cyclin D1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


76. Maris C, Rorive S, Sandras F, D'Haene N, Sadeghi N, Bièche I, Vidaud M, Decaestecker C, Salmon I: Tenascin-C expression relates to clinicopathological features in pilocytic and diffuse astrocytomas. Neuropathol Appl Neurobiol; 2008 Jun;34(3):316-29
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tenascin-C expression relates to clinicopathological features in pilocytic and diffuse astrocytomas.
  • AIMS: Tenascin-C (TN-C) is an extracellular matrix brain glycoprotein for which conflicting in vitro and in vivo results are reported in the literature dealing with its involvement in astrocytoma aggressiveness, in particular astrocytoma invasion.
  • In view of these conflicting results and the lack of data available on low-grade astrocytomas, the present study focuses on pilocytic World Health Organization (WHO) grade I, and diffuse WHO grade II astrocytomas, that is, two histological entities associated with very different invasive abilities.
  • METHODS: Using real-time reverse transcription polymerase chain reaction and immunohistochemistry, we analysed the TN-C expression in normal brain tissue as well as in a series of 54 pilocytic and 53 grade II astrocytomas.
  • Paralleling these observations, we showed that TN-C expression in low-grade astrocytomas similarly varies according to tumour site.
  • Cox regression analysis evidenced that TN-C provided an independent prognostic value which is enhanced in the case of grade II astrocytomas for which positive TN-C expression is associated with a higher risk of recurrence.
  • We also analysed TN-C expression specifically in vascular areas of low-grade astrocytomas without demonstrating any prognostic value for this additional feature.
  • RESULTS: Similarly to normal brain, low-grade astrocytomas exhibit variations in TN-C expression with site, and this expression is associated with an independent prognostic value in terms of recurrence.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Tenascin / biosynthesis
  • [MeSH-minor] Adult. Age Factors. Biomarkers, Tumor / analysis. Child. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Neoplasm Recurrence, Local / pathology. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Spinal Cord Neoplasms / metabolism. Spinal Cord Neoplasms / mortality. Spinal Cord Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17983425.001).
  • [ISSN] 1365-2990
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tenascin
  •  go-up   go-down


77. Yue WY, Chen ZP: Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem; 2005 Aug;53(8):997-1002
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does vasculogenic mimicry exist in astrocytoma?
  • Vasculogenic mimicry (VM) has been observed in melanoma and in some nonmelanoma tumor types.
  • It is unknown whether a similar VM phenomenon exists in astrocytoma.
  • The present study was to examine 45 astrocytomas (including World Health Organization grade II 15 cases, grade III 15 cases, and grade IV 15 cases) by CD34 endothelial marker periodic acid-Schiff (PAS) dual staining to see if VM existing in these tumors.
  • The results demonstrated that endothelium-lined vessels dominated the tumor microvasculature and stained positively for PAS, laminin, and endothelial marker.
  • PAS-positive pattern of VM was found in two grade IV astrocytomas.
  • Channels stained positively for PAS, laminin, and negatively for CD34 of the VM entrapped in the tumor tissue.
  • Furthermore, in astrocytoma, especially glioblastoma, focus of anaplastic tumor cells appeared with CD34 expression, whereas some tumor cells lost glial fibrillary acid protein expression.
  • It is assumed that genetically deregulated tumor cells in astrocytoma could lose the astrocyte-specific protein and express inappropriate markers not expected in cells of astrocyte lineage.
  • The present results suggest that VM phenomenon exists in some malignant astrocytoma.
  • [MeSH-major] Astrocytoma / blood supply. Brain Neoplasms / blood supply
  • [MeSH-minor] Antigens, CD34 / metabolism. Biomarkers / metabolism. Coloring Agents. Endothelium, Vascular / metabolism. Humans. Microcirculation. Neoplasm Staging. Periodic Acid. Schiff Bases

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923371.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers; 0 / Coloring Agents; 0 / Schiff Bases; 10450-60-9 / Periodic Acid
  •  go-up   go-down


78. Elsir T, Eriksson A, Orrego A, Lindström MS, Nistér M: Expression of PROX1 Is a common feature of high-grade malignant astrocytic gliomas. J Neuropathol Exp Neurol; 2010 Feb;69(2):129-38
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of PROX1 Is a common feature of high-grade malignant astrocytic gliomas.
  • PROX1 is a prospero-related transcription factor that plays a critical role in the development of various organs including the mammalian lymphatic and central nervous systems; it controls cell proliferation and differentiation through different transcription pathwaysand has both oncogenic and tumor-suppressive functions.
  • We investigated PROX1 expression patterns in 56 human astrocytic gliomas of different grades using immunohistochemistry.
  • An average of 79% of cells in World Health Organization Grade IV (glioblastoma, n = 15) and 57% of cells in World Health Organization Grade III (anaplastic astrocytoma, n = 13) were strongly PROX1 positive; low-grade diffuse astrocytomas (Grade II, n = 13) had 21% of cells that were strongly positive; Grade I tumors (n = 15) had 1.5%; and non-neoplastic brain tissue (n = 15) had 3.7% of cells that were PROX1 positive.
  • Analyses of coexpression with proliferation markers suggest that PROX1+ cells have a marginally lower rate of proliferation than other tumor cells but are still mitotically active.
  • We conclude that PROX1 may constitute a useful tool for the diagnosis and grading ofastrocytic gliomas and for distinguishing Grade III and Grade IV tumors from Grade I and Grade II tumors.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Homeodomain Proteins / metabolism. Tumor Suppressor Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20084020.001).
  • [ISSN] 1554-6578
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Biomarkers; 0 / Homeodomain Proteins; 0 / MAP2 protein, human; 0 / Microtubule-Associated Proteins; 0 / Nerve Tissue Proteins; 0 / Tubulin; 0 / Tumor Suppressor Proteins; 0 / neuronal nuclear antigen NeuN, human; 0 / prospero-related homeobox 1 protein
  •  go-up   go-down


79. Misra A, Chattopadhyay P, Chosdol K, Sarkar C, Mahapatra AK, Sinha S: Clonal mutations in primary human glial tumors: evidence in support of the mutator hypothesis. BMC Cancer; 2007;7:190
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A verifiable consequence of the mutator hypothesis is that even low grade neoplasms would accumulate a large number of mutations that do not influence the tumor phenotype (clonal mutations).
  • In this study, we have attempted to quantify the number of clonal mutations in primary human gliomas of astrocytic cell origin.
  • These alterations were identified in tumor tissue, microscopically confirmed to have over 70% neoplastic cells.
  • METHODS: Random Amplified Polymorphic DNA (RAPD) analysis was performed using a set of fifteen 10-mer primers of arbitrary but definite sequences in 17 WHO grade II astrocytomas (low grade diffuse astrocytoma or DA) and 16 WHO grade IV astrocytomas (Glioblastoma Multiforme or GBM).
  • The RAPD profile of the tumor tissue was compared with that of the leucocyte DNA of the same patient and alteration(s) scored.
  • The difference between high and lower grade tumors was statistically significant by both methods.
  • CONCLUSION: This study demonstrates the presence of extensive clonal mutations in gliomas, more in lower grade.
  • This is consistent with our earlier work demonstrating that technique like RAPD analysis, unbiased for locus, is able to demonstrate more intra-tumor genetic heterogeneity in lower grade gliomas compared to higher grade.
  • [MeSH-minor] Cell Line, Tumor. Cloning, Molecular. DNA / metabolism. DNA Primers / chemistry. Data Interpretation, Statistical. Glioma / genetics. Humans. Leukocytes / metabolism. Models, Genetic. Models, Theoretical. Polymerase Chain Reaction. Polymorphism, Genetic. Reproducibility of Results

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15121-6 [10611348.001]
  • [Cites] J Neurooncol. 2007 Feb;81(3):249-55 [17019533.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Feb;125(1):41-5 [11297766.001]
  • [Cites] Mutat Res. 2001 Jun 2;477(1-2):7-21 [11376682.001]
  • [Cites] Mutat Res. 2001 Dec 12;484(1-2):53-9 [11733071.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):755-8 [11891172.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1608-14 [12670912.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):111-6 [15015776.001]
  • [Cites] IUBMB Life. 2004 Feb;56(2):65-81 [15085930.001]
  • [Cites] Nat Rev Drug Discov. 2004 May;3(5):430-46 [15136790.001]
  • [Cites] Oral Oncol. 2004 Nov;40(10):1033-9 [15509495.001]
  • [Cites] Br J Cancer. 1987 Apr;55(4):353-6 [3580260.001]
  • [Cites] Nucleic Acids Res. 1990 Nov 25;18(22):6531-5 [1979162.001]
  • [Cites] Nucleic Acids Res. 1990 Dec 25;18(24):7213-8 [2259619.001]
  • [Cites] Cancer Res. 1991 Jun 15;51(12):3075-9 [2039987.001]
  • [Cites] Cancer Res. 1992 Jan 15;52(2):249-53 [1728397.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Jul 1;61(1):53-60 [1353409.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):558-61 [8505985.001]
  • [Cites] Nat Genet. 1994 Mar;6(3):273-81 [8012390.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1547-9 [7882363.001]
  • [Cites] Trends Genet. 1995 Jun;11(6):242-6 [7543710.001]
  • [Cites] Trends Genet. 1995 Oct;11(10):412-5 [7482768.001]
  • [Cites] Eur J Cancer. 1995 Oct;31A(11):1879-82 [8541117.001]
  • [Cites] Oncogene. 1996 Dec 5;13(11):2499-504 [8957095.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Jan;18(1):19-29 [8993977.001]
  • [Cites] Indian J Biochem Biophys. 1996 Dec;33(6):455-7 [9219429.001]
  • [Cites] Oncogene. 1997 Aug 14;15(7):871-4 [9266974.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3230-40 [9336360.001]
  • [Cites] Cancer Res. 1997 Dec 15;57(24):5469-74 [9407952.001]
  • [Cites] Gene. 1998 Jan 5;206(1):45-8 [9461413.001]
  • [Cites] Carcinogenesis. 1998 Jan;19(1):233-5 [9472718.001]
  • [Cites] Semin Cancer Biol. 1998 Dec;8(6):421-9 [10191176.001]
  • [Cites] Semin Cancer Biol. 1998 Dec;8(6):431-8 [10191177.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):338-41 [15549096.001]
  • [Cites] DNA Repair (Amst). 2006 Mar 7;5(3):294-302 [16359931.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1485-91 [16641899.001]
  • [Cites] Breast Cancer Res Treat. 2006 May;97(1):107-10 [16319977.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14140-5 [16966602.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18238-42 [17108085.001]
  • [Cites] J Neurooncol. 2000 May;48(1):1-12 [11026691.001]
  • (PMID = 17925012.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC2190769
  •  go-up   go-down


80. Chosdol K, Misra A, Puri S, Srivastava T, Chattopadhyay P, Sarkar C, Mahapatra AK, Sinha S: Frequent loss of heterozygosity and altered expression of the candidate tumor suppressor gene 'FAT' in human astrocytic tumors. BMC Cancer; 2009;9:5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent loss of heterozygosity and altered expression of the candidate tumor suppressor gene 'FAT' in human astrocytic tumors.
  • BACKGROUND: We had earlier used the comparison of RAPD (Random Amplification of Polymorphic DNA) DNA fingerprinting profiles of tumor and corresponding normal DNA to identify genetic alterations in primary human glial tumors.
  • METHODS: In this study we used RAPD-PCR to identify novel genomic alterations in the astrocytic tumors of WHO grade II (Low Grade Diffuse Astrocytoma) and WHO Grade IV (Glioblastoma Multiforme).
  • RESULTS: Bands consistently altered in the RAPD profile of tumor DNA in a significant proportion of tumors were identified.
  • One such 500 bp band, that was absent in the RAPD profile of 33% (4/12) of the grade II astrocytic tumors, was selected for further study.
  • Its sequence corresponded with a region of FAT, a putative tumor suppressor gene initially identified in Drosophila.
  • Fifty percent of a set of 40 tumors, both grade II and IV, were shown to have Loss of Heterozygosity (LOH) at this locus by microsatellite (intragenic) and by SNP markers.
  • Semi-quantitative RT-PCR showed low FAT mRNA levels in a major subset of tumors.
  • CONCLUSION: These results point to a role of the FAT in astrocytic tumorigenesis and demonstrate the use of RAPD analysis in identifying specific alterations in astrocytic tumors.
  • [MeSH-major] Astrocytoma / genetics. Cadherins / genetics. Central Nervous System Neoplasms / genetics. Genes, Tumor Suppressor. Loss of Heterozygosity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Dyn. 2000 Mar;217(3):233-40 [10741417.001]
  • [Cites] J Neurooncol. 2000 May;48(1):1-12 [11026691.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Feb;125(1):41-5 [11297766.001]
  • [Cites] Mutat Res. 2001 Dec 12;484(1-2):53-9 [11733071.001]
  • [Cites] Yonsei Med J. 2002 Apr;43(2):145-51 [11971207.001]
  • [Cites] Int J Cancer. 2002 May 10;99(2):193-200 [11979433.001]
  • [Cites] Cancer Lett. 2002 Aug 28;182(2):193-202 [12048165.001]
  • [Cites] Chin Med J (Engl). 2002 Aug;115(8):1201-4 [12215292.001]
  • [Cites] Histol Histopathol. 2003 Jan;18(1):207-16 [12507300.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jan;39(1):93-8 [14603447.001]
  • [Cites] EMBO J. 2004 Oct 1;23(19):3769-79 [15343270.001]
  • [Cites] Dev Biol. 1988 Oct;129(2):541-54 [3417051.001]
  • [Cites] Nucleic Acids Res. 1990 Nov 25;18(22):6531-5 [1979162.001]
  • [Cites] Cancer Surv. 1990;9(4):631-44 [1983210.001]
  • [Cites] Biotechniques. 1993 Sep;15(3):388-90 [8105827.001]
  • [Cites] Brain Pathol. 1993 Jan;3(1):19-26 [8269081.001]
  • [Cites] Trends Genet. 1995 Jun;11(6):242-6 [7543710.001]
  • [Cites] Biotechniques. 1995 Jul;19(1):38, 40-2 [7669294.001]
  • [Cites] Genomics. 1995 Nov 20;30(2):207-23 [8586420.001]
  • [Cites] Indian J Biochem Biophys. 1996 Dec;33(6):455-7 [9219429.001]
  • [Cites] Gene. 1998 Jan 5;206(1):45-8 [9461413.001]
  • [Cites] Mech Dev. 1999 Feb;80(2):207-12 [10072790.001]
  • [Cites] Arch Neurol. 1999 Apr;56(4):439-41 [10199332.001]
  • [Cites] Curr Opin Oncol. 2004 Nov;16(6):607-13 [15627025.001]
  • [Cites] Gene Expr Patterns. 2005 Apr;5(4):483-90 [15749076.001]
  • [Cites] Cancer. 2005 May 15;103(10):2132-42 [15830341.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jul;43(3):260-72 [15838843.001]
  • [Cites] World J Gastroenterol. 2005 May 28;11(20):3034-9 [15918185.001]
  • [Cites] J Cell Sci. 2005 Jun 1;118(Pt 11):2347-53 [15923647.001]
  • [Cites] World J Gastroenterol. 2005 Jul 14;11(26):4102-7 [15996039.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2220-3 [16172235.001]
  • [Cites] Int J Cancer. 2005 Nov 20;117(4):683-9 [15912534.001]
  • [Cites] Clin Chem. 2006 Mar;52(3):370-8 [16397012.001]
  • [Cites] Nat Genet. 2006 Oct;38(10):1142-50 [16980976.001]
  • [Cites] Curr Biol. 2006 Nov 7;16(21):2101-10 [17045801.001]
  • [Cites] Eur J Med Genet. 2007 Jan-Feb;50(1):66-72 [17081814.001]
  • [Cites] J Neurooncol. 2007 Feb;81(3):249-55 [17019533.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Oncogene. 2007 Aug 9;26(36):5300-8 [17325662.001]
  • [Cites] Mol Cell. 2007 Sep 21;27(6):962-75 [17889669.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2747-61 [17974916.001]
  • [Cites] BMC Cancer. 2007;7:190 [17925012.001]
  • [Cites] J Biol Chem. 2008 Feb 29;283(9):5496-509 [18158288.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):2789-94 [18413746.001]
  • (PMID = 19126244.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / DNA Primers; 0 / FAT1 protein, human
  • [Other-IDs] NLM/ PMC2631005
  •  go-up   go-down


81. Huang H, Hara A, Homma T, Yonekawa Y, Ohgaki H: Altered expression of immune defense genes in pilocytic astrocytomas. J Neuropathol Exp Neurol; 2005 Oct;64(10):891-901
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered expression of immune defense genes in pilocytic astrocytomas.
  • Pilocytic astrocytoma (WHO grade I) is a circumscribed, slowly growing, benign astrocytoma that most frequently develops in the cerebellar hemispheres and in midline structures and occurs predominantly in childhood and adolescence.
  • In contrast to diffusely infiltrating gliomas in adults (e.g. grade II astrocytomas, oligodendrogliomas), survival of patients with pilocytic astrocytoma is excellent after surgical intervention.
  • To search for potential molecular mechanisms underlying its benign biologic behavior, we compared gene expression profiles of pilocytic astrocytomas (8 cases) with those of normal cerebellum (4 cases), low-grade astrocytomas (WHO grade II; 15 cases), and oligodendrogliomas (WHO grade II; 17 cases) by cDNA array analysis.
  • A number of immune system-related genes such as HLA-DRalpha, HLA-DPB1, HLA-DQB1, IgG3, IgGK, FCER1G, A2M, FCRN, IFI-56K, and DAP12 were upregulated in pilocytic astrocytomas relative to normal cerebellum, grade II astrocytomas, and oligodendrogliomas.
  • Genes expressed at higher levels in pilocytic astrocytomas than in grade II astrocytomas and oligodendrogliomas include HLA-DRalpha, HLA-DPA1, HLA-DPB1, HLA-DQB1, A2M, TIMP1, TIMP2, CDKN1A, and SOCS3 and those expressed at lower levels include EGFR and PDGFRA.
  • Hierarchical clustering analysis using the entire set of 1176 genes distinguished pilocytic astrocytomas from grade II astrocytomas and oligodendrogliomas.
  • Clustering analysis using selected subgroups of genes based on their molecular functions revealed that immune system-related genes (75 genes) or cell adhesion, migration, and angiogenesis-related genes (69 genes) showed similar power to the entire gene set for separation of pilocytic astrocytomas from diffusely infiltrating low-grade gliomas.
  • Immunohistochemistry revealed that HLA-DRalpha is expressed diffusely in neoplastic cells in pilocytic astrocytomas, whereas in oligodendrogliomas, expression was limited to scattered reactive astrocytes.
  • These results suggest that gene expression profiles of pilocytic astrocytomas differ significantly from those of diffusely infiltrating low-grade gliomas and that their benign biologic behavior may be related to upregulation of immune defense-associated genes.
  • [MeSH-major] Astrocytoma / genetics. Astrocytoma / immunology. Brain Neoplasms / genetics. Brain Neoplasms / immunology. Gene Expression. Immunity / genetics


82. Broniscer A, Chintagumpala M, Fouladi M, Krasin MJ, Kocak M, Bowers DC, Iacono LC, Merchant TE, Stewart CF, Houghton PJ, Kun LE, Ledet D, Gajjar A: Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol; 2006 Feb;76(3):313-9
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
  • Chemotherapy is commonly used in the treatment of children with high-grade glioma, although its usefulness is uncertain.
  • We conducted a multi-institutional study to evaluate the efficacy of temozolomide given after radiotherapy in children with newly diagnosed high-grade glioma and unfavorable low-grade glioma (gliomatosis cerebri or bithalamic involvement).
  • The predominant histologic diagnoses were glioblastoma multiforme (n = 15, 48%) and anaplastic astrocytoma (n = 10, 32%).
  • Two patients had bithalamic grade II astrocytoma.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1976 Dec;34(6):585-612 [795448.001]
  • [Cites] Ann Oncol. 2001 Feb;12 (2):259-66 [11300335.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12 ):3851-7 [9850030.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):261-7 [12356356.001]
  • [Cites] Br J Cancer. 2004 Aug 2;91(3):425-9 [15266331.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4684-91 [12488414.001]
  • [Cites] Br J Cancer. 1998 Sep;78(5):652-61 [9744506.001]
  • [Cites] J Neurooncol. 1989 Jul;7(2):165-77 [2550594.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Dec;52(6):435-41 [13680158.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):112-23 [7799011.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3037-43 [9738573.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):197-207 [12816726.001]
  • [Cites] Cancer. 2004 Aug 15;101(4):817-24 [15305415.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):264-71 [11815986.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Cancer. 2005 Jan 1;103(1):133-9 [15565574.001]
  • [Cites] Clin Neuropathol. 2001 Nov-Dec;20(6):248-55 [11758780.001]
  • [Cites] Neurosurgery. 1996 Feb;38(2):258-64 [8869052.001]
  • [Cites] Cancer. 2000 Nov 15;89(10):2131-7 [11066055.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):41-8 [15701281.001]
  • (PMID = 16200343.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA21765
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 0H43101T0J / irinotecan; 7GR28W0FJI / Dacarbazine; XT3Z54Z28A / Camptothecin; YF1K15M17Y / temozolomide
  •  go-up   go-down


83. Hercules SA, Ramesh VG, Paramasivan S, Kodiarasan P, Kumar MS: Holoventricular glioma in a child. Case report. J Neurosurg; 2007 Feb;106(2 Suppl):134-5
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors report a unique case of a tetraventricular Grade II astrocytoma with evidence of extension into the basal cisterns in a 5-year-old boy who had a 1-month history of headache.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis
  • [MeSH-minor] Astrocytes / pathology. Cerebral Ventricles. Child, Preschool. Contrast Media. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Subarachnoid Space. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17330540.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


84. Nicolae L, Iacob G, Poparda M, Popescu BO: Case report. Gelastic seizures in a patient with right gyrus cinguli astrocytoma. J Med Life; 2010 Oct-Dec;3(4):433-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report. Gelastic seizures in a patient with right gyrus cinguli astrocytoma.
  • II astrocytoma.
  • CLINICAL PRESENTATION: A 27 year-old male, right handed, was admitted for a 2 years history of very frequent gelastic seizures accompanied sometimes by simple motor partial seizures in both arms, more often being involved his left arm, without impairment of his consciousness state.
  • Using an interhemispheric microsurgical approach, above the corpus callosum and the right pericallosal artery, at the level of gyrus cinguli, a yellow-gray, infiltrative tumor, having a moderate vascularisation, has been identified and totally removed.
  • The anatomopathological analysis revealed a grade II astrocytoma.
  • CONCLUSION: A case of gelastic seizures accompanied by simple motor partial seizures in both arms, without the impairment of his consciousness state induced by a grade II right gyrus cinguli astrocytoma is described and documented by radiological and electrophysiological studies.
  • Using microsurgical resection, the tumor was totally removed, the patient clinical condition improved.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Epilepsies, Partial / pathology. Gyrus Cinguli / pathology

  • Genetic Alliance. consumer health - Seizures.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 2001 Dec 26;57(12):2168-78 [11785496.001]
  • [Cites] Epileptic Disord. 1999 Dec;1(4):221-8 [10937157.001]
  • [Cites] Epilepsia. 1971 Mar;12(1):63-76 [5282883.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1976 Sep;39(9):823-8 [993802.001]
  • [Cites] Neuroradiology. 1997 Jan;39(1):44-5 [9121648.001]
  • [Cites] Neurology. 1957 Mar;7(3):189-92 [13407852.001]
  • [Cites] Epileptic Disord. 2005 Jun;7(2):137-41 [15929916.001]
  • [Cites] Epileptic Disord. 2006 Sep;8(3):209-12 [16987743.001]
  • [Cites] Clin Neurol Neurosurg. 2007 Feb;109(2):182-7 [16887259.001]
  • [Cites] Pediatr Neurol. 2007 Jul;37(1):29-34 [17628219.001]
  • [Cites] Epileptic Disord. 2007 Dec;9(4):453-8 [18077234.001]
  • [Cites] Epilepsy Behav. 2009 Jun;15(2):249-53 [19286474.001]
  • [Cites] Neurosurgery. 2009 Sep;65(3):438-49; discussion 449 [19687687.001]
  • [Cites] Brain Nerve. 2009 Aug;61(8):989-93 [19697890.001]
  • [Cites] Epilepsy Behav. 2009 Oct;16(2):360-5 [19733125.001]
  • [Cites] Epileptic Disord. 2009 Dec;11(4):333-8 [19995691.001]
  • [Cites] Med Princ Pract. 2010;19(2):153-8 [20134180.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1970 Aug;33(4):479-83 [5505675.001]
  • (PMID = 21254744.001).
  • [ISSN] 1844-122X
  • [Journal-full-title] Journal of medicine and life
  • [ISO-abbreviation] J Med Life
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  • [Other-IDs] NLM/ PMC3019062
  •  go-up   go-down


85. Tehrani M, Friedman TM, Olson JJ, Brat DJ: Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma. Brain Pathol; 2008 Apr;18(2):164-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma.
  • The presence of necrosis within a diffuse glioma is a powerful predictor of poor prognosis, yet little is known of its origins.
  • Intravascular thrombosis is a frequent finding in glioblastoma [GBM; World Health Organization (WHO) grade IV] specimens and could potentially be involved in astrocytoma progression to GBM or represent a surrogate marker of GBM histology.
  • We investigated whether intravascular thrombosis was more frequent or prominent in GBM than other central nervous system (CNS) malignancies and considered its prognostic significance in anaplastic astrocytoma (AA; WHO grade III), which lacks necrosis.
  • Histologic sections were examined for thrombosis, necrosis and microvascular hyperplasia from each of 297 CNS tumors, including 103 GBMs, 46 AAs, 20 diffuse astrocytoma (DAs; WHO grade II), eight anaplastic oligodendrogliomas (AOs; WHO grade III), 20 oligodendrogliomas (ODs; WHO grade II), 49 metastatic carcinomas (METs), 31 primary central nervous system lymphomas (PCNSLs) and 20 medulloblastomas (MBs).

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2584-91 [16510576.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39 [16783163.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Sep;65(9):846-54 [16957578.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10643-6 [17108099.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 May;62(2):126-36 [17293122.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Proc Staff Meet Mayo Clin. 1949 Feb 2;24(3):71-5 [18111063.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62 [11245209.001]
  • [Cites] Thromb Res. 2001 Jun 15;102(6):V215-24 [11516455.001]
  • [Cites] Curr Opin Pulm Med. 2001 Sep;7(5):326-31 [11584184.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):480-6 [1899696.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):375-80; discussion 380-1 [7731519.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1161-6 [8635139.001]
  • [Cites] Noshuyo Byori. 1996 Nov;13(2):115-8 [8958516.001]
  • [Cites] J Pathol Bacteriol. 1954 Jul;68(1):231-3 [13212575.001]
  • [Cites] Acta Pathol Microbiol Scand. 1950;27(1):51-64 [15406242.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1406-13 [15735028.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):122-33 [15831231.001]
  • [Cites] Trends Mol Med. 2002;8(4 Suppl):S62-7 [11927290.001]
  • [Cites] Clin Biochem. 2002 Jun;35(4):321-5 [12135696.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):2-12; discussion 12-3 [12182418.001]
  • [Cites] Ann Intern Med. 2003 Apr 15;138(8):659-68 [12693889.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):920-7 [14871821.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1147-52 [15001257.001]
  • [Cites] Lab Invest. 2004 Apr;84(4):397-405 [14990981.001]
  • [Cites] Cancer. 1983 Aug 1;52(3):550-4 [6305479.001]
  • [Cites] Cancer. 1987 May 1;59(9):1617-25 [3030531.001]
  • [Cites] Cancer. 1988 Nov 15;62(10):2152-65 [3179928.001]
  • (PMID = 18093251.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS053727-01; United States / NINDS NIH HHS / NS / R01 NS053727; United States / NINDS NIH HHS / NS / NS053727; United States / NINDS NIH HHS / NS / R01 NS053727-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ NIHMS82090; NLM/ PMC2610479
  •  go-up   go-down


86. Holland H, Koschny T, Ahnert P, Meixensberger J, Koschny R: WHO grade-specific comparative genomic hybridization pattern of astrocytoma - a meta-analysis. Pathol Res Pract; 2010 Oct 15;206(10):663-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WHO grade-specific comparative genomic hybridization pattern of astrocytoma - a meta-analysis.
  • To detect novel genetic alterations, many astrocytomas have been investigated by comparative genomic hybridization (CGH).
  • To identify aberration profiles characteristic of World Health Organization (WHO) grade I, II, III, and IV astrocytoma, we performed a meta-analysis of detailed genome wide CGH data of all 467 cases published so far.
  • After expansion of all given aberrations to the maximum of 850 GTG-band resolution, the frequencies of genetic imbalances were calculated for each chromosomal band, separately for all four WHO grades.
  • Low-grade astrocytoma has already demonstrated one characteristic of glioblastoma multiforme, gain of chromosome 7 with a hot spot at 7q32, but without loss of chromosome 10.
  • In anaplastic astrocytoma, a more complex aberration pattern emerges from diffuse genetic imbalances.
  • In contrast to lower tumor grades, glioblastoma multiforme demonstrates +7p12 as the most frequently affected band on chromosome 7.
  • To quantify the gradual transition from WHO grade II-IV astrocytoma, we calculated the relative increase and decrease in frequency for each detected aberration of the tumor genome.
  • The most pronounced and diverse changes of genetic material occur at the virtual transition from low-grade to anaplastic astrocytoma.
  • Summing up, the expansion of the CGH results to the 850 GTG-band resolution enabled a meta-analysis to visualize WHO grade-specific aberration profiles in astrocytoma.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Chromosome Aberrations. Comparative Genomic Hybridization. Glioblastoma / genetics. World Health Organization
  • [MeSH-minor] Gene Expression Regulation, Neoplastic. Genotype. Humans. Neoplasm Staging. Phenotype. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20570053.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Germany
  •  go-up   go-down


87. Ohgaki H, Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol; 2007 May;170(5):1445-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma is the most frequent and most malignant human brain tumor.
  • The majority of cases (>90%) are primary glioblastomas that develop rapidly de novo, without clinical or histological evidence of a less malignant precursor lesion.
  • Secondary glioblastomas develop through progression from low-grade diffuse astrocytoma or anaplastic astrocytoma and manifest in younger patients.
  • In the pathway to secondary glioblastoma, TP53 mutations are the most frequent and earliest detectable genetic alteration, already present in 60% of precursor low-grade astrocytomas.
  • [MeSH-minor] Chromosomes, Human, Pair 10 / genetics. Humans. Loss of Heterozygosity / genetics. Mutation. PTEN Phosphohydrolase / genetics. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetics Home Reference. consumer health - chromosome 10.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 1993 Jan;52(1):31-8 [8381161.001]
  • [Cites] Cancer Res. 1993 Jun 15;53(12):2736-9 [8504413.001]
  • [Cites] Bioessays. 1993 Oct;15(10):689-90 [7506024.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Nov;60(11):1099-104 [11706939.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8113-7 [11719438.001]
  • [Cites] Neuro Oncol. 2002 Jul;4(3):196-211 [12084351.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Aug;28(4):325-33 [12175345.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2894-901 [12231534.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6764-9 [12438278.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6613-25 [14583454.001]
  • [Cites] Acta Neuropathol. 2004 Jul;108(1):49-56 [15118874.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):131-6 [15193025.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1614-7 [9616126.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8292-7 [9653180.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Jul;57(7):684-9 [9690672.001]
  • [Cites] EMBO J. 1998 Sep 1;17(17):5001-14 [9724636.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):523-30 [9815715.001]
  • [Cites] Oncogene. 1998 Dec 3;17(22):2873-81 [9879993.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(12):1213-22 [9932120.001]
  • [Cites] Brain Pathol. 1999 Apr;9(2):241-5 [10219741.001]
  • [Cites] Genes Dev. 1994 Aug 1;8(15):1739-49 [7958853.001]
  • [Cites] Nat Genet. 1995 Mar;9(3):249-55 [7773287.001]
  • [Cites] Oncogene. 1995 Jun 1;10(11):2243-6 [7784070.001]
  • [Cites] Nucleic Acids Res. 1995 Jul 25;23(14):2584-92 [7651818.001]
  • [Cites] Glia. 1995 Nov;15(3):308-27 [8586466.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):783-8 [8631014.001]
  • [Cites] Neurology. 1996 Sep;47(3):684-90 [8797465.001]
  • [Cites] Brain Pathol. 1996 Jul;6(3):217-23; discussion 23-4 [8864278.001]
  • [Cites] J Biol Chem. 1997 Jan 31;272(5):2927-35 [9006938.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Feb;56(2):180-5 [9034372.001]
  • [Cites] Science. 1997 Mar 28;275(5308):1943-7 [9072974.001]
  • [Cites] Nat Genet. 1997 Apr;15(4):356-62 [9090379.001]
  • [Cites] Brain Pathol. 1997 Jul;7(3):871-5 [9217972.001]
  • [Cites] J Cell Biol. 1997 Aug 11;138(3):575-88 [9245787.001]
  • [Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9052-7 [9256433.001]
  • [Cites] Mol Cell Biol. 1997 Sep;17(9):5612-9 [9271436.001]
  • [Cites] Cancer Res. 1997 Sep 1;57(17):3672-7 [9288770.001]
  • [Cites] Nat Genet. 1997 Sep;17(1):32-9 [9288095.001]
  • [Cites] Int J Cancer. 1997 Sep 26;73(1):57-63 [9334810.001]
  • [Cites] Acta Neuropathol. 1997 Oct;94(4):303-9 [9341929.001]
  • [Cites] Genomics. 1997 Dec 1;46(2):291-3 [9417918.001]
  • [Cites] Int J Oncol. 1998 Apr;12(4):905-10 [9499454.001]
  • [Cites] Oncogene. 1998 Feb 26;16(8):1009-19 [9519875.001]
  • [Cites] Cell. 1998 Mar 20;92(6):713-23 [9529248.001]
  • [Cites] Genes Chromosomes Cancer. 1998 May;22(1):9-15 [9591629.001]
  • [Cites] J Biol Chem. 1998 May 29;273(22):13375-8 [9593664.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Mar;57(3):239-45 [9600216.001]
  • [Cites] Lab Invest. 2000 Jan;80(1):65-72 [10653004.001]
  • [Cites] Mutat Res. 2000 Apr;462(2-3):83-100 [10767620.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2368-71 [10811111.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jun;59(6):539-43 [10850866.001]
  • [Cites] Endocr Relat Cancer. 2000 Jun;7(2):115-29 [10903528.001]
  • [Cites] Lab Invest. 2001 Jan;81(1):77-82 [11204276.001]
  • [Cites] Brain Pathol. 2001 Apr;11(2):159-68 [11303791.001]
  • [Cites] Carcinogenesis. 2001 Oct;22(10):1715-9 [11577014.001]
  • [Cites] Genomics. 1999 Jun 1;58(2):181-7 [10366450.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):387-94 [10433932.001]
  • [Cites] Lab Invest. 2005 Feb;85(2):165-75 [15592495.001]
  • [Cites] Acta Neuropathol. 2005 Jan;109(1):93-108 [15685439.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Oncogene. 2005 Oct 27;24(47):7073-83 [16103883.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):159-67 [16397228.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):108-14 [16404364.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2182-9 [16331629.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Sep;65(9):846-54 [16957578.001]
  • [Cites] Acta Neuropathol. 2007 Mar;113(3):295-302 [17235514.001]
  • [Cites] Oncogene. 2004 Sep 2;23(40):6806-14 [15286718.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Proc Natl Acad Sci U S A. 1974 Mar;71(3):639-43 [4522778.001]
  • [Cites] Biochem J. 1975 Jun;148(3):521-5 [1200992.001]
  • [Cites] Prog Exp Tumor Res. 1984;27:1-16 [6385121.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Aug;87(16):6166-70 [2143581.001]
  • [Cites] Genes Chromosomes Cancer. 1991 Mar;3(2):79-88 [1676908.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4309-13 [1584765.001]
  • [Cites] Nature. 1992 Jul 2;358(6381):80-3 [1614537.001]
  • [Cites] Cell. 1992 Jun 26;69(7):1237-45 [1535557.001]
  • [Cites] Cancer Res. 1992 Aug 15;52(16):4550-3 [1322795.001]
  • (PMID = 17456751.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Number-of-references] 85
  • [Other-IDs] NLM/ PMC1854940
  •  go-up   go-down


88. Cha S, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, Nelson SJ, Prados M, Berger MS, Dillon WP: Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol; 2005 Feb;26(2):266-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging.
  • BACKGROUND AND PURPOSE: Histopathologic evaluation remains the reference standard for diagnosis of glioma and classification of histologic subtypes, but is challenged by subjective criteria, tissue sampling error, and lack of specific tumor markers.
  • Anatomic imaging is essential for surgical planning of gliomas but is limited by its nonspecificity and its inability to depict beyond morphologic aberrations.
  • The purpose of our study was to investigate dynamic susceptibility contrast-enhanced (DSC) MR imaging characteristics of the two most common subtypes of low-grade infiltrating glioma: astrocytoma and oligodendroglioma.
  • We hypothesized that tumor blood-volume measurements, derived from DSC MR imaging, would help differentiate the two on the basis of differences in tumor vascularity.
  • METHODS: We studied 25 consecutive patients with treatment-naive, histopathologically confirmed World Health Organization grade II astrocytoma (n = 11) or oligodendroglioma (n = 14).
  • Anatomic MR images were analyzed for morphologic features, and DSC MR data were processed to yield quantitative cerebral blood volume (CBV) measurements.
  • RESULTS: The maximum relative CBV (rCBV(max)) in tumor ranged from 0.48 to 1.34 (0.92 +/- 0.27, median +/- SD) in astrocytomas and from 1.29 to 9.24 (3.68 +/- 2.39) in oligodendrogliomas.
  • The difference in median rCBV(max) between the two tumor types was significant (P < .0001).
  • CONCLUSION: The tumor rCBV(max) measurements derived from DSC MR imaging were significantly higher in low-grade oligodendrogliomas than in astrocytomas.
  • Our findings suggest that tumor rCBV(max) derived from DSC MR imaging can be used to distinguish between the two low-grade gliomas.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709123.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / K23 NS 45013
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


89. Passarin MG, Moretto G, Musso AM, Ottaviani S, Masotto B, Ghimenton C, Iuzzolino P, Buffone E, Rudà R, Soffietti R, Vattemi E, Pedersini R: Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination. J Neurooncol; 2010 May;97(3):439-44
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination.
  • Leptomeningeal dissemination of low-grade gliomas is an uncommon event.
  • A nonenhancing lesion in the right cerebellar peduncle was identified, subtotally resected, and diagnosed as a grade II astrocytoma.

  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3133-8 [15284265.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):253-60 [12356355.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10 (11):3728-36 [15173079.001]
  • [Cites] J Neurooncol. 2002 May;57(3):231-9 [12125986.001]
  • [Cites] Ann Pharmacother. 2000 Oct;34(10):1173-8 [11054987.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):646-51 [12586801.001]
  • [Cites] Arch Neurol. 1995 Sep;52(9):912-7 [7661730.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3605-13 [15908671.001]
  • [Cites] Ann Oncol. 2003 Dec;14 (12 ):1715-21 [14630674.001]
  • [Cites] Clin Neurol Neurosurg. 2009 May;111(4):390-4 [19128871.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(2-4):84-92 [8042560.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3394-402 [10589750.001]
  • [Cites] J Neurooncol. 2007 Jul;83(3):303-6 [17245619.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2869-78 [8194029.001]
  • [Cites] Oncologist. 2006 Jun;11(6):681-93 [16794247.001]
  • (PMID = 19876600.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Liposomes; 04079A1RDZ / Cytarabine; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


90. Ruban D, Byrne RW, Kanner A, Smith M, Cochran EJ, Roh D, Whisler WW: Chronic epilepsy associated with temporal tumors: long-term surgical outcome. Neurosurg Focus; 2009 Aug;27(2):E6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: The authors undertook a study to review the clinical features and outcome in patients who underwent surgery for intractable chronic epilepsy caused by temporal lobe tumors.
  • METHODS: The Rush Surgical Epilepsy Database was queried to identify patients with chronic intractable epilepsy who underwent resection of temporal lobe tumors between 1981 and 2005 at Rush University Medical Center.
  • RESULTS: Thirty-eight patients were identified, all with low-grade tumors.
  • Gangliogliomas were the most common (36.8%), followed in descending order by dysembryoplastic neuroepithelial tumors (26.3%) and low-grade diffuse astrocytoma (10.5%).
  • The mean follow-up duration was 7.7 years (range 1.0-23.1 years), with 78.9% of patients having seizure status that improved to Engel Class I, 15.8% to Engel Class II, and 5.3% to Engel Class III.
  • [MeSH-minor] Adolescent. Adult. Amygdala / pathology. Amygdala / surgery. Astrocytoma / pathology. Astrocytoma / surgery. Child. Chronic Disease. Female. Ganglioglioma / pathology. Ganglioglioma / surgery. Glioma / pathology. Glioma / surgery. Hippocampus / pathology. Humans. Longitudinal Studies. Magnetic Resonance Imaging. Male. Middle Aged. Neurosurgical Procedures. Preoperative Care. Treatment Outcome


91. Jayawardena S, Sooriabalan D, Indulkar S, Kim HH, Matin A, Maini A: Regression of grade III astrocytoma during the treatment of CML with imatinib mesylate. Am J Ther; 2006 Sep-Oct;13(5):458-9
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of grade III astrocytoma during the treatment of CML with imatinib mesylate.
  • Astrocytomas are central nervous system neoplasms, which are derived predominately from astrocytes.
  • On the basis of the histopathologic characteristics astrocytomas are graded from I to IV.
  • The cells that demonstrate the greatest degree of anaplasia are used to determine the histologic grade of the tumor.
  • The mean age of survival are approximately 10 years from the time of diagnosis for pilocystic astrocytomas (World Health Organization grade I), more than 5 years for patients with low-grade diffuse astrocytomas (WHO grade II), 2 to 5 years for those with anaplastic astrocytomas (WHO grade III), and less than 1 year for patients with glioblastoma (WHO grade IV).
  • The treatment is a combination of surgery, radiation, and chemotherapy depending of the grade of astrocytoma.
  • We present a case of 31-year-old man with grade III astrocytoma with subsequent chronic myelogenous leukemia treated with imatinib mesylate as part of his chronic myelogenous leukemia treatment failing to show recurrence of the astrocytoma 10 years after standard treatment for astrocytoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Leukemia, Myeloid, Acute / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16988542.001).
  • [ISSN] 1075-2765
  • [Journal-full-title] American journal of therapeutics
  • [ISO-abbreviation] Am J Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


92. Arjona D, Bello MJ, Alonso ME, Isla A, De Campos JM, Vaquero J, Sarasa JL, Gutierrez M, Rey JA: Real-time quantitative PCR analysis of regions involved in gene amplification reveals gene overdose in low-grade astrocytic gliomas. Diagn Mol Pathol; 2005 Dec;14(4):224-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Real-time quantitative PCR analysis of regions involved in gene amplification reveals gene overdose in low-grade astrocytic gliomas.
  • We have studied gene amplification of genes located in 1q32 (GAC1, ELF3, MDM4, and ren1), 4q11 (PDGFR-alpha), and in 12q13-14 (MDM2 and CDK4) using quantitative real-time PCR in a group of 86 tumors consisting of 44 WHO grade IV glioblastomas (GBM) (34 primary and 10 secondary tumors), 21 WHO grade III anaplastic astrocytomas (AA), and 21 WHO grade II astrocytomas (AII).
  • GAC1 (51%) and MDM4 (27%) were the most frequently amplified genes within the 1q32 amplicon, and their higher amplification frequency was statistically significant (P<0.05, chi) in the low-grade astrocytomas.
  • Concordant co-amplification was determined for ELF3 and ren1 or ren1 and MDM4 in the grade III-IV tumors.
  • The present study shows that gene amplification in the studied regions is already present in low-grade astrocytic tumors and that amplification of some genes may represent another molecular marker to differentiate primary from secondary GBM.
  • [MeSH-major] Astrocytoma / genetics. Gene Amplification. Gene Dosage. Proto-Oncogenes / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. Humans. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16319692.001).
  • [ISSN] 1052-9551
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


93. Forshew T, Tatevossian RG, Lawson AR, Ma J, Neale G, Ogunkolade BW, Jones TA, Aarum J, Dalton J, Bailey S, Chaplin T, Carter RL, Gajjar A, Broniscer A, Young BD, Ellison DW, Sheer D: Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol; 2009 Jun;218(2):172-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas.
  • We report genetic aberrations that activate the ERK/MAP kinase pathway in 100% of posterior fossa pilocytic astrocytomas, with a high frequency of gene fusions between KIAA1549 and BRAF among these tumours.
  • An activating mutation of KRAS was identified in the single pilocytic astrocytoma without a BRAF or RAF1 fusion.
  • Further fusions and activating mutations in BRAF were identified in 28% of grade II astrocytomas, highlighting the importance of the ERK/MAP kinase pathway in the development of paediatric low-grade gliomas.
  • [MeSH-major] Astrocytoma / enzymology. Brain Neoplasms / enzymology. MAP Kinase Signaling System / physiology. Mitogen-Activated Protein Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pathol. 2010 Dec;222(4):324-8 [20976706.001]
  • (PMID = 19373855.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A8318; United Kingdom / Cancer Research UK / / C5321/A8318
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / GTPase-Activating Proteins; 0 / Oncogene Proteins, Fusion; 0 / SRGAP3 protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


94. Bartkova J, Hamerlik P, Stockhausen MT, Ehrmann J, Hlobilkova A, Laursen H, Kalita O, Kolar Z, Poulsen HS, Broholm H, Lukas J, Bartek J: Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas. Oncogene; 2010 Sep 9;29(36):5095-102
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant gliomas, the deadliest of brain neoplasms, show rampant genetic instability and resistance to genotoxic therapies, implicating potentially aberrant DNA damage response (DDR) in glioma pathogenesis and treatment failure.
  • Here, we report on gross, aberrant constitutive activation of DNA damage signalling in low- and high-grade human gliomas, and analyze the sources of such endogenous genotoxic stress.
  • Based on analyses of human glioblastoma multiforme (GBM) cell lines, normal astrocytes and clinical specimens from grade II astrocytomas (n=41) and grade IV GBM (n=60), we conclude that the DDR machinery is constitutively activated in gliomas, as documented by phosphorylated histone H2AX (gammaH2AX), activation of the ATM-Chk2-p53 pathway, 53BP1 foci and other markers.
  • Oxidative DNA damage (8-oxoguanine) was high in some GBM cell lines and many GBM tumors, while it was low in normal brain and grade II astrocytomas, despite the degree of DDR activation was higher in grade II tumors.
  • Markers indicative of ongoing DNA replication stress (Chk1 activation, Rad17 phosphorylation, replication protein A foci and single-stranded DNA) were present in GBM cells under high- or low-oxygen culture conditions and in clinical specimens of both low- and high-grade tumors.
  • The observed global checkpoint signaling, in contrast to only focal areas of overabundant p53 (indicative of p53 mutation) in grade II astrocytomas, are consistent with DDR activation being an early event in gliomagenesis, initially limiting cell proliferation (low Ki-67 index) and selecting for mutations of p53 and likely other genes that allow escape (higher Ki-67 index) from the checkpoint and facilitate tumor progression.
  • Overall, these results support the potential role of the DDR machinery as a barrier to gliomagenesis and indicate that replication stress, rather than oxidative stress, fuels the DNA damage signalling in early stages of astrocytoma development.
  • [MeSH-minor] Cell Line, Tumor. Histones / metabolism. Humans. Ki-67 Antigen / metabolism. Signal Transduction / genetics. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20581868.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / H2AFX protein, human; 0 / Histones; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


95. Salvan CV, Ulmer JL, Mueller WM, Krouwer HG, Prost RW, Stroe GO: Presurgical and intraoperative mapping of the motor system in congenital truncation of the precentral gyrus. AJNR Am J Neuroradiol; 2006 Mar;27(3):493-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 43-year-old man presented with a grade II astrocytoma in the left postcentral gyrus and superior parietal lobule.
  • Preoperative functional MR imaging and diffusion tensor imaging mapped distal upper-extremity primary motor cortex and white matter, respectively, adjacent to the tumor, within a congenitally truncated precentral gyrus.
  • The integration of preoperative and intraoperative mapping data facilitated resection of the tumor while avoiding a postoperative motor deficit.
  • [MeSH-major] Astrocytoma / pathology. Brain Mapping. Brain Neoplasms / pathology. Magnetic Resonance Imaging. Motor Cortex / abnormalities. Motor Cortex / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16551983.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Burim RV, Teixeira SA, Colli BO, Peria FM, Tirapelli LF, Marie SK, Malheiros SM, Oba-Shinjo SM, Gabbai AA, Lotufo PA, Carlotti-Júnior CG: ICAM-1 (Lys469Glu) and PECAM-1 (Leu125Val) polymorphisms in diffuse astrocytomas. Clin Exp Med; 2009 Jun;9(2):157-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ICAM-1 (Lys469Glu) and PECAM-1 (Leu125Val) polymorphisms in diffuse astrocytomas.
  • Single-nucleotide polymorphism in codon 469 of ICAM-1 and codon 125 of PECAM-1 were examined in 158 patients with astrocytomas and 162 controls using polymerase chain reaction and restriction enzyme analysis.
  • The distribution of PECAM-1 polymorphic genotypes in astrocytomas did not show any significant difference.
  • However, a specific ICAM-1 genotype (G/G, corresponding to Lys469Glu) exhibited higher frequency in grade II astrocytomas compared to controls, grade III, and grade IV astrocytomas; suggesting that this polymorphism could be involved in the development of grade II astrocytomas.
  • [MeSH-major] Antigens, CD31 / genetics. Astrocytoma / genetics. Intercellular Adhesion Molecule-1 / genetics. Polymorphism, Single Nucleotide

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 1990 Apr;110(4):1227-37 [2182647.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):217-28 [15674479.001]
  • [Cites] Science. 1989 Dec 8;246(4935):1303-6 [2588007.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] J Neurooncol. 1999 May;43(1):19-25 [10448867.001]
  • [Cites] J Hepatol. 2004 Mar;40(3):375-9 [15123348.001]
  • [Cites] Am J Pathol. 1994 Jan;144(1):104-16 [7904796.001]
  • [Cites] Am J Pathol. 1990 Jun;136(6):1309-16 [1972610.001]
  • [Cites] Cancer Lett. 1999 Nov 15;146(2):169-72 [10656622.001]
  • [Cites] Mol Hum Reprod. 2003 Jan;9(1):47-52 [12529420.001]
  • [Cites] Clin Exp Rheumatol. 2000 Sep-Oct;18(5):553-8 [11072593.001]
  • [Cites] Hum Immunol. 2003 Mar;64(3):345-9 [12590979.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):37-59 [9210052.001]
  • [Cites] J Rheumatol. 2001 May;28(5):1014-8 [11361181.001]
  • [Cites] Int J Immunogenet. 2006 Feb;33(1):49-53 [16426244.001]
  • [Cites] J Biol Chem. 1994 Jun 24;269(25):17183-91 [8006026.001]
  • [Cites] Blood. 1996 Dec 15;88(12):4429-34 [8977234.001]
  • [Cites] Cardiology. 1999;91(1):50-5 [10393398.001]
  • [Cites] Hum Gene Ther. 1997 May 1;8(7):851-60 [9143911.001]
  • [Cites] Indian J Med Res. 2005 Feb;121(2):92-9 [15756041.001]
  • [Cites] Histopathology. 1996 Jun;28(6):521-8 [8803595.001]
  • [Cites] Genomics. 1994 Jun;21(3):473-7 [7525451.001]
  • [Cites] Gut. 2003 Jan;52(1):75-8 [12477764.001]
  • [Cites] Heart. 2002 Feb;87(2):107-12 [11796541.001]
  • [Cites] J Clin Invest. 1997 Jan 1;99(1):3-8 [9011572.001]
  • [Cites] Ann N Y Acad Sci. 2001 Dec;947:259-69; discussion 269-70 [11795274.001]
  • [Cites] Lab Invest. 1998 May;78(5):583-90 [9605183.001]
  • [Cites] Clin Biochem. 2004 Dec;37(12):1091-7 [15589815.001]
  • [Cites] Wien Med Wochenschr. 2006 Jun;156(11-12):332-7 [16944363.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4945-9 [14557478.001]
  • [Cites] J Immunol. 2000 Oct 15;165(8):4658-66 [11035109.001]
  • [Cites] J Immunol Methods. 1996 May 27;191(2):97-112 [8666839.001]
  • [Cites] J Neurosurg. 2000 Jun;92(6):1080-1 [10839286.001]
  • [Cites] J Soc Gynecol Investig. 2005 May;12(4):267-71 [15866119.001]
  • [Cites] Atherosclerosis. 2003 May;168(1):131-8 [12732396.001]
  • [Cites] Eur J Immunogenet. 2000 Apr;27(2):73-6 [10792421.001]
  • [Cites] Biochem Biophys Res Commun. 2004 May 7;317(3):729-35 [15081401.001]
  • [Cites] Medicina (Kaunas). 2004;40(2):112-20 [15007269.001]
  • [Cites] Neurol Med Chir (Tokyo). 1994 Sep;34(9):583-7 [7526247.001]
  • [Cites] J Leukoc Biol. 1999 Apr;65(4):444-52 [10204572.001]
  • [Cites] N Engl J Med. 1996 Feb 1;334(5):286-91 [8532023.001]
  • [Cites] J Neurooncol. 2007 Feb;81(3):295-303 [17001519.001]
  • [Cites] Eur J Immunol. 1995 May;25(5):1154-62 [7539748.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):281-93 [16554966.001]
  • [Cites] J Korean Med Sci. 2003 Jun;18(3):415-8 [12808331.001]
  • [Cites] Clin Immunol. 2001 Dec;101(3):357-60 [11726228.001]
  • [Cites] J Clin Pathol. 2005 Jun;58(6):595-9 [15917409.001]
  • [Cites] Acta Neuropathol. 1993;85(6):628-34 [8337942.001]
  • [Cites] Am J Med Genet. 2002 Oct 30;115(3):194-201 [12407701.001]
  • [Cites] Cell. 1991 Jun 14;65(6):961-71 [1675157.001]
  • [Cites] Lancet. 2003 Nov 22;362(9397):1723-4 [14643123.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):671-7 [9284815.001]
  • [Cites] Am J Pharmacogenomics. 2003;3(5):317-28 [14575520.001]
  • [Cites] J Immunol. 1996 Nov 15;157(10):4347-53 [8906809.001]
  • [Cites] J Neuroimmunol. 2000 May 1;104(2):174-8 [10713357.001]
  • [Cites] Eur J Immunogenet. 2004 Aug;31(4):175-8 [15265022.001]
  • [Cites] J Immunol. 1997 Apr 1;158(7):3408-16 [9120301.001]
  • [Cites] Clin Exp Immunol. 1990 Jul;81(1):142-8 [1974176.001]
  • (PMID = 19306055.001).
  • [ISSN] 1591-8890
  • [Journal-full-title] Clinical and experimental medicine
  • [ISO-abbreviation] Clin. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD31; 126547-89-5 / Intercellular Adhesion Molecule-1
  •  go-up   go-down


97. Maiti AK, Ghosh K, Chatterjee U, Chakrobarti S, Chatterjee S, Basu S: Epidermal growth factor receptor and proliferating cell nuclear antigen in astrocytomas. Neurol India; 2008 Oct-Dec;56(4):456-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor and proliferating cell nuclear antigen in astrocytomas.
  • AIMS: The involvement of various growth factors, growth factor receptors and proliferative markers in the molecular pathogenesis of astrocytic neoplasms are being studied extensively.
  • Since EGFR and proliferating cell nuclear antigen (PCNA) are involved in mitogenic signal transduction and cellular proliferation pathway, we have studied the correlation between the expression of EGFR and PCNA labeling index in astrocytic tumors.
  • MATERIALS AND METHODS: We investigated the immunohistochemical expression of EGFR and PCNA using the appropriate monoclonal antibodies in 40 cases of astrocytic tumors of which 21 cases were glioblastoma, eight cases were Grade III or anaplastic astrocytomas and six cases were Grade II or diffuse astrocytomas and five cases were Grade I or pilocytic astrocytomas.
  • RESULTS: Both the EGFR expression and PCNA labeling index increase with increasing grades of astrocytomas with a significantly high percentage of cells showing positive staining for both EGFR and PCNA in GBM and Grade III astrocytomas compared to Grade II astrocytomas.
  • The expression levels of both EGFR and PCNA were low in Grade I or pilocytic astrocytomas.
  • CONCLUSIONS: A significant correlation was found between EGFR overexpression and PCNA labeling index in Grade III and Grade II astrocytomas and glioblastoma.
  • These suggest that the tumor proliferation, at least in higher grades of astrocytomas is dependent in some measure on EGF and EGFR-related signaling pathways.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Proliferating Cell Nuclear Antigen / metabolism. Receptor, Epidermal Growth Factor / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19127042.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


98. Manley S, Crooks D, Artingstall L, Buxton N, Appleton R, Riordan A, Cleary G, Pizer B: Diffuse central nervous system protoplasmic astrocytoma. Pediatr Blood Cancer; 2010 May;54(5):768-9
Genetic Alliance. consumer health - Diffuse Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse central nervous system protoplasmic astrocytoma.
  • Protoplasmic astrocytoma is an extremely rare form of grade II low grade glioma which usually presents as a discrete mass lesion.
  • We describe a 3-year-old female with diffuse protoplasmic astrocytoma with parenchymal involvement and leptomeningeal spread.
  • To our knowledge this case represents the distinct presentation of protoplasmic astrocytoma presenting as extensive diffuse meningeal disease.
  • [MeSH-major] Astrocytoma / pathology. Cerebellar Neoplasms / pathology. Meningeal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20049933.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Omura T, Nawashiro H, Osada H, Shima K, Tsuda H, Shinsuke A: Pilomyxoid astrocytoma of the fourth ventricle in an adult. Acta Neurochir (Wien); 2008 Nov;150(11):1203-6; discussion 1206

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilomyxoid astrocytoma of the fourth ventricle in an adult.
  • Pilomyxoid astrocytomas have been identified as a variant of pilocytic astrocytoma.
  • They are listed as a novel clinico-pathological entity in the 2007 World Health Organisation (WHO) classification of tumours of the central nervous system.
  • This tumour corresponds to a WHO grade II neoplasm whereas pilocytic astrocytoma corresponds to WHO grade I.
  • Pilomyxoid astrocytomas are not limited to the hypothalamic/chiasmatic region in children.
  • Additional knowledge and recognition of this entity is necessary to improve treatment of pilomyxoid astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Cerebral Ventricle Neoplasms / pathology. Fourth Ventricle / pathology
  • [MeSH-minor] Adult. Age Distribution. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Cranial Nerve Diseases / etiology. Cranial Nerve Diseases / physiopathology. Humans. Hyperacusis / etiology. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. Postoperative Complications / etiology. Postoperative Complications / physiopathology. Tinnitus / etiology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18958385.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


100. Della Puppa A, Zustovich F, Gardiman M, Manara R, Cecchin D, Scienza R: Haemorrhagic presentation of low-grade glioma in adults. Acta Neurochir (Wien); 2007 Nov;149(11):1151-5; discussion 1155
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haemorrhagic presentation of low-grade glioma in adults.
  • Intracranial bleeding is rare in patients with low-grade gliomas, above all in adult population.
  • We reviewed the literature of such cases and reported another case of a haemorrhagic low-grade glioma in a 54-year-old woman presenting with a left hemiparesis.
  • Late magnetic resonance images revealed a low-grade glioma at the bleeding site.
  • Tumour was removed and histopathologic examination revealed a WHO grade II mixed glioma.
  • [MeSH-major] Astrocytoma / diagnosis. Basal Ganglia Diseases / diagnosis. Basal Ganglia Hemorrhage / etiology. Brain Neoplasms / diagnosis. Magnetic Resonance Imaging. Positron-Emission Tomography. Putaminal Hemorrhage / etiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17676407.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 22
  •  go-up   go-down






Advertisement